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CD137 is an inducible T cell costimulatory molecule, and a subset of CD4+CD25+  T 
regulatory cells constitutively express CD137 (CD137pos Tregs). The nonobese diabetic (NOD) 
mouse spontaneously develops Type one diabetes (T1D), and genetic mapping studies have 
implicated CD137 as a candidate gene in the chromosome four Idd9.3 interval. We show that 
anti-CD137 treatment protects NOD mice from diabetes. Anti-CD137 antibody specifically binds 
to CD137pos Tregs cells in vivo. Antibody treatment increases the percentage of Tregs and 
these cells prevent diabetes in transfer studies. Depleting CD4+CD25+ T cells eliminated anti-
CD137 mediated diabetes protection. These studies demonstrate the importance of the 
CD137pos Treg subset, which express the same amount of Foxp3 as CD137neg Tregs but are 
functionally superior in contact dependent and independent suppression assays in vitro.  
Congenic NOD.B10 Idd9.3 mice (that have a 40% decreased incidence of diabetes compared to 
NOD), have significantly increased numbers of peripheral CD137pos Tregs compared to NOD. 
Mixed bone marrow chimeras using the two allotypically marked strains showed an intrinsic 
cellular basis for the accumulation of B10 Idd9.3 CD137pos Tregs. While CD137pos Tregs from 
NOD and NOD.B10 Idd9.3 showed no suppressive differences, the accumulation of the 
functionally superior Treg subset enables enhanced immunosuppression in the congenic mice. 
We show that CD137pos Tregs are the major T cell source for the alternatively spliced CD137 
isoform, soluble CD137, which causes reduced T cell proliferation. Increased serum soluble 
CD137 in NOD.B10 Idd9.3 versus NOD mice associates soluble CD137 with diabetes 
protection. Anti-CD137 treatment increases serum soluble CD137. Soluble CD137-Fc directly 
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reduces CD4pos T cells proliferation in a CD137 ligand dependent manner.   We used a lentiviral 
approach to produce recombinant soluble CD137 in vitro. The purified soluble CD137 is 
predominantly a dimer, and directly suppresses CD4 T cell proliferation. Soluble CD137 protein 
prevents diabetes and significantly reduces insulitis in NOD.  Our data shows that diabetes 
protection by both anti-CD137 treatment and in NOD.B10 Idd9.3 mice is associated with 
expansion of suppressive CD137pos Tregs and subsequent accumulation of immunosuppressive 
soluble CD137. These studies establish the importance of the CD137pos Treg subset and 
soluble CD137 in T1D and immunobiology. 
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1.0 INTRODUCTION 
 
 
 
1.1 TYPE 1 DIABETES (T1D) 
 
Human insulin-dependent diabetes mellitus or type 1 diabetes (T1D) is an inflammatory 
autoimmune disease characterized by the immunological destruction of insulin-producing 
pancreatic beta cells and the appearance of auto antibodies against self-proteins [1, 2]. In 
contrast to T1D, type 2 diabetes (T2D) is non-autoimmune-mediated and is characterized by 
insulin resistance and a lack of the pancreatic β-cells to compensate this insensitivity. The 
Juvenile Diabetes Research Foundation (JDRF) reports that estimated three million Americans 
have T1D. According to the Centers for Disease Control and Prevention (CDC) diabetes (both 
T1D and T2D) is the leading cause of heart disease and stroke and is the seventh leading 
cause of death in the United States. Studies have projected that the worldwide incidence of 
diabetes will rise to at least 366 million by 2030, qualifying as a ―diabetes epidemic‖ [3]. There 
are two main stages of autoimmune diabetes in humans and mice: i) a silent insulitis phase that 
occurs when autoreactive lymphocytes and other antigen presenting cells infiltrate the islets and 
ii) an overt diabetes phase after destruction of β-cells that leads to deficiency in insulin and 
resultant hyperglycemia [4]. Histological analysis of the pancreas shows that the immune 
infiltration consists of primarily CD8 T cells but has abnormalities in both T cells and antigen 
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presenting cells [5, 6]. The decrease in β-cell mass and the subsequent absence of 
endogenous insulin production requires patients to administer exogenous insulin to maintain 
their blood glucose levels. Patients with poor glycemic control have increased long-term risk of 
diabetes-related complications such as nephropathy, retinopathy and neuropathy and 
cardiovascular disease disorders which are the major causes of morbidity and mortality caused 
by the disease [7]. The disease pathogenesis is still unclear in humans but both genetic and 
environmental factors are important in disease progression and clinical onset [8]. Because of 
the nature of the disease, subjects are only diagnosed after the clinical onset of diabetes, 
making it hard to study the subsequent changes in immune mechanisms that lead to 
autoimmunity. Because of such practical constraints and other ethical issues in studying 
treatment mechanisms, animal models are indispensable to reveal the factors affecting 
development of T1D and its treatment. One of the most studied animal models for T1D is the 
nonobese diabetic (NOD) mouse model that spontaneously develops T1D.  
 
The NOD mouse model was incidentally discovered in 1979 at Shionogi Research Laboratories 
in Japan while breeding mice that spontaneously developed cataracts [9]. Two lines exhibited 
fasting hyperglycemia and one of these lines developed diabetes; this established the NOD 
strain that now spontaneously develops insulin-dependent diabetes. In three to four week old 
NOD female mice, there is a progressive accumulation of autoreactive lymphocytes, dendritic 
cells and macrophages in the pancreatic islets of Langerhans (insulitis) causing inflammation 
and destruction of insulin-producing islet β-cells. In males, insulitis starts at 3 months of age 
[10]. The β cells are eliminated by various mechanisms such as Fas/FasL interactions and 
perforin- and cytokine-mediated cell killing, leading to diabetes in 80% of mice by 20 weeks of 
age [11-13].  
 
The NOD mouse model has several similarities with T1D in human, such as presence of 
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autoantibodies, T cell–mediated insulitis and various susceptibility genes. Both humans and 
mice have at least 50 T1D susceptibility genes [14, 15]. Both species have an early autoimmune 
response to insulin and beta cell proteins caused by partial failure in central and peripheral 
tolerance [16, 17]. In addition, in both species T1D susceptibility is associated with MHC class II 
molecules [18], genetic variations of CTLA-4, IL-2 [19] and CD25 [20] genes. The MHC region is 
a major genetic determinant for T1D in both humans and NOD mice [21, 22] and non-MHC 
genes also contribute to T1D susceptibility in both species. The variation in the IL-2 allele 
reduces its signaling in T1D patients and NOD mice [23-25]. The resistant allele for Il2 produces 
two fold increases in IL-2 compared to the diabetes susceptible allele [19]. Since IL-2 is 
essential for the function of tolerance inducing Foxp3+ regulatory T cells [26], the change in the 
number or function of Tregs affects the suppression of pathogenic effector cells. The NOD 
mouse model also recapitulates the dependence on both environmental factors (diet & infection) 
and genetic factors as indicated in humans [8]. However, there are some differences between 
human T1D and the NOD mouse model. Unlike humans, the incidence of diabetes is higher in 
female than in male NOD mice [27, 28]. In NOD mice peripheral lymphoid organs and the 
submandibular salivary glands also show leukocyte infiltration [29]. Although there are 
differences and limitations in comparing NOD with human T1D, the study of this mouse model 
has enhanced our understanding of the etiologic complexity of type 1 diabetes and helped to 
understand the mechanism of disease protection, which can ultimately help treat the human 
disease. 
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1.2 IMMUNITY IN NOD MICE 
 
1.2.1 T cells in NOD diabetes 
 
Diabetes is a T cell-mediated (involving both CD4 and CD8 T cells) disease that also involves 
innate immunity. The importance of T cells in diabetes is indicated by the reversal of diabetes 
with anti-CD3 antibody treatment in NOD mice [30]. Both CD4 and CD8 T cells are required to 
transfer diabetes to immunocompromised NOD-scid mice [31]. Although there has been debate 
regarding the requirement of TCR specificity for islet infiltration, a recent study comparing islet 
specific and non-specific TCR in mixed bone marrow chimera and retrogenic mice showed that 
TCR specificity is required for islet entry and accumulation of T cells [32]. As noninvasive 
insulitis (―perinsulitis‖) progresses into invasive insulitis, beta cell destruction and overt diabetes, 
there is expansion of diabetogenic T cell clones, autoimmune response to new antigens or 
epitopes (―epitope spreading‖) and resistance of T effector cells to immune regulation. Beta cell 
death itself could release antigens that were either initially concealed (―clonal ignorance‖) or 
modified such that they escape immune tolerance [33], resulting in new T cell clones that 
infiltrate the islets. As the disease progresses, T cells with high avidity are preferentially 
expanded in the islets [34]. Finally, it has been shown in both humans and mice that T effector 
cells become more resistant to suppression by regulatory T cells as the disease progresses [35, 
36]. Thus there are multiple intrinsic and extrinsic factors that affect the pathogenicity of T cells 
during the progression of autoimmune diabetes.  
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1.2.2 Autoantigens in diabetes 
 
There are at least eighteen proposed T cell auto-antigens that contribute to T1D pathogenesis 
including Heat-shock protein 60 (Hsp60), Glutamic acid decarboxylase 65 (GAD65), 
preproinsulin, Regenerating gene II (Reg II) and Pancreatic duodenal homeobox 1 (Pdx1) [37].  
There is an unusually large repertoire of autoreactive T cells in NOD mice that is linked 
genetically to the MHC [38, 39]. MHC-linked and non–MHC-linked genes act together to cause 
a breakdown in tolerance. It has been shown that the diabetes-associated NOD MHC II 
molecule I-Ag7 interacts with pathogenic T cell receptors and causes diabetes on NOD genetic 
background but not in B6.G7 mice with all non-NOD genes except for NOD MHC interval [38, 
40]. This indicates that the NOD MHC II I-Ag7 molecule is not sufficient to initiate autoimmunity 
and that non-MHC genes present in NOD background are crucial for the disease process [41].  
 
1.2.3 Role of innate immunity and B cells in diabetes 
 
Although CD4 and CD8 T cells are both essential for the transfer of diabetes, other antigen 
presenting cells such as B cells, dendritic cells and macrophages also play a crucial role in the 
pathogenesis of the disease [42-44]. Dendritic cells and macrophages are observed in the 
pancreatic islets before T cell infiltration, suggesting a critical role in the disease pathogenesis 
[45]. These innate cells produce pro-inflammatory cytokines that change the milieu in which 
antigen specific T cell are activated, enhancing subsequent destruction of -cells.  Dendritic 
cells capture self antigen released as a result of -cell death between two to three weeks of age 
due to tissue remodeling or change in the metabolic rate at weaning [46]. These DCs then 
present self-antigen to T cells in the pancreatic lymph node and initiate priming that leads to 
generation of antigen specific T cells.  
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Macrophages and NK cells are also present in the pancreatic infiltrate and can contribute to 
beta cell destruction [47]. Blockade of adhesion promoting receptors in macrophages inhibits 
their homing into the pancreas and prevents diabetes [48]. In pancreatic islets the 
proinflammatory cytokines TNF and IL-1 produced by macrophages stimulate -cells to 
produce nitric oxide synthase (iNOS), which promotes tissue destruction [49]. Macrophages 
also produce IL-12 that promotes cytotoxic CD8 T cell differentiation [50]. Recent studies have 
shown that NK cell ligands are expressed by -cells in the pancreatic islets in both NOD mice 
and humans and play a role in destruction of islets [51, 52]. The NK cells from the pancreatic 
islets are also known to express programmed cell death 1 (PD1) and killer cell lectin-like 
receptor group G member 1 (KLRG1) indicating cytotoxic function [53]. However, several 
studies have also reported a protective role for NK cells in NOD. Freund‘s adjuvant induced 
prevention of diabetes is dependent on NK cells [54]. Studies have also reported impaired NK 
cell function in diabetic patients and NOD mice, indicating a protective role in disease 
prevention [55, 56]. Invariant NKT cells (iNKT cells) are innate-like T cells that also play a role in 
diabetes protection. Adoptive transfer studies have shown that an increase in iNKT cells 
protects NOD mice from diabetes [57]. Activation of iNKT cells with a specific agonist (-
galactosylceramide or its analogues) inhibits diabetes in NOD mice by induction of Th2 cell 
responses to islet antigens [58, 59]. 
 
B cells also play a role in T1D pathogenesis. Earlier studies have identified numerous 
autoantibodies to islet antigens, including insulin, glutamic acid decarboxylase, tyrosine 
phosphatase IA-2 [60-62]. However it has been shown that serum from diabetic mice is not 
sufficient to transfer disease, suggesting that B cells may also contribute via antigen 
presentation rather than simply autoantibody production [63]. B cells also bind and present 
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antigens through cell surface immunoglobulin [64]. B cells constitutively express MHC 
molecules and can present sequestered antigens to CD4 T cells, hence diversifying the immune 
response [65].  T cells in B cell deficient NOD mice have an impaired ability to respond to islet 
antigen indicating the role of B cells in antigen presentation [66]. B cells infiltrating the 
pancreatic islets also produce TNF-α that may contribute to inflammation and recruitment of 
other inflammatory cells [67]. B cell depletion through gene targeting and antibody treatment 
protects from T1D [68, 69]. These studies show that most innate and adaptive immune cell 
types participate in T1D pathogenesis. 
 
1.2.4 T regulatory cells in diabetes 
 
T regulatory cells (Tregs) have been shown to suppress a wide range of immune cells through 
both cell contact dependent and independent mechanisms. Tregs can suppress T effector cells 
via production of ―anti-inflammatory‖ cytokines (IL-10, TGF-, IL-35, galectin-1), or via granzyme 
mediated cytolysis or IL-2 consumption [70]. Tregs can also indirectly block the activation of 
effector T cells by acting on APCs to decrease co-stimulation, maturation or antigen 
presentation of APC through CTLA-4, LAG-3, CD39 and Nrp-1 [70]. Many studies have 
highlighted the importance of T regulatory cells in controlling T1D. CD28 deficient NOD mice 
that lack Tregs, develop diabetes at an accelerated rate [71]. In humans, mutation in the Treg 
transcription factor, Foxp3 (immunodysregulation, polyendocrinopathy, enteropathy, X-linked 
[IPEX] syndrome) can cause T1D [72]. The NOD mouse does not have a decline in the number 
of Foxp3+ CD4 T cells with age in spleen, pancreatic lymph node or the pancreas [73]. Rather, 
NOD autoimmunity is associated with the decline of CD4posCD25pos Treg function both in vitro 
and in vivo [73-76]. Gregori et al. has shown that CD4posCD25pos T cells isolated from 8-week-
old NOD are more suppressive than 16-week-old NOD against 16-week-old T responders in an 
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alloantigen-driven in vitro assay [75]. NOD Tregs also show loss of TGF- surface expression 
with age [35, 76, 77].  Since T regulatory cells can suppress through surface TGF-, the 
reduction in surface TGF-could decrease suppression of pathogenic T cells [78]. Treg defects 
in NOD are associated with relative lack of IL-2 and IL-2R signaling [79, 80]. The impairment of 
Treg function and decreased IL-2 in NOD is linked with an IL-2 SNP (single nucleotide 
polymorphism) in the Idd3 susceptibility locus [19].  
 
Apart from thymus-derived naturally occurring CD4POSCD25POSFoxp3+ Tregs, there are other 
subsets of ―adaptive‖ Tregs (Th2, Th3, Tr1 cells) that are generated in vitro and in vivo from 
CD4posCD25neg T cells. These precursor Foxp3 negative T cells under conditions such as 
specific antigenic stimulation, alter the nature of the APCs or cytokine milieu (IL-10 and TGF-) 
to differentiate into adaptive regulatory T cells [81-83]. Studies show that NOD mice (and not 
C57BL/6 and BALB/C mice) have TGF- dependent CD4posCD25neg FoxP3pos adaptive Tregs 
that arise from peripheral CD4posCD25neg T lymphocytes to control ongoing autoimmunity [84]. 
These CD4posCD25neg adaptive Tregs are also induced during protective anti-CD3 
immunotherapy in NOD mice [84]. In addition NOD mouse also have spontaneously arising IL-
10-dependent Tr1 adaptive Tregs specific for an epitope in an important target antigen, glutamic 
acid decarboxylase (GAD) that can efficiently protect against diabetes development in an 
adoptive transfer study [85]. Therefore both natural and adaptive Tregs contribute towards 
immune tolerance, however their overall effect is not sufficient to prevent T1D in NOD mice. 
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1.3 ENVIRONMENTAL FACTORS IN DIABETES 
 
Studies show a direct link between the composition of the gut microflora and diabetes 
development. Diabetes susceptibility is also linked to gut leakiness that allows trafficking of cells 
into the peritoneal cavity [86]. Since the pancreas, gastrointestinal tract and pancreatic lymph 
node have the same homing molecules, cells that leak into the peritoneum could traffic to the 
pancreatic lymph node [87]. Consequently, the intestinal microenvironment could drive activated 
APC to the pancreatic lymph node. As mentioned above, the initial islet infiltrates are activated 
macrophages and dendritic cells [33]. Consistent with these observations, the abrogation of 
signaling in Toll-like receptors (TLRs) through genetic deletion of MyD88, protects NOD mice 
from diabetes [88]. This suggests that intestinal microflora may trigger breakdown of tolerance 
and initiation of islet infiltration, which is an area of active research.  
 
Autoimmune T cell response also results from cross-reactive immune responses due to 
similarity between infectious and self-antigen epitopes. Such ―molecular mimicry‖ is one of the 
mechanisms responsible for the breakdown of self-tolerance. Viral or bacterial protein epitopes 
may have structural homology with β-cell autoantigens leading to activation of cross-reacting T 
or B cells that then cause destruction of β-cells. Similar epitopes are shared between -cell 
antigens and viruses such as coxsackie virus B4, rotavirus, rubella and CMV [89-92]. Viruses 
are also proposed to modulate the expression of T1D through other mechanisms; direct 
cytolysis of virus infected pancreatic β-cells [93], induction of autoimmune responses to 
altered/sequestered self antigens as a result of increased β-cell antigenicity [94], viral super 
antigen-driven bystander activation of autoreactive T cells [95] and virus-induced imbalance 
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between autoreactive T cells and Tregs [96, 97].  Viral infections can therefore activate 
pathogenic T cells by cross-reactivity and cytokines produced by the innate cells during infection 
can further accelerate diabetes.  
 
 
 
1.4 NOD CONGENICS  
 
1.4.1 NOD genetics and linkage analysis 
 
The initial genome scan of an NOD cross demonstrated disease associated regions called 
―insulin dependent diabetes‖ (Idd) loci that conferred genetic susceptibility or protection from the 
disease [98]. Linkage analysis was used to map the diabetic genes in the NOD mouse. For this, 
microsatellite genetic maps that showed the allelic differences between inbred strains were 
constructed [99, 100]. Backcrossing of (NOD X non-diabetic strain) F1 X NOD was performed 
and typed at each polymorphic locus for recombination events. The number of homozygotes 
and heterozygotes with disease was assessed and a bias different from equal numbers 
represented linkage of that locus with the disease; equal number of homozygotes and 
heterozygotes with disease was observed if there was no linkage of disease at a given marker. 
If linkage was detected in the analysis, new polymorphic markers that surround the original 
microsatellite marker were tested. The next step was to construct congenic mice using these Idd 
loci by introgressing resistant Idd loci (generally from B6 or B10) onto the NOD background to 
make congenic mice. The basic principle is to narrow the disease associated genetic interval 
while retaining the disease prevalence or protection phenotype. The resultant congenic mice 
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with resistant Idd loci showed variable protection from disease;  resistance intervals were further 
reduced through recombination [4]. With smaller intervals, candidate gene investigations 
became possible. This approach has been successful in identifying a series of candidate genes 
in T1D, such as IL-2, CTLA-4, CD30 and CD137 [101-105]. CD137, a key focus of this thesis, is 
the major candidate gene in the Idd9 region (see below). 
 
1.4.2 Limitations in congenic mapping 
 
NOD congenic mapping dissects critical genetic regions associated with T1D. However there 
are limits to congenic interval reduction. The development of smaller congenic interval depends 
upon recombination events near the gene of interest. As recombination events become small, 
larger colonies of mice are required to make congenic mice with even smaller intervals.  This 
creates a practical difficulty in creating such congenic mouse. The reduction of interval is also 
limited by the fact that all recombination events are not random and that there are hot spots for 
recombination [106, 107]. Genetic manipulation in NOD congenics can produce a variety of 
autoimmune syndromes, such as production of anti-nuclear antibodies (ANAs) and anti-Smith 
(anti-Sm) antibodies or autoimmune liver disease [108, 109]. Thus the process of narrowing or 
intermixing Idd loci can alter the disease phenotype. Another drawback of the congenic model is 
that it becomes difficult to determine if the phenotype controlled by the genetic region is 
associated with the disease. For example, NOD.B10 Idd9.3 congenic mice (1.2 Mb B10 region 
in NOD background) have increased protection against diabetes but produce anti-Smith auto-
antibodies, [109] but the production of anti-Smith auto-antibodies is not known to be linked with 
the diabetes protection.  
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1.5 MAPPING Idd9 AND ITS SMALLER INTERVALS 
 
1.5.1 Mapping Idd9 
 
Linkage mapping of the progeny of (NOD X B10.H2g7) F1 X NOD BC1 led to identifying Idd9 on 
chromosome 4 [110]. The increase in diabetes in mice with NOD homozygosity in the Idd9 
region suggested that the NOD alleles for these loci contained diabetes susceptibility genes. 
The first reciprocal backcross study using B10.H2g7 and NOD/Mrk strains showed weak linkage 
of chromosome 4 to diabetes [111]. The second outcross-backcross study was performed 
between the diabetes resistant strain B6.PL-ThyIa/Cy and NOD/Mrk, followed by (B6.PL- 
ThyIa/Cy and NOD/Mrk X)F1 X NOD/Mrk [110]. This cross showed significant linkage of the 
D4Nds16 marker to diabetes, which indicated that Idd9 locus was encoded in the distal region 
of chromosome 4. The Idd9 locus also controlled the frequency of diabetes, but had no effect on 
insulitis or cyclophosphamide-induced diabetes. Linda Wicker et al. next developed a congenic 
strain containing approximately 48 cM of B10 genetic region introgressed on the NOD 
background [104]. Resistance to diabetes confirmed the newly formed NOD.B10 Idd9 congenic 
strain. The islet infiltrating cells from NOD.B10 Idd9 mice primarily expressed IL-4 and CD30 
(encoded within the Idd9 genetic region) whereas NOD islet infiltrating cells expressed IFN- 
and TNF-[104]. In a different study, CD4 T cells from Idd9 mice prevented the loss of CD8 T 
cell tolerance to islet-specific glucose-6-phosphatase protein (IGRP) and indicated the potential 
role of Idd9 regulatory T cells within the CD4 T cell compartment [112].  
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1.5.2 Mapping Idd9 subcongenic strains 
 
The NOD.B10 Idd9 mouse, containing 48 cM of genetic interval (Idd9) from chromosome 4 of 
diabetes-resistant C57BL/10 mice has substantial resistance to diabetes, with 3-7% incidence in 
females [104, 113]. The Wicker group fine-mapped the Idd9 region by deriving two subcongenic 
strains, Idd9R28 and IddR11 from the original NOD.B10 Idd9 strain; both of these strains 
conferred significant protection from diabetes [104]. The Idd9R28 strain offered significantly 
more protection than the IddR11 strain and contained a 35.7 cM Idd9.1 region. The IddR11 
strain was used to develop a second set of subcongenic strains: Idd9R15, Idd9R38, Idd9R35 
and Idd9R73. The Idd9R15 and Idd9R38 strains were significantly protected from diabetes 
similar to NOD.B10 IddR11 strain. Subsequently the diabetes protection of NOD.B10 IddR11 
was identified to be within these two loci; a 5.6 cM Idd9.2 and a 2 cM Idd9.3 loci [104]. Thus the 
mechanism of diabetes protection in Idd9 mice is attributed to three different loci within the 
region; Idd9.1, Idd9.3 and Idd9.3.  
 
 
1.5.3 NOD.B10 Idd9.3 congenic strain 
 
NOD.B10 Idd9.3 congenic mice contain a 1.2 Mb B10 region on chromosome four on the NOD 
genetic background [114]. NOD.B10 Idd9.3 congenic females have at least 50% protection from 
diabetes compared to 20% in NOD females [104]. Unlike NOD, the NOD.B10 Idd9.3 congenic 
mice also have high penetrance of antinuclear and anti-Sm autoantibodies [109]. The Idd9.3 
region has 15 different candidate genes as listed in Table 1.1 [114].  CD137 is one of the 
candidate genes within the Idd9.3 region [104]. 
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Table 1.1 
 
Genes in Idd9.3 region 
 
Genes Description Protein function 
H6pd Hexose-6-
phosphate 
dehydrogenase 
Has H and G form. The H form dehydrogenates other 
hexose-6-phosphates. The G form is specific for 
glucose-6-phosphate [115].  
Gpr157 G protein-coupled 
receptor 157 
Transmembrane receptors that bind to the ligand and 
activate signal transduction pathways leading to cellular 
response [116]. 
Slc2a5 Solute carrier 
family 2, member 5 
Absorption of fructose in the intestine and generation of 
fructose-induced hypertension [117]. 
Slc2a7 Solute carrier 
family 2, member 7 
Intestinal absorption of glucose through diffusion [118]. 
Ca6 Carbonic 
anhydrase 6 
Zinc metalloenzymes that catalyze the reversible 
hydration of carbon dioxide. Found in salivary glands 
and saliva [119]. 
Eno1 Enolase 1 Aids during glycolysis and downregulates the activity of 
c-myc protooncogene [120].  
Rere Arginine-glutamic 
acid dipeptide (RE) 
repeats. 
 Associates with histone deacetylase and functions as 
transcriptional co-repressor during embryonic 
development [121].  
Dnb-5 Deleted in 
neuroblastoma 5  
Localized to membrane to mediate the uptake of 
glucose along the pH gradient. 
Mig-6 Mitogen-inducible 
gene 6 
Induces transcriptional activation of NF-kB gene. 
Overexpression leads to activation of SAPKs/JNKs 
 15 
pathways [122].  
Park7 Parkinson protein 7 Positive regulator of androgen receptor-dependent 
transcription. functions as a sensor for oxidative stress, 
and it protects neurons against oxidative stress and cell 
death [123].  
CD137  TNF receptor 
superfamily 9  
(Tnfrsf9) 
Co-stimulatory molecule expressed on activated CD4 
and CD8 T cells. Constitutively expressed by Tregs and 
DC. 
Uts2 Urotensin 2 An active cyclic heptapeptide that acts as a 
vasoconstrictor and expressed in the brain [124].  
Per3 Period circadian 
protein homolog 3 
Expressed in in a circadian pattern in suprachiasmatic 
nucleus of brain cells [125].  
Vamp3 Vescicle-
associated 
membrane protein 
3 
Localized in the secretory granules in pancreatic beta 
cells for insulin secretion and glucose uptake [126].  
Camta1 Calmodulin binding 
transcription 
activator-1 
Associated with memory performance [127].  
 
Table 1.1. There are fifteen candidate genes within Idd9.3 loci.  
The table shows the list of candidate genes within the Idd9.3 region and the function of the protein 
encoded by the gene. CD137 is one of the candidate genes within the Idd9.3 congenic interval [114]. 
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1.6 CD137 IN DIABTES 
 
1.6.1 CD137 (4-1BB) costimulatory molecule 
 
CD137  (also known as 4-1BB in mice and ―induced by lymphocyte activation‖ [ILA] in humans)  
is an inducible type 1 transmembrane protein of the TNF receptor superfamily that functions as 
a co-stimulatory molecule [10, 128]. CD137 is a glycoprotein expressed as a 30 kDa monomer 
or a 55 kDa homodimer on T cells [129]. It is upregulated in T cells 48 hours after in vitro 
activation [130]. CD137 expression kinetics are similar on CD4 and CD8 T cells [131]. CD137 is 
also expressed on B cells [132], natural killer cells [133] and in both splenic and bone marrow 
derived dendritic cells [134-136]. We and others have confirmed that CD137 is constitutively 
expressed by a subset of CD4posCD25pos T regulatory cells [136-140]. 
 
1.6.2 CD137 polymorphism 
 
Sequencing has identified three CD137 sequence variants between NOD and B10 alleles; a 
valine to alanine at position 24, a leucine to proline at position 211 and an alanine insertion 
between amino acids 174 and 175 in NOD as shown by Figure 1.1 [104]. 
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Figure1.1 
 
 
Figure1.1. Polymorphism in the Idd9.3 region in NOD mice.  
CD137 has three sequence variants between NOD and B10. The NOD Cd137 allele has the following 
SNPs: i) a valine to alanine at position 24 in the extracellular domain, ii) a leucine to proline at position 
211 in the extracellular domain and iii) an alanine insertion between amino acids 174 and 175 in the 
cytoplasmic domain  [104]. 
 
Furthermore, the Idd9.3 interval has been resequenced in the NOD and B6 strains to confirm 
these polymorphisms and assess other sequence variations throughout the 1.2 Mb Idd9.3 
interval, as shown in Figure 1.2. 
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Figure1.2 
 
 
Figure1.2. Idd9.3 gene content and sequence polymorphisms.  
(a) The gene content of the Idd9.3 interval is displayed in the T1DBase Gene Span track.  The NOD tile 
path track shows the ten NOD/Tac BAC clones forming a minimal tile path spanning the Idd9.3 region.  
The NOD BAC SNP graph displays the density of SNPs identified by comparing the NOD/Tac BAC clone 
sequence to the B6 reference (SNPs per 10 kb).  The NOD/ShiLtJ strain has been next generation 
sequenced (NGS) by the Wellcome Trust Sanger Institute and the NOD NGS SNP graph displays the 
density of SNPs identified by comparing the NOD/ShiLtJ NGS sequence to the B6 reference.  (b) Zoomed 
in view of Tnfrsf9.  The NOD variation track represents the location of polymorphic NOD/B6 SNPs across 
Tnfrsf9, identified by comparing the NOD/Tac BAC clones to B6; black, red, blue, and green lines 
represent G, T, C, and A NOD alleles, respectively.  The NGS NOD track shows the NOD/B6 SNPs 
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identified by comparing the NOD/ShiLtJ NGS sequence to the B6. Note that where multiple SNPs are 
located close together the lines in the B6/NOD SNPs tracks may represent more than one SNP [141]. 
 
Previously it has been shown that NOD and NOD.B10 Idd9.3 congenic mice expressed CD137 
similarly upon anti-CD3 activation in vitro [104]. However B10 allele for CD137 can provide 
greater signals for proliferation and IL-2 production compared to the NOD allele, when 
stimulated with CD137L [114]. Therefore the allelic polymorphism in CD137 affects the 
downstream signaling or cytokine production in T cells. However it is difficult to explain how the 
decreased signaling of the NOD CD137 allele could result in increased incidence of diabetes in 
NOD mice, and this is a major theme we have further explored in this thesis by focusing on the 
effects of the NOD and B6 alleles on Treg function.   
 
1.6.3 CD137 stimulation of T cells 
 
CD137 stimulation signals through TNF-receptor-associated factor 2 (TRAF2) which activates 
NF-κB and apoptosis signal-regulating kinase-1 (ASK-1), that ultimately regulate genes for 
cytokine production, effector function and survival [10]. Stimulation of CD137 by agonistic anti-
CD137 antibody, soluble CD137L or cell lines expressing CD137L in the presence of anti-TCR 
antibodies have shown T cell expansion, cytokine production and upregulation of anti-apoptotic 
genes that prevent activated-induced cell death [142, 143]. In vitro CD137 stimulation induces 
cell cycle progression, cytokine production and prevents activation-induced cell death by 
inducing anti-apoptotic genes [144]. CD137 signaling in T cells promotes survival and inhibition 
of apoptosis by induction of the anti-apoptotic molecule Bcl-xl [145, 146]. Viability studies of 
CD137 stimulated T cells have shown prevention of activation induced cell death (AICD) by 
repression of DNA fragmentation [147]. T cells with the B10 Cd137 allele have enhanced 
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proliferation and IL-2 production compared to NOD T cells when stimulated with CD137L [114]. 
These studies indicate that CD137 stimulation on T cells results in proliferation, IL-2 production, 
reduction of AICD and expression of anti-apoptotic molecules, and that variation in NOD and 
B10 cd137 allele affects these outcomes. 
 
1.6.4 Agonist anti-CD137 treatment 
 
Agonistic anti-CD137 (3H3) antibody has been shown to reduce the incidence and severity of 
different autoimmune diseases such as experimental autoimmune encephalomyelitis [148], 
collagen induced arthritis [149] and experimental allergic conjunctivitis in mice [150]. We have 
shown that anti-CD137 treatment prevents diabetes in NOD mice and is associated with IL-10 
and IL-4 cytokine production and increasing numbers of CD4posCD25pos T cells in vivo [137]. 
Since mouse CD137 is a dimer, crosslinking with bivalent high-affinity anti-CD137 antibody 
provides a supra-physiological stimulus that can form multimers on the surface [129]. The 
multimerized CD137 then recruits Traf2 and signals through nuclear factor NF-B and activator 
protein 1 (AP-1) and thereby can modify many genes at the transcriptional level. Anti-CD137 
antibody, therefore, probably acts by enhancing CD137 signaling which, as we noted above, is 
decreased in the NOD allele. However this does not address which cell type is affected by 
enhanced CD137 signaling. 
 
1.6.5 CD137 and human diabetes 
 
Initial studies of CD137 did not find linkage with human T1D [151]. However, another recent 
study has found that the Cd137 gene is differentially regulated in healthy first degree relatives of 
patients with type 1 diabetes compared to healthy controls [152]. Another study has shown that 
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an ubiquitin-editing enzyme TNFAIP3 (A20) was linked to human diabetes [153]. One function 
of A20 is to downregulate TRAF2 by transporting it to the lysosomal compartment, thus 
decreasing Traf2-mediated signaling [154]. Since CD137 signals via TRAF2, A20 might 
indirectly affect CD137 signaling [10]. A20 is also an important anti-apoptotic gene expressed by 
 cells in the pancreatic islets [155, 156] and loss of A20 expression renders  cells susceptible 
to apoptotic death [157]. However further studies need to be performed to understand the 
mechanistic connection between A20 and CD137 signaling in diabetes. 
 
1.6.6 CD137 and T regulatory cells 
 
We have shown that a subset of NOD CD4posCD25pos T regulatory cells constitutively expresses 
CD137 (see chapter two below). Marson et al. showed that Cd137 is one of a small set of genes 
directly upregulated by Foxp3 [158]. The Mathis group showed that Tregs isolated specifically 
from NOD pancreatic islets upregulated Cd137 (Tnfrsf9) [159]. CD137L-Fc fusion protein was 
used to show that CD137 costimulation increases proliferation of Tregs both in vitro and in vivo 
[138]. Another in vitro study has shown that streptavidin-bound CD137L (CD137L-strep) causes 
proliferation of CD4posCD25pos T cells in the presence of IL-2 [160]. Furthermore, this study also 
shows that proliferating CD4posCD25pos Tregs express high levels of transcription factor Foxp3, 
confirming them as true Tregs. More importantly, T regulatory cells pre-treated with CD137L-Fc 
or CD137L-strep remained functionally suppressive in vitro [138, 160]. Therefore CD137 
costimulation of Tregs may be important for proliferation both in vitro and in vivo. In particular, 
since a subset of Tregs constitutively express CD137 (unlike CD4 and CD8 T cells), they are 
natural targets for therapeutic effects of the anti-CD137 antibody, which we will explore further 
below. 
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1.6.7 Soluble form of CD137  
 
PCR on 768 bp of CD137 coding sequence produced two PCR products; a full length band and 
another, 135 bp shorter, band [161]. Alternate splicing produces two isoforms of CD137: full 
length CD137 that is expressed on the surface and soluble CD137 in which transmembrane 
exon 8 is spliced out as shown in Figure 1.3 [161].  
 
Figure1.3 
 
Figure1.3. A schematic of membrane bound and soluble CD137.  
The membrane bound CD137 contains the intracellular domain, the transmembrane domain (TM) and the 
extracellular domain. The soluble form of CD137 has exon 8 spliced out, which encodes the transmembrane domain 
[161].  
 
The production of soluble CD137 has been associated with decreased proliferation and 
increased cell death and DNA fragmentation in human PBMC and mouse splenocytes [162, 
163]. Soluble CD137 is increased in autoimmune diseases such as rheumatoid arthritis, multiple 
sclerosis and systemic lupus [162, 164] and, due to its anti-proliferative effects, its production 
has been hypothesized as a negative feedback mechanism to control autoimmunity or excess 
immune response [165]. However further studies are required to understand the function of 
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soluble CD137 in vitro and in vivo.  
 
 
1.7 CD137L and its signaling 
 
1.7.1 CD137 ligand (CD137L) 
 
CD137 ligand (CD137L) is a type II transmembrane glycoprotein that contains TNF homology 
domains [166]. In vivo, the CD137 ligand is expressed on monocytes, DCs and B cells [166]. 
CD137 ligand is also expressed by activated CD8 T cell and T cell-lines [167, 168]. However 
CD137L expression must be tightly regulated, as its expression is mostly detectable via PCR 
detection of mRNA levels during chronic and inflammatory conditions [169, 170]. Similarly 
several studies have reported very low expression of CD137L protein on CD4 T cells [134, 169].  
 
1.7.2 CD137L signaling on T cells. 
 
As with other members of the TNF and TNFR family, CD137L mediates reverse signaling. 
CD137L signaling is important in the maintenance of CD8 T cells after viral clearance [169, 
171]. The major effect of CD137L on CD8 T cell recall response is due to maintenance of T cell 
numbers at the end of the primary response and expansion of memory T cells during secondary 
response [172, 173].  Conversely, expression of CD137L on CD4 T cells has a minor effect on 
primary response and no effect in secondary response [174]. Notably, CD137L signaling may 
also be important for Treg survival as CD137 ligand knockout mice showed deceased frequency 
of Foxp3 expressing CD4posCD25pos Tregs [175]. However this can also be due the lack of 
 24 
CD137 stimulation. Soluble CD137-induced CD137L signaling reduced T cell proliferation and 
increased cell death [162, 176]. These studies indicate the variation and complexity of CD137L 
signaling in various cell types and that further studies are required to understand its role. 
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1.8 OUTLINE OF THE THESIS 
 
Previous genetic studies have established that NOD.B10 Idd9.3 mice are protected from 
diabetes compared to NOD mice and CD137 is the major candidate gene within the Idd9.3 
interval. Agonistic anti-CD137 treated mice are protected from different autoimmune diseases. 
Based on these observations, we hypothesized that anti-CD137 treatment might have a 
protective effect in NOD. Our study, discussed in Chapter two, showed that anti-CD137 
treatment significantly reduced the incidence of diabetes in NOD mice. Anti-CD137 antibody 
specifically bound to a subset of CD4posCD25pos T cells and increased the frequency of these 
Foxp3 expressing regulatory T cells. The importance of CD137 expressing CD4posCD25pos 
Tregs became clear and hence we undertook a comprehensive study of the phenotypic and 
functional differences between CD4posCD25posCD137neg and CD4posCD25posCD137pos Treg 
subsets. These two Treg subsets produced equal amounts of Foxp3 but CD137pos Tregs 
expressed high levels of CD69, IL-10 and ICOS. In vitro functional studies showed that 
CD137pos Tregs are more suppressive than CD137neg Tregs in contact-dependent and contact-
independent system. We further used blocking antibodies against IL-10 or TGF- or both to 
show that these factors did not play a significant role in suppressive differences between the 
two Treg subsets. 
 
Next we tried to understand the role of the CD137 polymorphism in NOD and NOD.B10 Idd9.3 
congenic mice. Previous studies showed that the CD137 allelic differences result in increased 
proliferation and IL-2 production by T cells with B10 CD137 versus NOD CD137. However it is 
not clear how the hypo-functional allele results in increased incidence of diabetes in NOD 
compared to NOD.B10 Idd9.3 mice. Since CD137 expressing CD4posCD25pos Tregs are 
functionally superior, we hypothesized that the increased incidence of diabetes in NOD 
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compared to NOD.B10 Idd9.3 mice is due to the differential effect of NOD and B10 CD137 
alleles on T regulatory cells. In particular, CD137 allelic variation on Tregs could have an effect 
on the protein expression and subsequent downstream signaling through CD137, which in T 
cells is required for proliferation and survival signal. Furthermore, since CD137 signaling affects 
effector function, we tested if NOD and B10 CD137 allelic variation would alter suppressive 
function of Tregs. Our studies in Chapter three show that the total number and the percentage 
of CD4posCD25posCD137pos T cells significantly declines with age in NOD spleen but not in 
NOD.B10 Idd9.3 spleen, suggesting that the B10 allele acted to increase accumulation of 
CD137 expressing Tregs. To understand the increased accumulation of B10 CD137 Tregs with 
age, we studied proliferation, survival and cell death between CD137pos Tregs from the two 
strains. We found that CD137pos Tregs proliferate more than CD137neg Tregs, but there was no 
difference between the two strains. Again, there was no difference in pro-survival molecules, 
Bcl-xl and Bcl2 protein levels and in vitro cell death between NOD and NOD.B10 Idd9.3 
CD137pos Tregs.  
 
In chapter 3, we also show that CD137pos, but not CD137neg Tregs, expressed higher levels of 
soluble CD137 mRNA ex vivo; in addition aged NOD.B10 Idd9.3 congenic mice had significantly 
higher levels of serum soluble CD137 than NOD mice. This is consistent with the increased 
frequency of CD137pos in aged NOD.B10 Idd9.3 mice than NOD mice. Therefore CD137 
polymorphism in NOD and NOD.B10 Idd9.3 congenic results in accumulation of suppressive 
CD137pos Tregs and increased soluble CD137 in NOD.B10 Idd9.3 mice. 
 
In Chapter four, we show studies on the mechanism of anti-CD137 mediated diabetes 
protection that integrate our prior findings on soluble CD137 and CD137pos Tregs. We 
hypothesized that anti-CD137 antibody treatment mediates protection at least partially through 
soluble CD137 and that soluble CD137 can prevent diabetes in NOD mice. First, we used CD25 
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blocking antibodies to show the importance of CD4posCD25pos in anti-CD137 mediated diabetes 
protection. We showed that anti-CD137 treatment specifically upregulates TRAF2 downstream 
signaling molecules in CD137pos Tregs, but not in CD137neg Tregs. The CD137pos Tregs from 
treated mice produce significantly higher levels of soluble CD137 in vitro compared to untreated 
mice; in addition the treated NOD also produce high levels of serum soluble CD137. The 
blockade of CD137L abrogates the CD137pos Treg mediated suppression indicating that Treg-
produced soluble CD137 could suppress T cells. CD137-Fc fusion proteins also suppress CD4 
T cell proliferation in culture suggesting a direct role of soluble CD137 suppression.  In order to 
develop a more physiological form of soluble CD137, we produced recombinant soluble CD137 
by transducing cell lines with lentiviral vectors containing soluble CD137 genome. The soluble 
CD137 thus obtained was purified and structurally characterized. In vitro the soluble CD137 is 
suppressive to CD4 T cells and further, also reduced the incidence of diabetes in NOD after 
treatment.  
 
In summary, this thesis is focused on CD137 which is genetically associated with increased 
protection from diabetes in NOD.B10 Idd9.3 mice. We have examined the role of CD137 in 
Tregs in an attempt to understand the genetic cause of disease protection in NOD.B10 Idd9.3 
congenic mice.  The maintenance and long-term accumulation of peripheral B10 CD137pos 
Tregs may play a critical role in disease protection.  We generated novel data showing that 
CD137pos Tregs are a major cellular source of soluble CD137, and that soluble CD137 directly 
suppresses CD4pos T effector function in an APC independent manner. Systemic administration 
of soluble CD137 is effective in preventing diabetes in NOD mice. Overall our studies suggest 
that CD137pos Tregs, and their production of soluble CD137, may play important homeostatic 
roles in immune regulation and could be used therapeutically to down regulate inflammation in 
autoimmune disease. 
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2.0   CD137 MODULATES PROTECTIVE CD4POSCD25POS T CELLS 
AND PATHOGENIC CD4 T CELLS IN NOD TYPE 1 DIABETES  
 
Some portions of chapter 2 have been adapted from Irie J, Wu Y, Kachapati K, Mittler RS, 
Ridgway WM. 2007. Diabetes. 56:186-96 and some portions adapted from Kachapati K, Adams 
DE, Wu Y, Steward CA, Rainbow DB, Wicker LS, Mittler RS, Ridgway WM. J Immunol. 2012. 
189:5001-15 while the remaining represents unpublished data. The use of data from published 
articles adheres to the copyright guidelines stated by Journal of Immunology and Diabetes. The 
initial antibody treatment, adoptive transfer study and in vitro results were generated by 
Junichiro Irie and Yuehong Wu. Kritika re-tested some earlier in vitro results and performed all 
studies with the T regulatory cell subsets. 
 
 
2.1 INTRODUCTION 
 
The NOD mouse spontaneous develops insulitis (infiltration of the pancreatic islet cells) at 3 
weeks of age and type 1 diabetes around 20 weeks [4]. The major histocompatibility complex 
(MHC) class II molecule, I-Ag7 is necessary but not insufficient to mediate diabetes when placed 
on a non-autoimmune non-MHC background, suggesting that the disease is a complex 
multigenetic process [177]. NOD mice have multiple recessive loci, known as ―insulin-dependent 
diabetes‖ (Idd) loci, which increase the susceptibility or resistance to diabetes [98]. There are at 
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least 20 known Idd loci [4]. B10 Idd9 is one protective locus, which is further divided into Idd9.1, 
Idd9.2 and Idd9.3 [104]. Idd9.3 has been mapped to a 1.2-mb interval with 15 genes, including 
Cd137 [104, 114]. The NOD allele for CD137 mediates decreased T cell signaling and 
interleukin (IL)-2 production when stimulated with CD137L compared with the B10 allele [114]. 
CD137 is an costimulatory molecule of the TNF receptor superfamily, that is upregulated on T 
cells after in vitro activation [10]. The CD137 ligand is expressed on activated antigen-
presenting cells (APCs), especially at the sites of inflammation in vivo [134, 170]. Stimulation 
through CD137 augments T cell proliferation and functions as a T cell costimulatory molecule in 
the absence of CD28 [130, 178]. In CD4 and CD8 T cells, CD137 costimulation causes 
expansion and survival [147, 179]. T cells from CD137−/− or CD137L−/− mice have decreased 
memory responses to antigen recall; CD137L−/− mice adoptively transferred with antigen-
specific CD8 TCR TG cells showed decreased late-stage T cell survival, which suggests a 
costimulatory role of CD137 later in T cell activation and in the preservation of memory T-cells 
[174]. Anti-CD137 blocked development of collagen arthritis, accompanied by suppression of 
anti-collagen antibodies and decreased CD4+ recall responses to type-2 collagen [149, 180]. 
Anti-CD137 antibody treatment reverses or reduces the incidence of autoimmune diseases such 
as murine lupus and experimental autoimmune encephalomyelitis (EAE) [148, 181]. Overall, 
these results demonstrate a powerful effect of CD137 on T cells and on the progression of 
autoimmune disease states. CD4posCD25pos T regulatory cells are known to be essential in 
controlling autoimmunity in human and animal models [182]. In NOD diabetes, CD4posCD25pos T 
regulatory cells have been shown to have quantitative and qualitative deficiencies, and transfer 
of these cells suppressed the onset of diabetes [71, 139, 183]. Two studies have shown that 
CD137 was upregulated in CD4POSCD25POS Tregs [138, 139], although conflicting results on the 
role of CD137 in Tregs have also been reported [140].  
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In this study, we demonstrate that treatment of NOD mice with anti-CD137 antibody prevents 
autoimmune diabetes but did not eliminate pancreatic insulitis. Transfer studies show that 
pathogenic cells persisted despite protection from diabetes. Unfractionated anti-CD137 treated 
CD4 T cell populations reduce adoptive transfer of diabetes into NOD-scid mice, compared to 
untreated CD4 T cells. Anti-CD137 significantly increases the percent of CD4posCD25pos T cells 
in treated mice. Transfer of anti-CD137 treated CD4posCD25pos T cells completely prevents 
diabetes in NOD-scid recipients, whereas the CD4posCD25neg T cells offer no significant 
protection.  CD4posCD25posCD137neg and CD4posCD25posCD137pos T cells express similar levels 
of Foxp3, TGF- and CTLA-4 but IL-10 and ICOS expression is higher in 
CD4posCD25posCD137pos T cells. In vitro suppression assays show that CD137pos Tregs are 
functionally superior to CD137neg Tregs but blockade of IL-10, TGF- or both do not alter the 
suppressive function of these Treg subsets. Our results show that CD137 expressing Tregs are 
functionally superior and play a significant role in diabetes protection. 
 
 
 
2.2 METHODS 
 
2.2.1 Mice and reagents:  
 
NOD and NOD-scid colonies were maintained under specific pathogen-free conditions in the 
animal facility at University of Pittsburgh School of Medicine. Mice were handled in accordance 
with the institutional animal care guidelines. Urinary glucose analysis was performed using Tes-
tape (Shionogi, Osaka, Japan) once a week. Plasma glucose levels were determined when 
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glycosuria was detected, and mice with a blood glucose level above 300 mg/dl were considered 
diabetic. Antibodies against mouse CD3, CD4, CD8, CD25, CD28, CD49b, and T-cell β-receptor 
were purchased from BD Bioscience. Anti-Foxp3 antibody was purchased from eBioscience. 
Anti-mouse CD137 antibody (3H3) was produced by R.S. Mittler as previously described [181].  
2.2.2 Histology:  
 
Pancreata were fixed in 10% formaldehyde and embedded in paraffin. Thin sections at six 
levels, 150 μm apart, were cut for staining with hematoxylin-eosin to evaluate islet-infiltrating 
cells by light microscopy. At least 35 islets from each recipient mouse were observed and 
scored using the following criteria: grade 0, islets free of insulitis; grade 1, peri-insulitis; grade 2, 
intra-insulitis with mononuclear cell infiltration of <50% of the area of each islet; and grade 3, 
intra-insulitis with mononuclear cell infiltration of >50% of the area of each islet.  
2.2.3 Cell purification and culture:  
 
CD4pos, CD4posCD25pos, CD4posDX5neg, or CD8pos T cells were purified using magnetic beads 
(Miltenyi Biotec, Auburn, CA). The cells were >90% pure when tested by Flow cytometry. 
Purified CD4 populations were sorted using flow cytometry. CD4+ cells (1 × 106) in 2 ml culture 
medium were transferred to 24-well anti-CD3 antibody precoated plates with or without soluble 
anti-CD28 antibody (1 μg/ml). The cells were cultured for 72 h at 37°C in a humidified 5% CO2 
incubator, and supernatant collected.  
2.2.4 Suppression Assay:  
 
For Treg suppression, 50,000 responder CD4 T cells or CD4posCD25pos cells or both were plated 
in 96-well plates with soluble anti-CD3 antibodies and irradiated splenocytes as APCs. For the 
Treg subset suppression assay 50,000 CD4posCD25negCD137neg T cells were cultured in U-
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bottom 96 well plates with 1ug/well soluble anti-CD3, 50,000 irradiated splenocytes (1500 rads) 
and varying numbers of CD4posCD25posCD137neg or CD4posCD25posCD137pos Tregs. All cells 
were cultured and pulsed with 1 µCi [3H] thymidine on Day 3, 16 hours before harvest. On Day 
4, thymidine incorporation was assessed using a beta scintillation counter. 
 
2.2.5 Treg Transwell Suppression Assay:  
 
100,000 sorted CD4posCD25negCD137neg T cells were cultured with 100,000 irradiated 
splenocytes (1500 rads) and 1.25ug/ml soluble anti-CD3 in the bottom wells of a 96 well 
transwell plate (Corning). 25,000 or 50,000 CD4posCD25posCD137neg or CD4posCD25posCD137pos 
Tregs were cultured in the top wells with 100,000 irradiated (1500 rads) splenocytes and 
1.25ug/ml soluble anti-CD3. In some assays the sorted CD4posCD25posCD137neg or 
CD4posCD25posCD137pos Tregs were also cultured in the bottom of the transwell along with the 
CD4posCD25negCD137neg T effector cells (with no Tregs in the top transwell) to directly compare 
contact dependent and independent suppression by the same sorted cells. The cells were 
cultured at 37°C in 5% CO2 and were pulsed with 1 µCi [3H] thymidine on Day 3. The cells in 
the bottom wells were harvested and counted using a beta scintillation counter.  
2.2.6 Flow cytometry:  
 
Cells were incubated with Fc blocker (Pharmingen) and stained with labeled antibodies for 25 
min at 4°C. Samples were analyzed on a FACS Caliber (Becton Dickinson, Miami, FL). 
Intracellular cytokine staining of Foxp3 was performed according to the manufacturer‘s 
instructions. For FACS analysis, cells were stained with CD4-APC, CD25-FITC and stained for 
CD137 using IgG2a anti-CD137 or IgG2a isotype, then anti- IgG2a biotin and strepavidin-APC. 
For surface expression of CTLA-4 and ICOS, CD4 cells were purified from whole spleen using 
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CD4 magnetic beads (Miltenyl Biotech, California). The CD4 T cells were then stained with 
CD25-FITC, anti-CD137/APC (as above), and CTLA-4-PE or ICOS-PE (or their matched isotype 
control) and analyzed on a Facs Caliber (BD Biosciences). For CD69 and CD62L staining, 
splenocytes from female NOD mice were stained with CD4-APC, CD25-Percp-Cy5.5, CD137-
PE, CD69-FITC and CD62L-APC-Cy7 and analyzed on FACS Cantos (BD Biosciences). All 
Facs data was analyzed using FlowJo (Treestar, Oregan). 
2.2.7 RT-PCR:  
 
CD4 T cells were extracted from splenocytes using CD4 magnetic beads (Miltenyl Biotech, 
California). The CD4 T cells were blocked with 2.4G2 and stained with CD4-APC, CD25-FITC, 
and anti-CD137-APC as above. The cells were sorted using a BD Facs Aria machine (BD 
bioscience) into CD4posCD25negCD137neg, CD4posCD25posCD137neg and CD4posCD25posCD137pos 
cell subsets, RNA was extracted from the sorted cells using an RNeasy mini kit (Qiagen) and 
converted into cDNA (Promega Reverse Transcription System). Quantitative Real Time 
Polymerase Chain Reaction (RT-PCR) was performed on the cDNA using primers for Gadph or 
B2m, Foxp3, Ctla4, Tgf-, Girtr and Icos using a StepOnePlus Real-Time PCR system (Applied 
Biosystems). The CT values of the gene of interest were subtracted from the CT of the 
housekeeping gene (Gadph or B2m) and the data graphed using GraphPad Prism 5 (Version 
5.02).  
2.2.8 ELISA:  
 
Cytokines (IFN-γ, IL-4, and IL-10) were measured by enzyme-linked immunosorbent assay 
(ELISA) as previously described [184]. Briefly, flat-bottom 96-well plates were coated with anti–
IFN-γ, anti–IL-4, or anti–IL-10 antibodies (Pharmingen), and supernatants were added. After 
incubation, biotinylated anti-cytokine antibodies and then europium-avidin solution (Perkin 
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Elmer, Turku, Finland) was added. After adding enhancement solution (Perkin Elmer), plates 
were measured with an ELISA reader (Perkin Elmer). Results are presented as means ± SE. 
Differences between the two groups were analyzed using Mann-Whitney U test for 
nonparametric unpaired observations.  
2.2.9 Adoptive transfer:  
 
Log-rank tests were used to compare the incidence of diabetes between two groups using JMP 
IN software (SAS Institute) and Graph-pad (Graph-pad Software).  
 
 
 
2.3 RESULTS 
 
2.3.1 Anti-CD137 prevents diabetes but not insulitis. 
First we tested the effect of agonist anti-CD137 on the course of type 1 diabetes in NOD mice 
[104] by treating 6-week-old female NOD mice with a total of three 200-μg doses of anti-CD137 
antibody (clone 3H3) administered over a 9-week interval every 3rd week. Control mice 
received PBS alone. Mice were tested for glycosuria every week. The administration of anti-
CD137 antibody significantly suppressed type 1 diabetes in NOD mice (Figure 2.1a; P = 
0.0005).  
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Figure 2.1 
 
Figure 2.1. Anti-CD137 antibody prevents type 1 diabetes in NOD mice but not insulitis. 
(a) Female NOD mice aged 42–44 days were treated three times with 200 μg anti-CD137 antibody (○; n = 
16) or 200 μg PBS (•; n = 16) (see arrows). The onset of diabetes was detected by checking for 
glucosuria every week and confirmed when the blood glucose levels were >300 mg/dl. *P = 0.0005 vs. 
control by log-rank test. (b) The pancreases of anti-CD137–treated, diabetes-free female NOD mice aged 
207–254 days were studied by hematoxylin-eosin staining. One representative of eight mice. (c) Female 
NOD mice aged 46–55 days were treated twice with 200 μg anti-CD137 antibody (n = 8) or 200 μg PBS 
(n = 6) and scored for insulitis 1 week after the second injection. (d) Splenocytes were harvested from 
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anti-CD137–treated NOD mice aged over 200 days and transferred into a total of nine NOD-scid mice 
(n=3).  
 
NOD.B10 Idd9 mice that have decreased diabetes incidence show no reduction in insulitis 
[104]. Consistent with this report, the histology of the pancreas showed that anti-CD137 did not 
suppress pancreatic islet infiltration (―insulitis‖) in mice protected from diabetes (Figure 2.1b). 
Next we scored pancreata for insulitis in anti-CD137 antibody treated or PBS treated mice. The 
insulitis score between treated and control NOD mice showed no difference (Figure 2.1c). 
Therefore anti-CD137 treatment prevents type 1 diabetes but not by preventing insulitis. To test 
if the anti-CD137 treatment directly or indirectly altered or regulated the pathogenic effectors, 
we transferred 20 × 106 splenocytes from anti-CD137 treated non-diabetic NOD mice, aged 
over 200 days, into NOD-scid recipients. Although the donor mice were protected from diabetes, 
the NOD-scid recipients developed diabetes, indicating that the donors retained pathogenic T 
cells that were regulated in the donor mice (Figure 2.1d). The transfer of splenocytes into NOD-
scid mice would also cause homeostatic expansion of autoreactive cells in the lymphopenic 
environment [185], which might overwhelm the remaining regulatory effect. These results 
showed that pathogenic T-cells were not destroyed or inactivated in anti-CD137–treated NOD 
mice. 
  
2.3.2 CD4 T cells from anti-CD137 treated mice prevent adoptive transfer of diabetes.  
Next we tested if unfractionated CD4 T cells from recently treated mice would ameliorate 
disease in a NOD-scid transfer model. To test this, we transferred CD4 T cells from anti-CD137 
or PBS treated pre-diabetic NOD mice along with diabetic NOD CD8 into NOD-scid recipients. 
As a control we transferred diabetic NOD CD4 with diabetic NOD CD8 into NOD-scid recipients. 
The anti-CD137 treated CD4 T cells significantly reduced incidence of diabetes compared to 
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CD4 cells from the PBS-treated age-matched controls (Figure 2.2; P = 0.0016). The diabetic 
CD4 and CD8 caused a rapid onset of diabetes in the recipient mice (Figure 2.2). Therefore 
CD4 T cells from NOD mice recently treated with anti-CD137 counteract the disease process 
even in the NOD-scid transfer model. Notably, the protective effect of anti-CD137 antibody in 
the NOD-scid transfer model was less than in normal NOD mice (Figure 2.1a). This is likely due 
to rapid homeostatic effector expansion in NOD-scid mice. 
Figure 2.2 
 
Figure 2.2. CD4 T cells from anti-CD137 treated mice prevent diabetes in NOD-scid mice.  
Female NOD-scid mice received (0.5–2) × 10
6
 diabetic CD8 T cells with 2 × 10
6
 CD4
 
T cells from pre-
diabetic female NOD mice (74 days old), either treated with anti-CD137 or PBS as above (see transfer 
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0.0016 by log-rank test. A group receiving CD4
 
and CD8
 
T cells from diabetic NOD donors is shown for 
comparison of diabetes onset between diabetic and pre-diabetic donors.  
 
We also tested the protective role of CD8 T cells in a similar NOD-scid transfer model where we 
transferred diabetic CD4 T cells with CD8 T cells from either anti-CD137 treated or PBS treated 
NOD mice into NOD-scid recipients. The CD8 T cells from treated NOD mice showed no 
protection from diabetes, indicating that these cells are unlikely to participate in anti-CD137–
induced diabetes protection (data not shown). Our results matched a previous study that 
showed that anti-CD137 mediated reversal of systemic lupus erythematosus (SLE) was 
independent of CD8 T cells [181]. Our results confirmed that anti-CD137 mediated protection is 
within the CD4 T cell population. 
 
2.3.3 Anti-CD137 treatment alters the cytokine phenotype of CD4 T cells. 
The CD4 T cell subset was clearly important in anti-CD137 antibody mediated diabetes 
protection. Next we tested the cytokine profile of the CD4 T cells from anti-CD137 treated 
versus untreated control. The CD4 T cells from anti-CD137 treated mice produced significantly 
more IL-4 and IL-10 and less IFN-γ than CD4 T cells from untreated mice (Figure 2.3).  
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Figure 2.3 
 
Figure 2.3. Anti-CD137 treatment increases IL-4 and IL-10 production and the fraction of 
CD4posCD25pos T cells. 
Female NOD mice aged 49–55 days were treated with 200 μg anti-CD137 antibody (n = 7) or 200 μg 
PBS (n = 5) every 3 weeks and studied 1 week after the second CD137 treatment. CD4 T cells were 
purified by magnetic beads and stimulated with plate-bound anti-CD3 antibody for 3 days. The 
supernatants were collected and IFN-γ (i), IL-4 (ii), and IL-10 (iii) concentrations were measured by 
ELISA. The europium counts for each sample are shown.  P=0.0074; P=0.0074; and P=0.04 by Mann-
Whitney U test. (b) Female NOD mice 5–8 weeks of age were treated with 200 μg anti-CD137 antibodies 
twice at 3-week intervals, and splenocytes were tested for the ratio of number of CD4
pos
CD25
pos
 T cells to 
CD4 T cells, one week after the second treatment.   
 
Next, we asked to what extent the change in cytokine production in the CD4 population was due 
to Dx5+ cells. CD4+Dx5+ cells produced significantly high levels of IL-4 and IL-10 after 
treatment but these cells did not protect NOD-scid mice in an adoptive transfer model [137]. The 
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transfer of type 1 diabetes from splenocytes of anti-CD137–treated non-diabetic mice and the 
protective capability of anti-CD137–treated CD4 subsets indicated that anti-CD137 treatment 
did not destroy/inactivate pathogenic CD4 T cells but acted on regulatory cells. It has been well 
established that CD4+CD25+ T regulatory cells can modulate the development of type 1 
diabetes in the presence of pathogenic T-cells. CD4posCD25pos T regulatory cells are known to 
modulate the development of type 1 diabetes in the presence of pathogenic T cells. Quantitative 
and qualitative defects of CD4posCD25pos Treg cells have been reported in NOD mice, and 
CD4posCD25pos Tregs can prevent type 1 diabetes in NOD mice [71].Therefore, we first 
investigated the quantitative phenotype of CD4posCD25pos T cells in anti-CD137 treated NOD 
mice. Anti-CD137 antibody treatment increased the fraction of CD4posCD25pos T cells in NOD 
mice (Figure 2.3b). This highlighted the importance of CD137 expressing CD4posCD25pos T cells 
for treatment mediated diabetes protection. 
 
2.3.4 Naive CD4posCD25pos T cells express CD137 and continue expressing Foxp3 after 
treatment. 
 
Since anti-CD137 treatment increased Treg frequency, we looked at the expression of CD137 
within the CD4posCD25pos T cell population. NOD CD4posCD25pos T cells upregulate CD137 
compared with CD4posCD25neg T cells, consistent with previous reports (Figure 2.4a) [139]. To 
confirm that increased CD4posCD25pos T cells were true regulatory cells and not polyclonally 
activated T cells upregulating CD25, we performed intracellular Foxp3 staining. The 
CD4posCD25pos T cells in anti-CD137 treated mice predominantly expressed Foxp3 (Figure 
2.4b). This indicated that the administration of anti-CD137 antibody induced CD4posCD25pos T 
cells that are true Tregs with Foxp3 expression and could be associated with diabetes protection 
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Figure 2.4 
 
 
Figure 2.4. Naïve CD4posCD25pos T cells express CD137 and continue expressing Foxp3 
after anti-CD137 treatment. 
(a) Splenocytes from 50- to 75-day-old NOD mice were analyzed for CD137 expression on 
CD4
pos
CD25
pos
 and CD4
pos
CD25
neg
 T cells. One representative of 11 NOD mice is shown. (b) Female 
NOD mice aged 43 days were treated with 200μg anti-CD137 antibody or PBS twice within 3-week 
intervals and studied at 1 week after the second treatment. Surface expression of CD4 and CD25 and 
intracellular staining for Foxp3 were analyzed.  
 
2.3.5 Anti-CD137 antibody specifically binds to CD4posCD25pos cells in vivo.  
 
Next we tested whether anti-CD137 had a preferential cell target in vivo. We harvested 
splenocytes from NOD mice treated twice with anti-CD137 antibody and stained for CD4 and 
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CD25 or CD8 and C44 and used the second-step (anti-IgG2a-bio) antibody specific for anti-
CD137, followed by streptavidin-PE.  
 
 
Figure 2.5 
 
Figure 2.5. Anti-CD137 antibody specifically binds to CD4posCD25pos T cells in vivo.  
Female NOD mice were treated with 200 mg anti-CD137 antibody (3H3) or PBS twice at 3-week intervals 
and stained at 1 week after the second treatment. Splenocytes were stained with CD4 and CD25 or CD8 
and CD44 in addition to anti-IgG2a-bio antibodies followed by strepavidin phycoeythrin or stepavidin 
APC. One representative of five experiments.  
 
Anti-CD137 antibody bound only to CD4posCD25pos T cells but not to CD4posCD25neg T cells in 
vivo (Figure 2.5). The secondary antibody also did not bind to CD8posCD44pos or CD8posCD44neg 
T cells subsets (Figure 2.5). Therefore anti-CD137 antibody treatment specifically targeted 
CD4posCD25neg T cells in vivo and studying these Treg subsets might be essential to understand 
the mechanism of anti-CD137 mediated protection.  
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2.3.6 Anti-CD137 treated CD4posCD25pos T cells prevent adoptive transfer of diabetes 
 
Next, in order to find the protective CD4 subset, we tested if anti-CD137 induced CD4posCD25pos 
T cells were protective against diabetes. For this, we transferred CD4posCD25pos or 
CD4posCD25neg T cells from anti-CD137 treated mice, along with diabetic CD8 T cells, to NOD-
scid recipients. The NOD-scid recipients transferred with CD4posCD25pos cells were completely 
protected from diabetes compared with those that received CD4posCD25neg T cells (Figure 2.6, P 
< 0.0001). Moreover, mice receiving anti-CD137 treated CD4posCD25neg T cells showed no 
significant difference in disease onset compared with CD4  T cells from PBS treated NOD mice 
(Figure 2.6, P = 0.91). This explains the results shown in Figure2.2 (above) and supports the 
hypothesis that anti-CD137 therapy acts on CD4posCD25pos cells. We also found that some of 
the mice receiving CD4posCD25neg T cells developed inflammatory bowel disease (IBD), 
manifested by wasting and rectal prolapse or neuropathy which was consistent with previous 
reports (data not shown) [186, 187]. Five of nine mice receiving CD4posCD25neg T cells 
developed diabetes, whereas four of nine developed either IBD or neuropathy. The finding that 
diabetes and neuropathy/IBD were mutually exclusive is consistent with the report of Setoguchi 
et al. [186].  
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Figure 2.6 
 
Figure 2.6. Anti-CD137 treated CD4posCD25pos T cells protect from diabetes.  
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 T cells from anti-CD137 treated mice protect against diabetes. Female NOD mice aged 
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two separate experiments are shown. 
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2.3.7 CD137 expressing CD4posCD25pos T cells express high levels of IL-10 and ICOS. 
 
Since anti-CD137 antibody preferentially binds to CD4posCD25posCD137pos T cells in vivo, we 
studied the phenotypic characteristic of this Treg subset. Previously we have shown that anti-
CD137 treated CD4posCD25pos T cells express high levels of Foxp3 (Figure 2.5b).  
Figure2.7 
 
Figure 2.7. CD137pos Tregs have higher levels of Il-10 and Icos mRNA compared to 
CD137neg Tregs.    
Splenocytes from 4-12 week old NOD females were stained with CD4APC, CD25FITC, and anti-
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converted to cDNA as described in the methods. Quantitative Real Time Polymerase Chain Reaction 
(RTPCR) was performed on the cDNA using GAPDH and (a) Foxp3 (n=8), (b) IL-10 (n=6), (c) TGF-b 
(n=6), (d) CTLA-4 (n=6), (e) ICOS (n=6) and (f) GITR (n=4) primers (Applied Bioscience). Statistical 
analysis was performed using the unpaired T test.  
 
In order to further investigate the role of CD137, we sorted CD4posCD25pos Tregs with or without 
CD137 from untreated mice and analyzed mRNA levels of various Tregs markers using RT-
PCR. First we showed that both CD137neg and CD137pos Tregs express similar levels of Foxp3 
mRNA, significantly greater than CD4posCD25negCD137neg T cells (Figure 2.7a). Since Tregs are 
known to mediate some suppression through expression of TGF- and IL-10 [78], we studied 
the expression of these molecules in the two subsets of CD4posCD25pos T cell. CD137pos cells 
produced significantly higher IL-10 mRNA than CD137neg cells (Figure 2.7b). Previously we 
observed that anti-CD137 antibody treatment increased IL-10 production by CD4 T cells in vitro 
(Figure 2.3) and our results show that CD137 expressing CD4posCD25pos T cell may contribute 
towards the increase in IL-10 production. Next we showed that both subsets of CD4posCD25pos T 
cell have similar levels of TGF- and GITR transcript (Figure 2.7c, f), although the CD137pos 
subset showed an increased trend for CTLA-4 and ICOS mRNA expression (Figure 2.7d, e).  
2.3.8 CD137pos Tregs express high levels of CD69 and ICOS. 
 
We further analyzed the surface expression of characteristic Treg proteins in the two subsets of 
CD4posCD25pos T cell. Compared to CD137neg Tregs, CD137pos Tregs were CD69high and 
CD62low, indicating an activated phenotype (Figure 2.8a, b). In contrast virtually all CD137neg 
Tregs were CD62Lhigh and CD69low (Figure 2.8a, b).  
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Figure 2.8 
 
Figure 2.8. CD137pos Tregs upregulate CD69 and ICOS higher than CD137neg Tregs. 
(a) 6-7 week old NOD splenocytes were mini-macs bead purified for CD4+ T cells. The CD4 T cells were 
stained with 2.4G2-Fc block followed by CD25FITC, three-step staining for CD137 using 3H3 (anti-
CD137)  followed by IgG2a biotin and strepavidin APC and CD69-PE (a) or CD62L-PE (b) or CTLA-4-PE 
(c) or GITR-PE (d) or ICOS-PE (e) and their matched isotype control. The surface expression of CD69, 
CD62L, CTLA-4, GITR and ICOS were analyzed by flow cytometry and analyzed by FlowJo. The isotype 
staining on CD4
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 T cells is marked as shaded histogram. Surface expression of the 
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 (solid line) 
are shown as indicated. One representative of three experiments each. 
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and CD137posCD69high Tregs were both CD62Llow and CD62Lhigh (Supplemental Figure 1). This 
is important because CD62Lpos Tregs can express CD69 as previously noted [188]. Both 
subsets of Tregs expressed similar levels of cell surface CTLA-4 and GITR, consistent with the 
RT-PCR results discussed above (Figure 2.8c, d). Previous studies have shown that 
costimulation through ICOS is effective in enhancing IL-10 production [189, 190]. Since we 
observed high IL-10 production in CD137pos Tregs, we looked at ICOS levels. Consistent with 
our PCR results, CD137pos Tregs produce significantly high levels of ICOS compared to 
CD137neg Tregs (Figure 2.8e). Hence CD137pos Tregs express an activated phenotype and 
produce high levels of the immunosuppressive cytokine IL-10 and activation induced co-
stimulatory molecule ICOS, which could play a role in their suppressive function. 
2.3.9 CD137 expressing CD4posCD25pos T cells are highly suppressive in vitro 
 
To further understand the role of CD137 expressing Tregs, we investigated functional 
differences between CD137neg and CD137pos Treg subsets. We performed an in vitro Treg 
contact dependent suppression assay using NOD CD4posCD25negCD137neg T effector cells and 
titrated numbers of syngeneic NOD CD137pos or CD137neg Tregs (Figure 2.9). CD137pos Tregs 
were significantly functionally superior to CD137neg Tregs at every ratio (through 1:32, P=0.002) 
of Treg:T effector tested (Figure 2.9).   
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Figure 2.9 
 
Figure 2.9. NOD CD137pos Tregs are functionally superior to CD137neg Tregs in contact-
dependent mechanism.  
(a, b) CD4
pos
CD25
neg
CD137
neg
 T cells and CD137
neg
 and CD137
pos
 Tregs were sorted from spleen of 4-12 
week old NOD female mice as described in the methods. 50,000 CD4
pos
CD25
neg
CD137
neg
 T cells were 
plated in U-bottom 96 well plates with 1.25ug/well soluble anti-CD3, 50,000 irradiated (1500 rads) 
syngeneic splenocytes and titrated numbers of syngeneic CD137
neg
 or CD137
pos
 Tregs. Unstimulated 
CD4
pos
CD25
neg
CD137
neg
 T cells and irradiated splenocytes alone were used as negative controls. The 
cells were pulsed with 
3
H labeled thymidine on day 3 and harvested after 16 hours. The data was pooled 
from n=10 experiments for 1:2 (CD4 T cell:Treg ratio), n=7 experiments for 1:4, n=8 experiments for 1:8, 
n=8 experiments for 1:16 and n=7 experiments for 1:32. 
CD137pos Tregs are therefore functionally superior in vitro and thus anti-CD137 antibody 
treatment targeting these cells subsets might be important for diabetes protection. 
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Next we tried to understand the mechanisms for suppressive difference between CD137pos and 
CD137neg Tregs. We again showed that CD137pos Tregs suppressed significantly better than 
CD137neg Tregs (Figure 2.10a). Since we have seen high production of IL-10 by CD137pos 
Tregs, we added IL-10R blocking antibodies to the culture. The addition of anti-IL-10R blocking 
antibodies did not alter the suppression of either CD137pos or CD137neg Tregs although the two 
subsets no longer differed significantly in suppression in the presence of IL-10R antibody 
(although this could simply be due to the small numbers of samples tested) (Figure 2.10a). As 
an additional control, we observed that IL-10R blocking antibody did not cause an effect on the 
proliferation of CD4 T cells without Tregs (Figure 2.10a).   
 
Next, the addition of TGF- neutralizing antibodies did not affect the suppressive function of 
either CD137pos or CD137neg Tregs (Figure 2.10b). Furthermore, the combination of both anti-IL-
10R and TGF- blocking antibodies did not alter the suppressive differences between CD137pos 
and CD137neg Tregs (Figure 2.10c). Our result is consistent with that seen by others where anti-
IL-10R and/or TGF- antibodies did not eliminate the in vitro suppression by Tregs although 
these cells are known to express IL-10 and TGF- [191-194]. 
 
The ineffectiveness of the antibodies could reflect the multiple mechanisms of suppression that 
Tregs use to suppress such as CTLA-4, granzyme, perforin or by cytokine deprivation-mediated 
apoptosis [195-198]. These experiments do not rule out the possibility that these soluble 
immunosuppressive molecules could still be important for Treg function but it makes it difficult to 
interpret the role of IL-10 in CD137pos Treg mediated suppression.  
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Figure 2.10 
 
 
Figure 2.10. Suppression by CD137pos Tregs is not abrogated by both IL-10 and TGF-
blocking in vitro. 
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CD137
pos
 Tregs were added to the wells as indicated. (a) Some wells were left untreated (n=6 
experiments) and 20ug/ml of IL-10R (n=3 experiments) blocking antibodies were added to some wells as 
indicated. (b) Under similar conditions, 20ug/ml of TGF- (n=3 experiments) blocking antibodies or 
untreated wells (n=3 experiments) were tested simultaneously. (c) Some untreated wells (n=5 
experiments) and combination of 20ug/ml of both IL-10R and TGF- (n=3 experiments) blocking 
antibodies were added to another set of similar cultures. As a control, the blocking antibodies were also 
added to the proliferating CD4 T cells without Tregs in all types of cultures. The cells were pulsed with 3H 
labeled thymidine on Day 3 and harvested after 16 hours. The percentage proliferation was calculated by 
dividing the CPM counts of the wells with the mean CPM count of the wells containing only 
CD4
pos
CD25
neg
CD137
neg
 T cells (without blocking antibodies). Statistical analysis was performed using 
the unpaired T test.  
 
2.3.11 CD137pos Tregs are functionally superior to CD137neg Tregs in contact-independent 
suppression. 
 
Next we tested whether CD137pos Tregs can mediate suppression in a contact-independent 
manner. Using transwell plates, we cultured CD4posCD25negCD137neg T cells in the bottom well 
and Treg subsets in the upper well; both wells had irradiated splenocytes and anti-CD3 
antibodies. At a 1:2 ratio, both CD137pos and CD137neg Tregs significantly suppressed the 
proliferation of T cells in a contact independent manner, but CD137pos Tregs were significantly 
more suppressive than CD137neg Tregs (P=0.008, Figure 2.11a). Next, we directly compared 
Tregs from the same donor in both contact dependent suppression (Tregs in the bottom well in 
contact with T effectors) and contact independent suppression (Tregs in the top well). Tregs 
were significantly more suppressive in the contact dependent assay than in the contact 
independent assay (Figure2.11a, P=0.009 for CD137neg Tregs and P=0.0001 for CD137pos 
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Tregs). However, in both assays the CD137pos subset mediated significantly more suppression 
than the CD137neg subset. 
 
Figure 2.11 
 
Figure 2.11. CD137pos Tregs are functionally superior to CD137neg Tregs in contact-
independent suppression. 
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conditions). Control wells contained either CD4
pos
 T cells alone (first column), irradiated splenocytes alone 
(second column) or no Tregs (third column).  (b) Mean percent proliferation in transwell suppression 
assays performed at 1:2 (n=10) and 1:4 (n=3) ratios of Treg:T cell. The percentage proliferation was 
calculated by dividing the CPM counts of the wells containing Tregs by the mean CPM count of the wells 
with only CD4
pos
CD25
neg
CD137
neg
 T cells. Statistical analysis performed using the unpaired T test.  
 
Finally, we assessed contact independent suppression via serial dilution assays. Ratios of Treg 
to effector below 1:2 did not show a significant difference in suppression between the CD137pos 
vs. CD137neg Tregs, consistent with a dilutional effect on a soluble factor (Figure 2.11b).  This 
also shows that contact dependent mechanism is more important for suppression in both Treg 
subsets. These results suggest that in a contact independent system, both Treg subsets 
produce soluble suppressive factors when activated, but that CD137pos Tregs can produce 
either quantitatively higher or different soluble factors that contribute to their functional 
superiority to CD137neg Tregs.  
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2.4 DISCUSSION 
 
Antibody treatment directed to the protein product of the Idd9.3 candidate gene, CD137, 
prevented the onset of diabetes in NOD mice.  In NOD mice, anti-CD137 preferentially bound to 
CD4posCD25pos T cells and increased their number. Adoptive transfer models into NOD-scid 
mice showed that the antibody affected the regulatory function of CD4posCD25pos T regulatory 
cells and enhanced their ability to control the pathogenicity of autoreactive T cells. 
Previous studies have shown that anti-CD137 antibody treatment prevented murine SLE, EAE 
and collagen arthritis [148, 180, 181]. Here we have shown, for the first time, that anti-CD137 
also prevents autoimmune diabetes. Paradoxically, transgenic expression of membrane-bound 
agonistic anti-4-1BB scFv in pancreatic islets increased the incidence of diabetes [199]. This 
may be explained by overstimulation of early autoreactive T cells that home the islets. For 
example, another member of TNF receptor superfamily, TNF-α has dual effects in type 1 
diabetes: anti–TNF-α treatment at 9–10 weeks prevents diabetes, whereas TNF-α given to 
neonates increase diabetes severity [200-202]. Since CD137 is also a member of the TNF 
receptor superfamily, the dual effect of CD137 in diabetes is perhaps not unexpected. Our study 
has also shown this dual effect; anti-CD137 treatment at an early age prevented the onset of 
diabetes (Figure 2.1a), but does not prevent diabetes after adoptive transfer of diabetic cells into 
NOD-scid recipients, in fact it may worsen disease in this setting [137]. Anti-CD137 is most 
effective at preventing diabetes when given early in the disease process but once a cadre of 
autoreactive T cells is fully developed, anti-CD137 cannot prevent disease and may even 
worsen it. In this case, anti-CD137 antibody may target activated pathogenic CD4 T cells that 
upregulate CD137, thus expanding the autoimmune repertoire and opposing the protective 
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effect of CD4posCD25pos Tregs. Furthermore, the splenocytes taken from aged anti-CD137 
treated mice can transfer diabetes, suggesting a limit to the regulatory capacity of the anti-
CD137 induced Treg cells.  
Nevertheless, our results are important for several reasons. Cd137 is a strong candidate gene 
for the Idd9.3 locus, which reduced the incidence of diabetes in NOD genetic background [104]. 
However neither the genetic insertion of protective B10 Idd9 nor treatment with anti-CD137 
prevented insulitis. Moreover, the insulitic lesions in the Idd9 congenic upregulated IL-4, 
consistent with our results of IL-4 production in anti-CD137 treated CD4 T cells [104]. T cells 
from NOD.B10 Idd9.3 congenic mice proliferated more vigorously to anti-CD3 plus anti-CD137 
stimulation and produced more IL-2 compared to NOD T cells [114].  This suggested that NOD 
Cd137 allele may have relatively defective signaling capability, presumably related to its three 
sequence polymorphisms compared to the B10 allele [114]. Cannons et. al speculated that 
decreased signaling through NOD CD137 could result in defective regulatory cell production. 
Our results are consistent with this hypothesis, because we showed that stimulation through 
CD137 prevented diabetes in NOD mice by the induction of a regulatory cell population. The 
specific binding of anti-CD137 to CD137pos Tregs (Figure 2.5 above) supported the hypothesis 
that the agonist antibody boosts the ―defective‖ NOD CD137 signal in Tregs and enhanced their 
regulatory function—which we will explore in more detail in later chapters. Although our results 
do not prove that Cd137 is the Idd9.3 gene, they are entirely consistent with this conclusion and 
supportive of prior studies defining the role of CD137 in type 1 diabetes.  
Our study showed that anti-CD137 mediated protection from diabetes via effects on 
CD4posCD25pos Tregs. We have seen that CD4posCD25pos T cells expressed CD137 and more 
importantly, anti-CD137 antibody specifically bound to CD4posCD25pos T cells in vivo. These 
findings are consistent with previous reports showing that a subset of CD4posCD25pos T cells 
upregulate CD137 [138, 139]. Previous studies have reported qualitative defects of NOD 
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CD4posCD25pos Tregs and that boosting NOD CD4posCD25pos Tregs can prevent diabetes [71, 
73]. Similarly, stimulation through CD137 ligand induced proliferation of CD4posCD25pos T cells 
that maintain their suppressor function [140]. More importantly, we have seen that transfer of 
the CD4posCD25pos T cells from treated mice completely prevented diabetes in an adoptive 
transfer model, whereas the CD4posCD25neg T cell subset offered no significant protection. Our 
study here links NOD CD4posCD25pos Treg function with the Idd9.3 candidate gene, Cd137 and 
indicates the protective role of these Tregs. 
 
The effects of anti-CD137 antibody on CD4posCD25pos Treg cells are still controversial (and we 
will further explore this topic in Chapter 4).  Regulatory cells from CD137−/− mice could control 
CD45RBhigh T cell induced colitis, implying that CD4posCD25pos Treg cells may exist independent 
of CD137 signaling [203]. Moreover, anti-CD137 antibody treatment in the setting of 
experimental autoimmune thyroiditis breaks tolerance and worsens the disease [204]. The 
double-edged effect of CD137 signaling likely depends on the balance of pathogenic and 
protective subsets at the time of treatment in any given model system. Nonetheless, the specific 
binding of anti-CD137 antibody to CD4posCD25pos cells in vivo and the protective effect of anti-
CD137 treated CD4posCD25pos T cells strongly suggest that the CD4posCD25posCD137pos Treg 
cell subset is a critical protective subset in type 1 diabetes.  
 
Here we also confirmed the previous observation that CD25-depleted CD4 cells transfer several 
autoimmune diseases [186, 187]. In particular, we provided additional evidence for the 
observation that the transfer of diabetes versus another organ-specific autoimmune syndrome, 
such as IBD or peripheral neuropathy, is mutually exclusive in this system [186, 187]. The 
mechanism for this striking organ specificity and exclusivity of autoimmune attack remains 
unknown. However, a similar effect of genetic manipulation on disease outcome is also seen in 
a case where addition of B6/B10 Idd9.3 loci onto the NOD background induces anti-Sm 
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antibodies, which are highly specific for SLE in humans [109]. The remarkable ―switching‖ of the 
tissue focus of autoimmune attack via environmental (CD25 depletion) or genetic (introgression 
of congenic regions) mechanisms is incompletely explained but is clearly of great importance to 
understanding the pathogenesis of autoimmunity and type 1 diabetes.  
 
Our results differentiate two sub-populations of CD4posCD25pos Tregs; one that express CD137 
and another that does not. The similar Foxp3 mRNA level in both CD4posCD25posCD137neg and 
CD4posCD25posCD137pos T cells is consistent with similar Foxp3 intracellular expression in the 
two Treg subsets. Also, CD137pos Tregs are distinctly CD69pos, which suggested that these cells 
have an activated phenotype. The activated phenotype of CD137pos T regulatory cells may be 
important for efficient suppression at the site of autoimmunity. CD137posCD69pos Tregs also 
included some CD62L, required for adhesion and homing [188] (Supplemental Figure 1). The 
high expression of IL-10 mRNA by CD137pos Tregs suggested that it is important for 
suppression. IL-10, which is an anti-inflammatory and immunosuppressive TH2 cytokine, is 
important for preventing TH1 mediated diseases such as diabetes [205]. Microarray studies 
have demonstrated that there is a high expression of IL-10 and CD137 genes in pancreatic 
Tregs [159]. Induced Type 1 regulatory T cells (Tr1) are also known to produce high levels of IL-
10 [191-193]. IL-10 produced by CD137pos Tregs may prevent cytokine production and 
proliferation of antigen specific CD4 T effector cells by inhibiting the antigen-presenting cells 
(APCs) such as DCs, Langerhan‘s cells and macrophages [206]. Furthermore we observed 
CD137pos Tregs expressed significantly high levels of ICOS compared to the CD137neg Tregs. 
Our results are consistent with other studies which have shown that costimulation through ICOS 
is effective in enhancing IL-10 production [189, 190, 207]. Previous studies showed that Tregs 
in the pancreatic lesions express high levels of ICOS and IL-10 in BDC2.5 mice [208]. Although 
we have not directly linked the ICOS expression with IL-10 production in CD137pos Tregs, there 
is a strong literature supporting that hypothesis, although we have not proven an effect of IL-10 
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here. Finally, Treg subsets are not merely phenotypically differentiated by cell surface 
expression of CD137, but CD137pos Tregs are also functionally superior to CD137neg Tregs in 
contact mediated suppression. 
We also explored the mechanism for suppressive function of CD137pos Tregs compared to 
CD137neg Tregs. The IL-10R and TGF-blockade experiments showed that blockade could not 
abrogate the suppressive advantage of CD137pos Tregs indicating that this subset suppresses 
through additional mechanism(s). We showed that CD137pos Tregs are functionally superior to 
CD137neg Tregs in contact independent suppression in vitro, indicating that soluble suppressive 
factors may contribute towards the superior suppression of CD137pos Tregs. Treg mediated 
contact independent mechanisms include multiple short-range suppressive factors such as IL-
10 [209] and TGF-[210] galectin [211], and IL-35 [212]. While contact independent 
suppression is still not well understood, many papers have now demonstrated contact 
independent suppression mediated in transwell plate assays [188, 213-223]. While our study 
here has not identified the mechanism for functional superiority of CD137pos Tregs, it shows that 
these Tregs are activated potent suppressors. In later chapters we will explore the finding that 
soluble CD137 is a source of soluble suppression mediated via CD137pos Tregs. Moreover, the 
finding of soluble CD137 will show that this Treg subset is not simply an ―activated‖ set of 
normal Tregs but has unique phenotypic and functional characteristics. 
In conclusion, for the first time, we report that anti-CD137 antibody therapy suppressed diabetes 
in NOD mice and that this effect involved CD4posCD25pos Tregs. The antibody treatment must be 
initiated before the development of a cadre of autoreactive T cells, indicating competing effects 
of anti-CD137 on protective and pathogenic cell subsets. These results implicate a role for the 
Idd9.3 candidate gene, Cd137, in type 1 diabetes pathogenesis and identify 
CD4posCD25posCD137pos Tregs as activated functionally superior subset that could be essential 
for preventing diabetes.  
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3.0 THE B10 IDD9.3 LOCUS MEDIATES ACCUMULATION OF 
FUNCTIONALLY SUPERIOR CD137POS T REGULATORY CELLS IN 
TYPE 1 DIABETES MODEL 
 
 
 
Chapter 3 has been partially adapted from Kachapati K, Adams DE, Wu Y, Steward CA, 
Rainbow DB, Wicker LS, Mittler RS, Ridgway WM. J Immunol. 2012. 189:5001-15 but also 
includes unpublished data. The use of data from published articles adheres to the copyright 
guidelines stated by Journal of Immunology. Kritika Kachapati generated all the data presented 
in this chapter.  
 
 
3.1 INTRODUCTION 
 
In Non Obese Diabetic (NOD) Type I diabetes (T1D) several genetic elements likely mediate 
pathogenesis through their effects on disruption of immune tolerance [224]. NOD 
CD4posCD25posFoxp3pos regulatory T cells are insufficient to control immune destruction of the 
beta cells in the pancreatic islets during progression to diabetes. NOD.B10 Idd9.3 congenic 
mice have a 40% reduced incidence of diabetes compared to NOD mice [104, 225].  As 
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mentioned above, the Idd9.3 region includes the  Tnfrsf9 gene, which encodes the CD137 co-
stimulatory molecule [10] and there are three coding variants between the NOD and B10 Tnfrsf9 
gene, two non-synonymous SNPs and an alanine insertion in NOD [225]. T cells with the B10 
Tnfrsf9 allele have enhanced proliferation and IL-2 production when stimulated via CD137 
compared to NOD T cells [225]. As shown by others and in chapter 2, CD137 is constitutively 
expressed by a subset of CD4posCD25pos T regulatory cells [136-140]. CD137 signaling 
promotes proliferation and survival of natural Tregs in vitro, which is enhanced by IL-2 [138, 
160]. Here we show, for the first time, that the B10 Idd9.3 region mediates enhanced 
accumulation of peripheral CD137pos Tregs in vivo. NOD.B10 Idd9.3 congenic mice accumulate 
significantly more CD137pos Tregs with age compared to NOD mice.  Previously we showed that 
CD137pos Tregs are functionally superior to CD137neg Tregs in suppressing T cells in vitro by 
both contact dependent and independent suppression (Chapter 2). Alternate splicing produces 
two isoforms of CD137: full length CD137 that is expressed on the cell membrane and soluble 
CD137 in which transmembrane exon 8 is spliced out [161]. Soluble CD137 is increased in 
autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus [162, 
164]. It has been shown that soluble CD137 can inhibit T cell proliferation, and hypothesized 
that increased soluble CD137 functions as a negative feedback mechanism to control 
overactivation of pathogenic cells in autoimmunity [162, 165]. We present novel data showing 
that CD4posCD25posCD137pos Tregs are the major cellular source of soluble CD137. We also 
show that older NOD.B10 Idd9.3 congenic mice have significantly increased serum soluble 
CD137 compared to NOD mice. We suggest that the maintenance and long-term accumulation 
of functionally superior peripheral CD137pos T regulatory cells (as we show in NOD.B10 Idd9.3 
congenic mice protected from T1D), and their production of soluble CD137, may play a critical 
role in protection from autoimmune diseases such as type one diabetes.  
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3.2 METHODS 
3.2.1 Mice and reagents:  
 
NOD/MrkTac mice were obtained from Taconic.  NOD.B10 Idd9.3 mice were developed as 
previously described [104, 225] and are available from The Jackson Laboratory as Stock No. 
012311.  The NOD.B6-Ptprc (hereafter referred to as ―NOD.CD45.2‖), which has a 1 Mb 
congenic interval, was developed as previously described [226] and is available from The 
Jackson Laboratory as Stock No. 014149). NOD.Foxp3-GFP knock-in mice (Hereafter 
―NOD.Foxp3-GFP mice‖) were a kind gift from Vijay Kuchroo and Ana Anderson of Harvard 
University. The mice were generated by crossing the C57BL/6 Foxp3-GFP KI generated in Dr. 
Kuchroo's laboratory [227] to NOD Mrk/Tac for 12 generations and then intercrossed for 
hemi/homozygosity for Foxp3-GFP KI mutation. NOD.B10 Idd9.3 Foxp3-GFP mice were 
produced by crossing the NOD.B10 Idd9.3 to NOD.Foxp3-GFP mice, intercrossing and 
selecting mice positive for both the Idd9.3 region and the Foxp3-GFP KI mutation.  NOD.Foxp3-
GFP mice have normal incidence of T1D in our Cincinnati LAMS facility while the NOD.B10 
Idd9.3 Foxp3-GFP mice show protection from T1D similar to NOD.B10 Idd9.3 mice in our 
colony.  Mice were maintained under specific pathogen-free conditions in our animal facilities. 
Mice were handled in accordance with the institutional animal care guidelines of University of 
Pittsburgh School of Medicine and University of Cincinnati School of Medicine. Anti-CD137 
monoclonal antibody (clone 3H3) has been previously described [228]. Antibodies against 
mouse 2.4G2-Fc, CD4-APC, CD4-APC-Cy7, CD25-PerCP-Cy5.5, CD25-FITC, Strepavidin-PE 
and Strepavidin-APC were purchased from BD Biosciences. CD3/CD28 coated beads and 
recombinant mouse IL-2 were purchased from Invitrogen (California). Primers for mouse Gapdh 
(4352339E-0801016) and Beta-2 microglobulin (Mm00437762_m1) were purchased from 
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Applied Bioscience (California). We used custom designed primers for membrane bound and 
soluble CD137 (Applied Bioscience). For membrane bound CD137, the forward primer was 
CCCCCTGTGGTGAGCTTC and the reverse primer was AGGAGGGCACTCCTTGCA. For 
soluble CD137, the forward primer was CCCCCTGTGGTGAGCTTC and the reverse primer 
was GGGAGGACCAGCATTTAAGAAGA. The probe for both the primers is 
TCCCAGTACCACCATT. 
3.2.2 Re-sequencing the Idd9.3 interval in the NOD mouse strain:  
 
The resequencing of Idd9.3 in the NOD mouse strain involved aligning the bacterial artificial 
chromosome (BAC) clone end sequences of the NOD library against the B6 mouse genome 
sequence [229]. From this, ten NOD BAC clones that formed a minimal sequencing tile path 
spanning the 1.2 Mb Idd9.3  interval were selected and sequenced at the Wellcome Trust 
Sanger Institute and deposited at the European Molecular Biology Laboratory 
http://www.ebi.ac.uk/embl (clone DN-135J18, accession number CU463327; DN-79L21, 
CU210939; DN-382D20, CU207373; DN-272K19, CU424443; DN-192H14, CU210934; DN-
117C24, CU210933; DN-106G2, CU210932; DN-129I7, CU207371; DN-266N3, CU207342; 
DN-404A18, CU407306). As all the B6 and B10 SNPs were found to be identical by descent 
throughout the Idd9.3 region (Mouse phenome database: http://phenome.jax.org), we identified 
polymorphisms between NOD and B6 in the Idd9.3 interval. The NOD BAC clone sequences 
spanning the Idd9.3 interval were aligned to the B6 mouse genome sequence (NCBI m37 
mouse assembly) by using the sequence search and alignment by hashing algorithm program 
[230]. The polymorphisms were entered into T1DBase [231, 232] and displayed graphically 
using GBrowse [233] (Supplemental Figure 1). The SNP density plots were generated by 
counting the number of SNPs in 10-kb windows, sliding 2 kb at a time, and plotting the count at 
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the midpoint of each window (Supplemental Figure 1). The Wellcome Trust Sanger Institute has 
next generation sequenced 17 mouse strains, including NOD/ShiLtJ  
(http://www.sanger.ac.uk/resources/mouse/genomes/).  The SNP information was downloaded 
for the Idd9.3 region and entered into T1DBase, and can be viewed at www.t1dbase.org. 
3.2.3 Flow Cytometry:  
 
For absolute cell counts, NOD and NOD.B10 Idd9.3 splenocytes or thymocytes were extracted 
and counted using a hemocytometer. For staining membrane bound CD137, the cells were 
incubated with 2.4G2 Fc block. For FACS analysis, cells were stained with CD4-APC, CD25-
FITC and stained for CD137 using IgG2a anti-CD137 or IgG2a isotype control antibody, then 
stained with anti-IgG2a biotin and strepavidin-PE and analyzed on a FacsCaliber (BD 
Biosciences). The cells were serially gated for total number of lymphocytes (by Fsc and Ssc), 
CD4, CD4posCD25pos, CD4posCD25posCD137neg and CD4posCD25posCD137pos T cells. The 
percentage staining in each gate was multiplied by the absolute number of cells to calculate the 
total number of lymphocytes, CD4pos, CD4posCD25pos and CD4posCD25posCD137neg and 
CD4posCD25posCD137pos T cells. For intracellular staining, the splenocytes were stained with 
CD4-APC-Cy7, CD25-Percp-Cy5.5, CD137-PE and fixed with 2% formaldehyde (methanol free) 
and permeabilized with 0.3% saponin. Intracellular staining was performed with Foxp3-PE or 
IgG2a isotype-PE (eBioscience), Bclxl-Alexa-Fluor488 or IgG isotype-Alexa-Fluor488 (Cell 
Signaling), Bcl2-Alexa-Fluor488 or IgG1 isotype-Alexa-Fluor488 (BioLegend) and Ki-67-Alexa-
Fluor488 or IgG isotype-Alexa-Fluor488 (Novus Biologicals). Anti-mouse Ki-67 or IgG isotype 
control antibody was labeled with APEX Alexa-Fluor488 Antibody Labeling Kit (Invitrogen). 
Foxp3 staining was performed using eBioscience Fixation/Permeabilization Kit. (NOD.CD45.2 X 
NOD.B10 Idd9.3) F1 bone marrow chimera spleen and pancreatic lymph nodes were stained 
with CD4-APC-Cy7, CD25-Percp-Cy5.5, CD45.1-FITC, CD45.2-APC and CD137-PE or IgG2a 
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isotype-PE and analyzed on a FACSCantos (BD Biosciences). All FACS data was analyzed 
using FlowJo (Treestar, Oregan). 
3.2.4 Bone Marrow Chimera construction:  
 
9-13 week old (NOD.CD45.2 X NOD.B10 Idd9.3) F1 mice were irradiated with 800 -1200 Rads 
(the dose was varied as we gained experience in this procedure, to optimize depletion of host 
cells). 15-25 million bone marrow cells from 5-12 week old NOD.B10 Idd9.3 and NOD.CD45.2 
mice were extracted without RBC lysis. Mature CD4, CD8 and CD90 cells were removed using 
magnetic beads (Miltenyi Biotech, California) and the bone marrow was then mixed at a 1:1 
ratio and injected into the irradiated F1 mice. Recipient mice were given water treated with 
antibiotic (neomycin trisulfate salt hydrate) for two weeks after transfer. The recipient F1 mice 
were sacrificed 12-20 weeks post injection for analysis of peripheral T cell populations by FACS. 
3.2.5 RT-PCR:  
 
CD4 T cells were extracted from splenocytes using CD4 magnetic beads (Miltenyi Biotech, 
California). The CD4 T cells were blocked with 2.4G2 and stained with CD4-APC-Cy7, CD25-
FITC, and anti-CD137-APC as above. The cells were sorted using a BD FacsAria machine (BD 
Bioscience) into CD4posCD25negCD137neg, CD4posCD25posCD137neg and CD4posCD25posCD137pos 
cell subsets, RNA was extracted from the sorted cells using an RNeasy mini kit (Qiagen) and 
converted into cDNA (Promega Reverse Transcription System). Quantitative Real Time 
Polymerase Chain Reaction (RT-PCR) was performed on the cDNA using primers for B2m, 
soluble CD137 and membrane bound CD137 using a StepOnePlus Real-Time PCR system 
(Applied Biosystems). The CT values of the gene of interest were subtracted from the CT of the 
housekeeping gene (Gadph or B2m) to produce the delta CT (designated ―ΔCT‖) and the data 
graphed using GraphPad Prism 5 (Version 5.02).  
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3.2.6 Proliferation Assay:  
 
The CD4posCD25negCD137neg, CD4posCD25posCD137neg and CD4posCD25posCD137pos 
splenocytes were stained and sorted using BDAria (BD Bioscience) with 90-95% purity. 50,000 
sorted cells were cultured at 37°C with 5% CO2 with (a) 25U/ml IL-2 or (b) 25U/ml/IL-2 and 
1.25ug/ml anti-CD3 in triplicate wells. The cells were pulsed with 1 µCi 3H labeled thymidine on 
day 3 and harvested after 16 hours using a beta scintillation counter. For the suppression assay 
50,000 CD4posCD25negCD137neg T cells were cultured in U-bottom 96 well plate with 1ug/well 
soluble anti-CD3, 50,000 irradiated splenocytes (1500 rads) and varying numbers of 
CD4posCD25posCD137neg or CD4posCD25posCD137pos Tregs. All cells were cultured and pulsed 
with 1 µCi [3H] thymidine on Day 3, 16 hours before harvest. On Day 4, thymidine incorporation 
was assessed using a beta scintillation counter.  
3.2.7 Treg Transwell Suppression Assay:  
 
100,000 sorted CD4posCD25negCD137neg T cells were cultured with 50,000 CD3/CD28-coated 
beads (Invitrogen) and 1.25ug/ml soluble anti-CD3 in the bottom wells of a 96 well transwell 
plate (Corning). 25,000 or 50,000 CD4posCD25posCD137neg or CD4posCD25posCD137pos Tregs 
were cultured in the top wells with 50,000 CD3/CD28-coated beads and 1.25ug/ml soluble anti-
CD3. The cells were cultured at 37°C in 5% CO2 and were pulsed with 1 µCi [
3H] thymidine on 
Day 3. The cells in the bottom wells were harvested and counted using a beta scintillation 
counter.  
3.2.8 ELISA:  
 
Mouse 4-1BB DuoSet Elisa system (R&D Systems, California) was used to detect soluble 
CD137 from serum and culture supernatants. The kit uses rat anti-mouse 4-1BB capture 
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antibody and biotinylated goat anti-mouse 4-1BB detection antibody. Recombinant mouse 4-
1BB, provided in the kit, was used as a standard. DeltaSoft software was used to calculate the 
amount of soluble CD137 in each well based on the standard for each experiment. 
3.2.9 Treg culture:  
 
50,000 CD4posCD25posCD137neg or CD4posCD25posCD137pos Tregs were cultured in 96 well U-
bottom plate with no IL-2 (unstimulated),  25U/ml mouse recombinant IL-2 alone with or without 
1.25ug/ml of anti-CD3 antibody for 4 days, and the supernatants were tested for soluble CD137 
as above by ELISA. All statistical analysis was performed using either the unpaired T test or the 
Mann-Whitney test in GraphPad Prism 5 (Version 5.02). 
 
 
3.3 RESULTS 
 
3.3.1 Increased accumulation of CD137pos Tregs with the B10 versus the NOD region in 
vivo  
 
We previously demonstrated that agonist anti-CD137 treatment prevents diabetes in NOD mice, 
that a subset of Tregs constitutively expresses CD137, and that anti-CD137 binds to 
CD4posCD25posCD137pos Tregs in vitro and in vivo [137]. Our results suggested that CD137pos 
Tregs may be important in T1D pathogenesis.  We quantified CD137 expression on 
CD4posCD25pos T cells as previously published [137] and as in Figure 1a, which shows a well-
defined CD137pos population compared to isotype control; CD137pos cells constitute 30% of all 
CD4posCD25pos T cells in the representative example shown. Since it has been previously shown 
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that CD137 promotes CD4 and CD8 T cell survival [10, 145, 173], we investigated changes in 
the frequency and the number of CD137pos T regulatory cells with age in non-diabetic NOD and 
NOD.B10 Idd9.3 congenic mice. The percentage of CD137pos cells within the CD4posCD25pos T 
cell population significantly declines with age in NOD, but not in NOD.B10 Idd9.3 spleen 
(P=0.006, Figure 3.1b). At both younger (3-9 weeks) and older (21-36 week) ages, the 
percentage of splenic CD137-expressing Tregs are significantly higher in NOD.B10 Idd9.3 mice 
than in NOD mice (P=0.01 and P<0.0001 Figure 3.1b). The absolute number of CD137pos Tregs 
significantly increased with age from 3-9 weeks to 21-36 weeks in NOD.B10 Idd9.3 congenic 
mice (P=0.03, Figure 3.1c). In addition there was a significant increase in the absolute number 
of CD137pos splenic Tregs in older NOD.B10 Idd9.3 congenic mice compared to age matched 
NOD mice (P=0.03, Figure 3.1c). However the number of NOD CD137pos Tregs did not change 
with age despite an age related decline in the percentage NOD CD137pos Tregs. (We also 
looked at the percentage of CD137pos Tregs at 10-20 weeks of age and observed no significant 
differences compared the other age groups of either strain - data not shown). 
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Figure 3.1 
 
Figure 3.1. CD137pos Tregs are significantly lower in aged NOD versus NOD.B10 Idd9.3 
spleen.   
Splenocytes from six week old NOD mice were stained with CD4-APC, CD25-FITC and anti-CD137-PE or 
IgG2a isotype control, and analyzed by flow cytometry. The IgG2a istoype control staining was used to 
establish true CD137 staining. Percentages below the Figureshow the percent CD137
pos
 vs. CD137
neg 
in 
the CD4
pos
CD25
pos
 gate. One representative of multiple experiments. (b, c, d) NOD and NOD.B10 Idd9.3 
splenocytes were isolated from younger (3-9 week) and older (21-36 week) non-diabetic females, stained 
with CD4-APC, CD25-FITC and anti-CD137-PE and analyzed by flow cytometry. (b) Isotype staining was 
used to gate for percentage of CD137
pos 
T cells in the CD4
pos
CD25
pos
T cell subset in NOD (n=18, 3-9 wk 
old and n=12, 21-36 wk old mice) and NOD.B10 Idd9.3 (n=12, 3-9 wk old and n=16, 21-36 wk old) 
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spleen. (c) The number of CD4
pos
CD25
pos
CD137
pos 
T cells was counted in NOD (n=8, 3-9 wk old and n=7, 
21-36 wk old) and NOD.B10 Idd9.3 (n=5, 3-9 wk old and n=7, 21-36 wk old) spleen. (d) The mean 
florescence intensity of CD137 on CD137
pos
CD4
pos
CD25
pos
 T cells was analyzed on NOD (n=10, 3-9 wk 
old and n=5, 21-36 wk) and NOD.B10 Idd9.3 (n=7, 3-9 wk old and n=9, 21-36 wk old mice) spleen.  
 
Consistent with previously published observations [77], the number of splenic CD4posCD25pos T 
cells increased significantly with age in both strains with no difference between the strains 
(Figure 3.2a). This explains the lack of decline of CD137pos Treg number in NOD with age 
despite a significant drop in the percent of CD137pos Tregs.  Similarly, it also explains the 
significant increase in the total number of CD137pos Tregs with age in NOD.B10 Idd9.3 mice 
(P=0.03, Figure 3.1c), despite the finding that the percentage of CD137pos Tregs did not 
increase with age (Figure 3.1b). Thus the increased number of NOD.B10 Idd9.3 
CD4posCD25posCD137pos T cells with age is due to a combination of an increased percentage of 
CD137pos T cells and an increased absolute number of CD4posCD25pos T cells in older NOD.B10 
Idd9.3 mice. There was also no difference in the percentage of CD4posCD25pos T cells with age 
in either strain (Figure 3.2b). Both NOD and NOD.B10 Idd9.3 congenic mice showed significant 
increases in CD4pos T cells and total numbers of splenic lymphocytes with age (Figure 3.2 c, d), 
but there was no difference between NOD.B10 Idd9.3 and NOD mice in the corresponding age 
groups.  
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Figure 3.2 
 
Figure 3.2. NOD and NOD.B10 Idd9.3 CD4pos, CD4posCD25pos, and splenic lymphocytes 
increase with age. 
NOD and NOD.B10 Idd9.3 splenocytes were counted with a hemocytometer and stained with CD4-APC, 
CD25-FITC and anti-CD137-PE. The number of CD4
pos
CD25
pos
 T cells (a), the number of CD4 cells (c), 
and the number of splenic lymphocytes (d) were calculated by multiplying the total number of splenocytes 
by the percentage of cells in each gate. (b) shows the percentage of CD4
pos
CD25
pos
 T cells. (a-d) 
performed on NOD (n=8, 3-9 wk old and n=7, 21-36 wk old) and NOD.B10 Idd9.3 (n=5, 3-9 wk old and 
n=7, 21-36 wk old) spleen using the staining protocol from Figure 1d. 
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We next studied the percentages and total number of thymic CD137pos Tregs in NOD and 
NOD.B10 Idd9.3 congenic mice and found that they were consistent with the peripheral 
population results. The percentage and absolute number of thymic CD137pos Tregs was 
significantly higher in 21-36 week old NOD.B10 Idd9.3 versus NOD mice (P=0.002, Figure 3.3a 
and P=0.02, Figure 3.3b). The total number of thymic CD4posCD25pos T cells, however, 
remained approximately constant with age in both strains (Figure 3.3c). The percentage of 
NOD.B10 Idd9.3 CD4posCD25pos thymocytes rose significantly (P=0.02, Supp Figure 3d). The 
number of CD4pos thymocytes significantly declined with age in both strains with no difference 
between the two strains (Figure 3.3e). The total number of thymocytes significantly decreased 
with age in NOD (P=0.007, Figure 3f); it decreased, but not significantly, in older NOD.B10 
Idd9.3 mice. In summary, it is clear that the decreased number of NOD thymic CD137pos Tregs 
with age was due to a decreased percentage of these cells; in older NOD.B10 Idd9.3 mice a 
significant increase in the percentage of CD137pos Tregs caused a significant increase in the 
number of thymic CD137pos Tregs. It is also possible that the increased accumulation of 
CD137pos Tregs in the periphery is due to the increased thymic output but here we have not 
stained for thymic output markers to test this possibility. 
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Figure 3.3 
 
Figure 3.3. Thymic CD4posCD25posCD137pos T cells decline with age in NOD but not in 
NOD.B10 Idd9.3 mice. 
NOD and NOD.B10 Idd9.3 thymocytes were stained with CD4-APC, CD25-FITC and anti-CD137-PE. (a) 
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3-9 wk old and n=11, 21-36 wk old mice) and NOD.B10 Idd9.3 (n=13, 3-9 wk old and n=14, 21-36 wk old) 
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thymus.  (b - f) The number of CD4
pos
CD25
pos
CD137
pos
 T cells (b), the total number of CD4
pos
CD25
pos
 T 
cells (c), and the percentage of CD4
pos
CD25
pos
 T cells within CD4 T cells (d), the total number of CD4
pos
 T 
cells (e), and the total number of thymic lymphocytes (f), were calculated from counting the absolute 
number of thymocytes in NOD (n=5, 3-9 wk old and n=7, 21-36 wk old) and NOD.B10 Idd9.3 (n=4, 3-9 wk 
old and n=6, 21-36 wk old) and applying the indicated gates.  
 
In order to begin to understand possible reasons for increased NOD.B10 Idd9.3 CD137pos Treg 
accumulation with age we examined the per cell surface expression of CD137 at the same time 
points.  The mean florescence intensity of CD137 on CD4posCD25posCD137pos T cells was 
significantly greater in young (3-9 week old) NOD.B10 Idd9.3 versus age matched NOD 
(P=0.009, Figure 3.4a). Although the percentage of CD4posCD25posCD137pos T cells declined 
markedly in 21-36 week old NOD spleen (P= 0.006, Figure 3.1b), the CD137pos Tregs found in 
old NOD spleen expressed a significantly higher level of CD137 per cell compared to young 
NOD splenic Tregs (P=0.003, Figure 3.4a); not significantly different from old NOD.B10 Idd9.3 
cells (Figure 3.4a).  
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Figure 3.4 
 
Figure 3.4. Cellular CD137 increase in older NOD and younger NOD.B10 Idd9.3 congenic 
than young NOD 
Splenocytes and thymocytes from NOD mice were stained with CD4-APC, CD25-FITC and anti-CD137-PE or IgG2a 
isotype control, and analyzed by flow cytometry. The mean florescence intensity of CD137 on 
CD137
pos
CD4
pos
CD25
pos
 T cells was analyzed i (a) NOD (n=10, 3-9 wk old and n=5, 21-36 wk) and NOD.B10 Idd9.3 
(n=7, 3-9 wk old and n=9, 21-36 wk old mice) spleen and thymus of (b) NOD (n=5, 3-9 wk old and n=4, 21-36 wk) 
and NOD.B10 Idd9.3 (n=9, 3-9 wk old and n=8, 21-36 wk old mice) mice. Statistical analysis was performed using the 
unpaired t test. 
 
Similar CD137 MFI was found in thymic CD4posCD25posCD137pos T cells with age— old thymic 
NOD CD137pos Tregs expressed more CD137 per cell than young NOD cells (P=0.0004, Figure 
3.4b) and young thymic NOD.B10 Idd9.3 CD137pos Tregs were significantly higher than on 
young NOD cells (P=0.0003, Figure 3.4b).  These findings suggest that early, increased 
expression of CD137 on Tregs might enhance long term accumulation of those cells, consistent 
with the previously published role of CD137 on CD8 and CD4 T cell survival in vivo and in vitro 
[145, 173, 234]. The increased expression of CD137 on a per cell basis in young NOD.B10 
Idd9.3 congenic spleen is associated with the increase in the number of 
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CD4posCD25posCD137pos T cells with age.  Overall, these studies show that the B10 Idd9.3 
region enhances accumulation of CD137pos Tregs in the NOD.B10 Idd9.3 congenic mice, and 
supports the hypothesis that CD137 is important for the long-term accumulation of CD137pos 
Tregs.  
 
3.3.2 CD137neg and CD137pos Tregs express similar levels of intracellular Foxp3 in NOD 
and NOD.B10 Idd9.3  
 
The above results depended on identifying Tregs by CD25 expression. While this is a 
recognized Treg marker, it can also be a marker of T cell activation, as can CD137. It was 
important to evaluate the peripheral Treg subsets by intracellular Foxp3 expression to ensure 
that the increased number of NOD.B10 Idd9.3 CD4posCD25posCD137pos T cells with age were 
truly Tregs. To evaluate this, we first performed intracellular Foxp3 staining at all age points.  
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Figure 3.5 
 
 
Figure 3.5. NOD and NOD.B10 Idd9.3 Treg subsets show no difference in intracellular 
Foxp3 levels.  
(a, b) Splenocytes from 5-9 week old NOD (n=3) and NOD.B10 Idd9.3 (n=2) and 20-30 wk old NOD (n=4) 
and NOD.B10 Idd9.3 (n=6) female mice were surface stained with CD4-APC.Cy7, CD25-Percep-Cy5.5 
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and anti-CD137APC, followed by intracellular staining for Foxp3-PE or IgG2a isotype control. (The 
CD137 gates are based on isotype staining for CD137, as shown in Figure 3.1a). (c) Representative dot 
plots of the FACS gating used to calculate the percent Foxp3 staining in parts (a) and (b) using seven 
week old NOD (left) and six week old NOD.B10 Idd9.3 (right). Within the CD4
pos
CD25
pos
 gate, the 
CD4
pos
CD25
pos
CD137
neg
 and CD4
pos
CD25
pos
CD137
pos
 Tregs were gated for Foxp3 or isotype histograms. 
The isotype histogram was used to establish gates for Foxp3 positive staining. The percent overlapping 
isotype staining in the gate was subtracted from the percent Foxp3+ in the gate (as noted on the top of 
each histogram) to calculate the true percent Foxp3.  
 
We showed that the overwhelming majority of CD4posCD25posCD137pos T cells are Foxp3 
positive (Figure 3.5a, b) and that there is no significant difference in percentage of Foxp3 
positive cells between CD4posCD25posCD137neg and CD4posCD25posCD137pos T cells in either 5-9 
week old or 20-30 week old NOD or NOD.B10 Idd9.3 congenic mice (Figure 3.5a, b). Our 
results match a previous study that showed similar percent Foxp3 expression in CD4posCD25pos 
T cells in NOD with age [73], and shows that the increased number of NOD.B10 Idd9.3 
CD4posCD25posCD137pos T cells is not due to an expansion of non-Tregs in this subset. We also 
found a slight increase in isotype staining with age (not shown), and since we subtracted the 
isotype staining (see Figure3.5c for a representative example for gating) to calculate ―true 
positive‖ Foxp3 cells, we may have underestimated the true Foxp3 expression.  
 
After all the studies in this paper were performed, we obtained NOD.Foxp3-GFP mice, and used 
these mice to create NOD.B10 Idd9.3 Foxp3-GFP mice. We aged these mice and used them to 
evaluate the percent of Foxp3-GFP positive cells in the CD4posCD25posCD137neg and 
CD4posCD25posCD137pos subsets in NOD and NOD.B10 Idd9.3 at the same time points as we 
examined above (Figure 3.5a, b).  
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Figure 3.6 
 
Figure 3.6. CD137pos Tregs from NOD and NOD.B10 Idd9.3 Foxp3-GFP mice express high 
Foxp3. 
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(a, b) Splenocytes from NOD.Foxp3-GFP (n=3, 3-9 wk old and n=2, 21-25 wk old) and NOD.B10 
Idd9.3.Foxp3-GFP (n=3, 3-9 wk old and n=3, 21-25 wk old) were stained for CD4-APC-Cy7, CD25-
Percep-Cy5.5 and CD137-APC or IgG2a isotype control. The cells were analyzed for Foxp3-GFP 
expression in CD137
pos
 and CD137
neg
 Tregs in (a) 3-9 week and (b) 21-25 week old mice. (c) 
Representative dot plots showing Foxp3/CD137 staining within the CD4
POS
CD25
POS
 gate for each strain 
and age group shown in section a and b.  FACS staining and gating were used to calculate the percent 
Foxp3 in the CD137
neg
 and CD137
pos
 subsets from young (top) and old (bottom) NOD.Foxp3-GFP (left) 
and NOD.B10 Idd9.3.Foxp3-GFP (right). (The CD137 gates are based on isotype staining for CD137, as 
shown in Figure 1a). 
 
The Foxp3-GFP stainings (Figure3.6) support the conclusions of Figureures five above and 
show that well over 90% of CD4posCD25posCD137neg and CD4posCD25posCD137pos subsets in 
NOD and NOD.B10 Idd9.3, both young and old, were Foxp3-GFP positive, and that there were 
no significant differences between the strains (Figureures 3.6a, b show the pooled result while 
Figure3.6c shows representative FACS plots in NOD.Foxp3-GFP and NOD.B10 Idd9.3 Foxp3-
GFP mice). The combined results of Figureures two and three very strongly show that the 
increase of CD4posCD25posCD137pos cells in NOD.B10 Idd9.3 mice with age truly represents a 
significant increase in Foxp3 expressing CD137pos Tregs. 
 
3.3.3 Increased accumulation of CD137pos Tregs with the B10 versus the NOD Idd9.3 
region in mixed bone marrow chimeras in vivo 
 
The finding of increased CD137pos Tregs in NOD.B10 Idd9.3 compared to NOD mice with age 
probably reflects multiple biological processes and complex intrinsic/extrinsic cellular effects in 
separate animals/strains. In order to confirm the finding of increased accumulation of Tregs 
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expressing the B10 Idd9.3 region, we sought to demonstrate increased accumulation of these 
cells compared to cells with the NOD Idd9.3 region, in the same animal. To do this, and to test 
whether the B10 Idd9.3 region intrinsically mediated increased accumulation of CD137pos Tregs, 
we constructed mixed bone marrow chimeras using NOD and NOD.B10 Idd9.3 CD137pos bone 
marrow transferred into irradiated (NOD.CD45.2 x NOD.B10 Idd9.3 (CD45.1)) F1 mice. The 
resulting chimeric mice were analyzed for effective reconstitution and relative ratios of 
allotypically marked cells as shown in Figure3.7. 
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Figure 3.7 
 
Figure 3.7. CD137pos Tregs expressing the B10 Idd9.3 region demonstrate an intrinsic cell 
accumulation. 
15-25 million bone marrow cells from 5-12 week old NOD.B10 Idd9.3 mice and NOD.CD45.2 mice were 
mixed at 1:1 ratio and injected into 9-13 week old irradiated (800 -1200 Rads in different experiments) 
(NOD.CD45.2 X NOD.B10 Idd9.3 ) F1 mice. Recipient non-diabetic mice were sacrificed 12-20 weeks 
after reconstitution. (a) One representative experiment showing the expression of the CD45.1 (NOD.B10 
Idd9.3) vs. CD45.2 (NOD) allotype by CD137
neg
 (left) and CD137
pos
 (right) Tregs 12 weeks after 
reconstitution of the bone marrow chimera. (b) Spleen (n=5), and (c) pancreatic lymph nodes (n=4) were 
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harvested and stained with CD4-APC-Cy7, CD25-Percp-Cy5.5, CD45.1-APC, CD45.2-FITC and anti-
CD137-PE and analyzed on a FACS Cantos cytometer. Percentage of each F1 (host) cells not shown. 
Statistical significance was calculated using the unpaired t test.  
 
In the mixed bone marrow chimera mice, the percentage of peripheral (splenic or pancreatic 
lymph node) CD4posCD25posCD137pos T cells expressing the B10 CD137 allotype was 
significantly increased compared to the NOD allotype (Figure 3.7b, c).  CD4posCD25posCD137neg 
Tregs from the same individual mice, in contrast, showed no significant CD45.1 vs. CD45.2 
population differences (Figure 3.7a-c). Since the percentage of B10 and NOD allotype were 
from the CD137pos Treg population in the same bone marrow chimeric mouse, the total number 
of splenocytes or lymph node cells were the same for each cell population; hence the total 
numbers of B10 or NOD allotype CD137pos Tregs in the bone marrow chimeric mice were 
exactly proportional with these percentages. There was statistically no significant difference in 
thymic CD45.1 vs. CD45.2 proportions inCD4posCD25posCD137neg and CD4posCD25posCD137pos 
T cell populations (data not shown). These results, which are entirely consistent with the studies 
in Figure 4.1, strongly support the hypothesis that the B10 CD137 region intrinsically and 
selectively mediates enhanced accumulation of CD137pos Tregs in the periphery.  
 
3.3.4 Enhanced proliferation of CD137pos Tregs ex vivo and in vitro but no significant 
difference between NOD and NOD.B10 Idd9.3 congenic mice. 
 
CD137 co-stimulation causes proliferation of Tregs in vitro [160, 228] and in vivo [179]. The 
increased frequency and accumulation of CD137pos Tregs in NOD.B10 Idd9.3 congenic mice 
could be due to intrinsic factors, such as greater proliferative capacity or enhanced cell survival 
mediated by the B10 CD137 allotype. To test proliferative capacity, we cultured NOD and 
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NOD.B10 Idd9.3 CD137pos and CD137neg Tregs in the presence of IL-2 (Figure 3.8a) or IL-2 and 
CD3 (Figure 3.8b).  
 
Figure 3.8 
 
Figure 3.8. No proliferative differences between NOD and NOD.B10 Idd9.3 CD137pos Tregs 
ex vivo or in vitro.  
(a, b) Splenocytes from 4-6 week old NOD and NOD.B10 Idd9.3 females were stained with CD4-APC-
Cy7, CD25-Percep-Cy5.5, and anti-CD137-APC, and FACS-sorted for CD4
pos
CD25
pos
CD137
neg
 and 
CD4
pos
CD25
pos
CD137
pos
 cells. 50,000 sorted cells were cultured with (a) 25U/ml IL-2 or (b) 25U/ml IL-2 
and 1.25ug/ml anti-CD3 in triplicate wells. The cells were pulsed with 
3
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harvested after 16 hours and the data was pooled from n=3 experiments. (c) Splenocytes from 5-7 week 
old NOD (n=3) and NOD.B10 Idd9.3 (n=3) females were surface stained with CD4-APC-Cy7, CD25-
Percep-Cy5.5 and anti-CD137-APC, followed by intracellular staining for Ki-67-Alexa-488. The stained 
cells were analyzed by flow cytometry. Statistical significance was calculated with the unpaired t test. 
 
The proliferation of CD137pos Tregs was significantly greater than CD137neg Tregs under both 
culture conditions and in both strains, but there was no difference in proliferation of CD137pos 
Tregs between NOD and NOD.B10 Idd9.3 mice (Figure 3.8a, b). Tregs cultured with no IL-2 
showed virtually no proliferation (data not shown). Next, we quantified expression of the nuclear 
protein Ki-67, as a marker for proliferation ex vivo. Consistent with the in vitro results, a 
significantly higher percentage of CD137pos Tregs were Ki-67 positive ex vivo compared to 
CD137neg Tregs in both NOD and NOD.B10 Idd9.3 mice (Figure 3.8c). Again, we found no 
difference in percentage of Ki-67 positive CD137pos Tregs between NOD and NOD.B10 Idd9.3 
mice. These studies suggest that the increased numbers and frequency of CD137pos Tregs in 
NOD.B10 Idd9.3 congenic mice with age could not be explained by enhanced proliferation 
mediated by the B10 allotype.     
 
Viability studies in CD137 stimulated and unstimulated T cells have shown that CD137 signaling 
prevents activation induced cell death (AICD) by repressing DNA fragmentation [147]. Since 
CD137 signaling can upregulate the pro-survival molecule Bcl-xL[145], we tested the expression 
of Bcl-xL in NOD and NOD.B10 Idd9.3 Treg subsets. We found significantly increased Bcl-xL 
mRNA expression in NOD.B10 Idd9.3 versus NOD CD137pos Tregs (P=0.04, Figure 3.9a). We 
also found increased expression of Bcl-xL in NOD.B10 Idd9.3 versus NOD CD137neg Tregs (P= 
0.008), which suggests CD137 is not necessary for upregulation of Bcl-xL in these NOD.B10 
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Idd9.3 cells. We next tested Bcl-xL mRNA expression in the mixed bone marrow chimera cell 
subsets, stratified by allotype. In the mixed bone marrow chimera experiments, CD137pos, but 
not CD137neg Tregs with the B10 allotype expressed significantly increased Bcl-xL (P=0.008, 
Figure 3.9b). As a control, we tested levels of Bcl-2, a pro-survival molecule not known to be 
associated with CD137 signaling. There were no significant differences in expression of Bcl2 in 
NOD vs. NOD.B10 Idd9.3 CD137pos or CD137neg Tregs, in contrast to Bcl-xL (Figure 3.9c).  In 
the mixed bone marrow chimeric mice, the CD137pos but not the CD137neg Treg subset showed 
significantly increased Bcl2 mRNA  in B10 allotype vs. NOD allotype cells (p=0.0003, Figure 
3.9d). To summarize, the CD137pos Treg subsets (in both normal NOD.B10 Idd9.3 mice and in 
the B10 allotype cells of bone marrow chimera mice) showed significant increases of Bcl-xL 
mRNA. However in CD137neg Tregs, NOD.B10 Idd9.3 Tregs also show increased Bcl-xL mRNA 
compared to NOD, and B10 allotype CD137pos Tregs in the bone marrow chimeras also showed 
upregulated Bcl2 message.  
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Figure 3.9 
 
Figure 3.9. Peripheral NOD.B10 Idd9.3 CD137pos Tregs express higher levels of Bcl-xL 
mRNA than NOD. 
(a) Splenocytes from 4-7 week old NOD (n=9) and NOD.B10 Idd9.3 (n=6) females were used for sorting 
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described above. RNA was extracted from the sorted cells and converted to cDNA as described in the 
methods. Quantitative Real Time Polymerase Chain Reaction (RTPCR) was performed on the cDNA 
using either B2m or Gapdh and Bcl-xL primers. (b) NOD.B10 Idd9.3 and NOD.CD45.2 mixed bone 
marrow chimeric mice were made as above. Recipient non-diabetic mice were sacrificed 9-10 week post 
injection. CD137
neg
 and CD137
pos
 Tregs were sorted according to their CD45.1 (NOD.B10 Idd9.3) and 
CD45.2 (NOD) allotype and used for RT-PCR with B2m and Bcl-xL primers. The mean of (n=3) separate 
experiments is shown.  (c) 4-7 week old NOD (n=3) and NOD.B10 Idd9.3 (n=3) female splenocytes were 
used for sorting 50,000 CD4
pos
CD25
neg
CD137
neg
, CD4
pos
CD25
pos
CD137
neg
 and CD4
pos
CD25
pos
CD137
pos
 
cells and used for RT-PCR with B2m and Bcl2 primers. (d) CD45.1 or CD45.2 expressing CD137
neg
 and 
CD137
pos
 Tregs were sorted from mixed bone marrow chimera as in (b) and used for RT-PCR with B2m 
and Bcl2 (n=3). (e, f) Splenocytes from 4-9 week old NOD (n=4) and NOD.B10 Idd9.3 (n=3) females were 
surface stained with CD4APC.Cy7, CD25Percep-Cy5.5 and anti-CD137APC, followed by intracellular 
staining for Bcl-xL Alexa-Fluor 488 (e) or Bcl2 Alexa-Fluor 488 (f) and their matched isotype control. The 
stained cells were analyzed by flow cytometry for MFI for Bcl-xL or Bcl2 within CD4
pos
CD25
pos
CD137
neg
 
and CD4
pos
CD25
pos
CD137
pos
 cells. All statistical calculations were performed using the unpaired t test. 
 
To understand the significance of these findings, we examined protein levels of these survival 
molecules in both NOD and NOD.B10 Idd9.3 Treg subsets. Contrary to the PCR results, the 
Bcl-xL expression per cell did not vary between the NOD.B10 Idd9.3 versus NOD CD137pos 
Tregs (Figure 3.9e). Similarly, CD137pos Tregs showed no difference in Bcl2 MFI in between 
NOD.B10 Idd9.3 and NOD (Figure 3.9f).  
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Figure 3.10 
 
Figure 3.10: In vitro cell death does not differ between NOD vs. NOD.B10 Idd9.3 CD137pos 
Tregs. 
(a, b, c, d) Splenocytes from 8-9 week old NOD and 6-7 week old NOD.B10 Idd9.3 female mice were 
sorted for CD4
pos
CD25
pos
CD137
pos
 T cells as above. 50,000 sorted cells were cultured with (a,) 25U/ml IL-
2 (NOD n=2, NOD.B10 Idd9.3 n=4) or (b) 25U/ml/IL-2 and 1.25ug/ml anti-CD3 (NOD n=4, NOD.B10 
Idd9.3 n=5).   On day 4, the cultured cells were stained with Annexin-FITC and PI staining and analyzed 
by flow cytometry. ―Live‖ cells refer to the Annexin negative and PI negative gate. 
 
The greater accumulation of NOD.B10 Idd9.3 CD137pos Tregs compared to NOD could be due 
to enhanced survival of cells expressing the B10 CD137 allele. We tested this in vitro by 
culturing NOD and NOD.B10 Idd9.3 Tregs subsets in the presence of IL-2 or IL-2/CD3 as 
above. Under both conditions, the percentage of live, early apoptotic (Annexin positive), late 
apoptotic (Annexin /PI double positive) or dead (PI positive) cells do not differ between NOD 
and NOD.B10 Idd9.3 in CD137pos Tregs (Figure 3.10a, b). CD137neg Tregs also showed no 
difference between culture condition and mouse strains (data not shown). Therefore while the 
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increased expression of Bcl-xL mRNA in Tregs expressing the B10 CD137 allele is intriguing, it 
is not definitive. In addition, since we have no evidence of increased survival in vitro, we cannot 
confirm or exclude the possibility that expression of the B10 CD137 allele causes survival 
advantage of Tregs without further studies. 
 
3.3.4 NOD and NOD.B10 Idd9.3 CD137pos Tregs do not differ in contact-dependent 
suppression. 
 
Our results show enhanced accumulation of CD137pos Tregs in NOD.B10 Idd9.3 mice. 
Previously we have seen that NOD CD137pos Treg are functionally superior to CD137neg Tregs 
(Chapter 2).To understand the possible significance of increased percentages and numbers of 
CD137pos Tregs in the congenic mice with age, we compared the functional differences between 
NOD and  NOD.B10 Idd9.3 CD137neg and CD137pos Treg subsets. Previously, we performed an 
in vitro Treg contact dependent suppression assay using NOD CD4posCD25negCD137neg T 
effector cells and titrated numbers of Tregs and showed that CD137pos Tregs were significantly 
functionally superior to CD137neg Tregs at every ratio (through 1:32, P=0.002) of Treg:T effector 
tested (Figure 2.9).   
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Figure 3.11 
 
Figure 3.11. NOD and NOD.B10 Idd9.3 CD137pos Tregs do not differ in suppression in 
vitro. 
(a) CD4
pos
CD25
neg
CD137
neg
 T cells and CD137
neg
 and CD137
pos
 Tregs were sorted from spleen of 4-12 
week old NOD.B10 Idd9.3 female mice as described in the methods. 50,000 CD4
pos
CD25
neg
CD137
neg
 T 
cells were plated in U-bottom 96 well plates with 1.25ug/well soluble anti-CD3, 50,000 irradiated (1500 
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rads) syngeneic splenocytes and titrated numbers of syngeneic CD137
neg
 or CD137
pos
 Tregs. 
Unstimulated CD4
pos
CD25
neg
CD137
neg
 T cells and irradiated splenocytes alone were used as negative 
controls. The cells were pulsed with 
3
H labeled thymidine on day 3 and harvested after 16 hours. The 
data was pooled from n=3 experiments for 1:2, n=2 experiments for 1:4, n=3 experiments for 1:8, n=4 
experiments for 1:16 and n=5 experiments for 1:32.  (b, c) CD4
pos
CD25
neg
CD137
neg
 T cells and CD137
pos
 
Tregs were sorted from spleen of 5-8 week old NOD and NOD.B10 Idd9.3 females as described above. 
(b) 50,000 NOD or NOD.B10 Idd9.3 CD4
pos
CD25
neg
CD137
neg
 T cells were plated in U-bottom 96 well 
plates with 1.25ug/well soluble anti-CD3, 50,000 irradiated (1500 rads) syngeneic splenocytes and 
titrated numbers of syngeneic NOD or NOD.B10 Idd9.3 CD137
pos
 Tregs. The data was pooled from n= 
experiments for 1:4 and n= experiments for 1:8 and 1:16 for both NOD and NOD.B10 Idd9.3 mice. (c) 
50,000 NOD CD4
pos
CD25
neg
CD137
neg
 T cells were plated in U-bottom 96 well plates with 1.25ug/well 
soluble anti-CD3, 50,000 irradiated (1500 rads) NOD splenocytes and titrated numbers of NOD or 
NOD.B10 Idd9.3 CD137
pos
 Tregs. The data was pooled from n=2 experiments for 1:4 and n=5 
experiments for 1:8 and 1:16 for both NOD and NOD.B10 Idd9.3 mice.  In both (b) and (c) sections, the 
cells were pulsed with 
3
H labeled thymidine on day 3 and harvested after 16 hours. The percentage 
proliferation was calculated by dividing the CPM counts in wells with Tregs by the mean CPM count of the 
wells containing only CD4
pos
CD25
neg
CD137
neg
 T cells. Statistical significance was calculated with the 
unpaired t test.  
 
First we tested NOD.B10 Idd9.3 Treg subsets in the same assay system and again found that 
NOD.B10 Idd9.3 CD137pos Tregs were functionally superior to CD137neg Tregs when 
suppressing NOD.B10 Idd9.3 CD4posCD25negCD137neg T effector cells (Figure 3.11a). Next we 
compared the suppressive function of CD137pos Tregs against their syngeneic responders. Our 
results showed that the amount of suppression by NOD CD137pos and NOD.B10 Idd9.3 
CD137pos Tregs is comparable against their syngeneic T responder cells (Figure 3.11b). Next 
we directly compared the suppressive capacity of NOD and NOD.B10 Idd9.3 CD137pos Tregs, in 
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the same experiment, against NOD CD4posCD25negCD137neg T effector cells and found no 
significant difference in the suppressive capacity of the CD137pos Tregs of these two strains 
(Figure 3.11c). These experiments show that NOD and NOD.B10 Idd9.3 CD137pos Tregs does 
not differ functionally in vitro. 
 
3.3.5 CD137pos Tregs are the major cellular source of alternately spliced soluble CD137 
protein 
 
Alternate splicing produces two isoforms of CD137: full length CD137 expressed on the cell 
membrane and soluble CD137 in which transmembrane exon 8 is spliced out [161]. Previously, 
however, production of soluble CD137 by Tregs has not been studied. We designed RT-PCR 
primers (see Methods) that discriminate soluble versus membrane bound CD137 and used 
them to detect soluble CD137 versus membrane bound CD137 from freshly sorted NOD and 
NOD.B10 Idd9.3 subsets. CD137pos Tregs expressed significantly higher levels of soluble and 
membrane CD137 mRNA compared to CD137neg Tregs in NOD and NOD.B10 Idd9.3 mice 
(Figure 3.12a, b); CD4posCD25negCD137neg T cells produced negligible amounts of both isoforms 
of CD137 mRNA ex vivo (Figure 3.12a, b).  
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Figure 3.12 
 
Figure 3.12. NOD and NOD.B10 Idd9.3 CD137pos Tregs are the major cellular source of 
soluble CD137 in vitro.  
(a, b) RT-PCR for soluble and membrane CD137: NOD and NOD.B10 Idd9.3 CD4
pos
CD25
neg
CD137
neg
, 
CD4
pos
CD25
pos
CD137
neg
 and CD4
pos
CD25
pos
CD137
pos
 T cells were sorted from 4-8 week old females as 
above. RNA was immediately extracted and converted to cDNA. RT-PCR was performed with a set of 
custom designed primers used to detect either membrane (a) or soluble (b) CD137, (n=3 experiments for 
both (a) and (b)). B2m was used as an endogenous control. (c, d, e, f) ELISA for soluble CD137: 
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CD4
pos
CD25
neg
CD137
neg
, CD4
pos
CD25
pos
CD137
neg
 and CD4
pos
CD25
pos
CD137
pos
 Tregs from 5-8 week 
NOD and NOD.B10 Idd9.3 mice were sorted as above. 50,000 cells were cultured in 96-well U-bottom 
plate with (c) 25U/ml IL-2 (NOD n=2, NOD.B10 Idd9.3 n=5) or (d) 1.25ug/ml of anti-CD3 and 25U/ml IL-2 
(NOD n=4, NOD.B10 Idd9.3 n=4) for 4 days. ELISA for soluble CD137 was performed on the 
supernatants. Statistical analysis was performed using the unpaired t test. 
 
Next we sorted the CD137pos and CD137neg Tregs from NOD and NOD.B10 Idd9.3 mice and 
cultured them (with IL-2 alone, to promote survival in vitro under non-activating conditions) to 
assess CD137 protein production. The cultured CD137pos Tregs (from both NOD and NOD.B10 
Idd9.3 mice) produced significantly higher levels of soluble CD137 protein compared to 
CD137neg Tregs; CD4 non-Treg cells did not produce significant amounts of soluble CD137 
protein (Figure 3.12c). There was no significant difference in soluble CD137 protein production 
between NOD and NOD.B10 Idd9.3 CD137pos Tregs (Figure 3.12c, d). We did not detect 
significant soluble CD137 production from cell subset in the absence of IL-2 (data not shown).  
We have thus established, for the first time, that CD137pos Tregs are the primary T cell source of 
soluble CD137.  
 
Given that activated T cells express CD137, it was possible that our CD137neg Tregs start 
producing soluble CD137 under activating conditions. To test this, we cultured CD137pos and 
CD137neg Tregs from NOD and NOD.B10 Idd9.3 mice with IL-2 and anti-CD3, and tested culture 
supernatants on day 4 for soluble CD137. Under these activating conditions, CD137neg Tregs 
produced some soluble CD137, although still significantly less than CD137pos Tregs in both 
strains (Figure 3.12d). Again there was no significant difference in soluble CD137 production 
between the two strains. These results suggest that Treg activation causes CD137neg Tregs to 
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increase alternate splicing of Tnfrsf9 with subsequent production of soluble CD137 protein, 
although still significantly less than CD137pos Tregs.  Notably, non-Treg CD4pos cells still did not 
produce significant amounts of soluble CD137 after stimulation under these activating 
conditions (Figure 3.12d).  
 
We also tested CD137 membrane expression in CD137pos and CD137neg Tregs from both 
strains upon IL-2 and CD3 stimulation as above. As expected, the cells sorted as CD137neg 
Tregs did not express any CD137 pre-culture (Supplemental Figure2). However after IL-2 and 
CD3 stimulation for 3 days, CD137neg Tregs from both strains showed increased CD137 
expression on a per cell basis, but the expression was still much lower than CD137pos Tregs 
(Supplemental Figure2). Our data suggested that upon in vitro IL-2 and CD3 stimulation, 
CD137neg Tregs start expressing membrane and soluble CD137 but the expression level is still 
much lower than Tregs that originally express CD137 pre-culture.   
 
Next we tested if soluble CD137 is produced by NOD Tregs during in vitro suppression in the 
presence of CD4 T cells and CD3/CD28 beads, in the absence of APCs. Under these 
conditions, CD137neg Tregs produced soluble CD137 protein but still significantly less 
(P=0.0001) than CD137pos Tregs (Figure 3.13).  
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Figure 3.13 
 
Figure 3.13. CD137pos Tregs produce more soluble CD137 during suppression. 
NOD CD4
pos
CD25
neg
CD137
neg
, CD4
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CD25
pos
CD137
neg
 and CD4
pos
CD25
pos
CD137
pos
 T cells were sorted 
from 5-7 week old NOD mice as above. 50,000 CD4
pos
CD25
neg
CD137
neg
 T cells were plated in U-bottom 
96 well plates with 50,000 CD3/CD28 beads and 25,000 (1:2, n=5 experiments) CD137
neg
 or CD137
pos
 
Tregs. The supernatant was collected on day 4 and ELISA was performed on the supernatants for soluble 
CD137. The statistical analysis was performed using the unpaired t test. (f) 20-37 week old non-diabetic 
NOD (n=6) and NOD.B10 Idd9.3 (n=7) were sacrificed and their serum tested for soluble CD137 by 
ELISA. Statistical analysis was performed using the unpaired t test. 
 
CD4 T cells cultured with CD3/CD28 beads (rather than irradiated APCs) also produced some 
soluble CD137 but significantly less than CD137neg Tregs (P<0.0001). Our findings show that 
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in vitro culture conditions CD137neg Tregs can produce some soluble CD137 but significantly 
less than CD137pos Tregs.  
 
3.3.6 Increased serum soluble CD137 in older NOD.B10 Idd9.3 mice 
 
We have shown that NOD.B10 Idd9.3 mice accumulate significantly increased numbers of 
CD137pos Tregs with age (Figure 1c). We have also shown that CD137pos Tregs are more 
suppressive (Figure 2.9) and express more soluble CD137 than CD137neg Tregs (Figure 3.12). 
However, NOD and NOD.B10 Idd9.3 CD137pos Tregs do not differ in either direct contact 
mediated suppression (Figure 2.9) or soluble CD137 production on a per cell basis (Figure 
3.12). We hypothesized that the increased numbers of CD137pos Tregs with age in NOD.B10 
Idd9.3 mice might be reflected in increased soluble CD137 serum levels in vivo.  
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Figure 3.14 
 
Figure 3.14: NOD.B10 Idd9.3 congenic mice have higher serum soluble CD137 levels than 
NOD.   
20-37 week old non-diabetic NOD (n=6) and NOD.B10 Idd9.3 (n=7) were sacrificed and their serum 
tested for soluble CD137 by ELISA. Statistical analysis was performed using the unpaired t test. 
 
In fact old NOD.B10 Idd9.3 mice had significantly greater amount of serum soluble CD137 
levels than age matched NOD mice (Figure 3.14). This result shows that the immunological 
effect of the B10 CD137 allotype could be quantitative, mediated by altering the accumulation of 
the affected cell subset (i.e., CD137pos Tregs). Increased numbers of Tregs expressing the B10 
allele thereby produce increased total amounts of soluble CD137 and also quantitatively expand 
the overall available contact mediated suppression.  
 
In summary Tregs expressing the B10 Idd9.3 region, compared to the NOD allotype, show 
increased peripheral accumulation of the functionally superior CD137pos Tregs with age. We 
have also established that soluble CD137 may be one of the mechanisms of CD137pos Tregs 
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suppression.  NOD.B10 Idd9.3 mice show a correlation between accumulation of CD137pos 
Tregs with age and increased serum soluble CD137. The data presented here strongly support 
a critical role for CD137pos Tregs in the regulation of T1D. 
 
 
 
3.4 DISCUSSION 
 
 
Our previous studies showed that anti-CD137 antibody treatment increased the number of 
CD4posCD25pos T cells in NOD mice and that anti-CD137 antibodies bound specifically to 
CD4posCD25posCD137pos Tregs in vivo while preventing diabetes (Chapter one) [137].  The B10 
Tnfrsf9 allele differs from the NOD allele by three coding variants [104, 225]. These sequence 
polymorphisms differences are likely responsible for the previously described decreased T cell 
signaling by the NOD allele when stimulated through CD137 [225], and it is known that CD137 
signaling enhances Bcl-xL production and mediates cell survival [145]. It remained unclear how 
the decreased NOD allotype CD137 signaling could mediate increased T1D susceptibility [225]. 
We hypothesized that decreased signaling through the NOD CD137 allele, or increased 
signaling through the B10 CD137 allele, could influence T1D incidence by affecting Treg 
accumulation, and investigated this hypothesis using NOD and NOD.B10 Idd9.3 mice. We 
found increased accumulation of Tregs expressing the B10 Idd9.3 locus in two separate 
systems, i.e. ex vivo in NOD vs. NOD.B10 Idd9.3 mice and in a mixed bone marrow chimera 
system. The absolute number of splenic lymphocytes, CD4 cells and CD4posCD25pos T cells 
increased with age in both NOD and NOD.B10 Idd9.3 mice; however the number of 
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CD4posCD25posCD137pos Tregs increased only in NOD.B10 Idd9.3 mice, reflecting a specific 
increase in their percentage in NOD.B10 Idd9.3 and a decreased percentage in NOD. 
Conversely, in the thymus, the number of CD4posCD25posCD137pos T cells decreased in NOD 
and increased in older NOD.B10 Idd9.3 mice, reflecting a significantly increased percentage of 
thymic CD137pos Tregs in older NOD.B10 Idd9.3 mice. Our data suggests that increased thymic 
output of CD4posCD25posCD137pos T cells in older NOD.B10 Idd9.3 mice could contribute to the 
increased accumulation of these cells in the periphery. However we have not conclusively 
proven increased thymic output, and there could be additional mechanisms for peripheral 
accumulation of CD4posCD25posCD137pos Tregs. Our data on cell numbers in spleen and thymus 
of NOD vs. NOD.B10 Idd9.3 suggests a specific increase in CD137pos Tregs in the NOD.B10 
Idd9.3 mice, but these results could be influenced by many intrinsic and extrinsic causes. To 
address this point and to show in a separate system that the B10 Idd9.3 region supported 
increased accumulation of CD137pos Tregs, we used a mixed bone marrow chimera approach, 
in which NOD and B10 Idd9.3-expressing Tregs could develop in the same mouse and hence 
have the same extrinsic cellular environment. The studies in bone marrow chimeras show that 
the increased accumulation of B10 Idd9.3 expressing Tregs is a cell intrinsic feature in CD137pos 
Tregs. This does not exclude the possibility that extrinsic factors, particularly IL-2 production 
from T cells, could also be contributing to expansion or survival of various cell types and 
protection from diabetes in NOD.B10 Idd9.3 mice. Given that the B10 allele mediates enhanced 
IL-2 production in NOD.B10 Idd9.3 CD4pos T cells [225], this is a likely contributing factor that 
makes the system more complex and multifactorial.   
We also explored possible mechanisms for accumulation of CD137pos Tregs in old NOD.B10 
Idd9.3 mice. First we observed that the NOD.B10 Idd9.3 CD137pos Tregs do not proliferate more 
in vitro or in vivo than the same cell subset in NOD mice, suggesting that proliferation does not 
account for increased accumulation of CD137pos Tregs in NOD.B10 Idd9.3 mice. Next, we 
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showed that increased CD137pos Treg accumulation is correlated with increased CD137pos Treg 
Bcl-xL mRNA expression in both NOD.B10 Idd9.3 mice and in the CD137pos Tregs with the B10 
allotype in the mixed bone marrow chimera mice. The lack of increased Bcl-xL protein 
expression and the increased Bcl-xL in CD137neg Tregs in NOD.B10 Idd9.3 mice, however, 
makes this correlation hard to interpret. Furthermore, we did not see any difference in cell death 
between NOD and NOD.B10 Idd9.3 Treg subsets upon in-vitro stimulation. Hence further 
studies need to be performed to establish the mechanism of accumulation of CD137pos Tregs in 
old NOD.B10 Idd9.3 mice. 
It has been reported that Foxp3posTGF-bpos T cells significantly decline with age in NOD mice 
and that the aged CD4posCD25pos T cells are less suppressive against aged CD4posCD25neg T 
cells [76, 77]. In addition, the increased protection from diabetes in the NOD BDC2.5 model is 
also associated with increased Foxp3+ T cells with age [235]. Therefore it is possible that the 
increased number of CD137pos Tregs in NOD.B10 Idd9.3 mice with age could result in increased 
peripheral immune regulation that could regulate the onset of T1D. We observed that the 
amount of CD137 (MFI) on the cell surface of CD4posCD25posCD137pos Tregs is not decreased 
on aged NOD CD137pos Tregs—the accumulating CD137pos Tregs on aged NOD are all CD137-
high expressers. The CD137 MFI is also higher in young NOD.B10 Idd9.3 compared to young 
NOD CD137pos Tregs.  The decrease in cellular CD137 expression in young NOD vs. NOD.B10 
Idd9.3 CD137pos Tregs might affect the accumulation of total number of surviving cells long term. 
Increased expression of an allele that in itself mediates increased signaling could combine to 
produce an intrinsically mediated signal that results in accumulation of these CD137pos Tregs in 
NOD.B10 Idd9.3 mice.  This is entirely consistent with studies of the function of CD137 in 
CD137 knockout mice, which have decreased long term survival of antigen specific CD8 T cells 
[10]. Since we have shown that CD137pos Tregs are functionally superior at regulation, an 
increase of this cell subset over time could result in increased peripheral regulation and 
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increased protection from T1D. Our study has not been able to link increased accumulation with 
increased cell proliferation, cell survival or cell death. Although further studies are needed to 
understand the link between CD137 and accumulation of Tregs, our results strongly suggest 
that CD137 co-stimulation is important for Treg mediated diabetes prevention. 
Mouse CD4posCD25pos Tregs have been differentiated into subsets based on their expression of 
cell surface molecules such as CD134 [236], integrin alpha E beta 7[237] and CD62L [188, 238] 
that affect their suppressor activity, or by molecules such as CD45RApos [239] and P-selectin 
[240] that delineate Treg differentiation in-vitro or in-vivo. Our results differentiate two sub-
populations of CD4posCD25pos Tregs, CD137pos and CD137neg. These subsets are not merely 
phenotypically differentiated by cell surface expression of CD137, but by differences in 
functional cell mediated suppression, and by differences in the production of 
immunosuppressive soluble CD137.  
Soluble CD137 has been reported in the sera of RA patients and in the CSF of MS patients, and 
MS patients have decreased expression of CD137 on their Tregs [164, 241-243]. It has been 
shown that soluble CD137 acts to inhibit T cell proliferation [162, 165]. Although the mechanism 
for soluble CD137 mediated suppression is not fully understood, it has been shown to bind with 
CD137L in vitro and likely mediates its effect through CD137L [162]. In addition, soluble CD137 
has been reported to arise later in the immune response to counteract overactivation of the 
immune system [165].  These previous reports combined with the findings presented here 
suggest that production of soluble CD137 may act as a ―brake‖ upon normal immune activation. 
In this scenario, activation of antigen specific CD137pos Tregs could produce soluble CD137 
which, in combination with contact dependent suppression, would down regulate the immune 
activation of both T cells and APCs expressing CD137L [244]. Insufficient production of soluble 
CD137 (for example, in our system, mediated by a decrease in frequency of NOD Tregs 
producing soluble CD137 with age) could lead to exaggerated immune activation; conversely 
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increased numbers of such Tregs could act to decrease immune activation in NOD.B10 Idd9.3 
mice. These considerations are strengthened by our observation of increased serum soluble 
CD137 in the protected NOD.B10 Idd9.3 mice with age (Figure 3.14), correlating with the 
increased accumulation of CD137pos Tregs in these mice, compared to NOD mice. We showed 
that there was no intrinsic cellular difference between NOD and NOD.B10 Idd9.3 cells in either 
contact mediated suppression (Figure 3.11) or production of soluble CD137 (Figure 3.12). 
However, the accumulation of CD137pos Tregs in the NOD.B10 Idd9.3 mice was correlated with 
increased total amount of serum soluble CD137 (Figure 3.14) and thus increased overall 
immunosuppression. Similarly, while NOD and NOD.B10 Idd9.3 CD137pos Tregs do not differ in 
contact dependent suppression on a per cell basis (Figure 3.11), increased numbers of 
CD137pos Tregs increases the total available contact mediated immunosuppression in NOD.B10 
Idd9.3 mice. Thus, the B10 Idd9.3 allele acts primarily to enhance accumulation of CD137pos 
cells, rather than by changing the immunosuppressive function on a per cell basis-- but the net 
overall effect is increased systemic immunosuppression. These conclusions are strongly 
supported by the evidence presented here but not directly proven, as will be done in future 
studies. 
Our study explains how the hyporesponsive NOD CD137 allotype can contribute to increased 
T1D susceptibility in NOD mice, compared to the B10 allotype in the NOD.B10 Idd9.3 mice. 
Thus, the NOD.B10 Idd9.3 allele could lead to increased accumulation of functionally superior 
CD137pos Tregs with age and thus downregulate autoimmunity; whereas NOD would have a 
quantitative deficiency of CD137pos Tregs compared to NOD.B10 Idd9.3, contributing to 
enhanced NOD autoimmunity with age. A decreased number of CD137pos Tregs results in 
decreased total cell mediated suppression as well as decreased production of counter-
regulatory soluble CD137, which might be even more important at the site of inflammation (e.g. 
the pancreatic islet). These considerations lead us to suggest that enhancing site specific 
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expression of soluble CD137 could downregulate autoimmunity, and we will explore this 
hypothesis in future studies.  
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4.0 THE SOLUBLE FORM OF CD137 IS SUPPRESSIVE AND 
PREVENTS DIABETES IN NOD MICE 
 
This manuscript is being prepared for submission. The initial studies on CD137pos Tregs and 
soluble CD137 production by Tregs were performed by Kritika Kachapati. David Adams 
developed the lentiviral vectors and tranduced cell lines for soluble CD137 production. Soluble 
CD137 was purified and characterized by Kyle Bednar and tested in vitro by both Kyle and 
Kritika. NOD soluble CD137 treatment and histology was performed by Kyle.  
 
 
4.1. INTRODUCTION 
 
As discussed in Chapter 1, NOD mice serve as an excellent model for understanding genetic 
factors influencing disease, and genetic mapping studies performed over the last 25 years have 
identified multiple Insulin dependent diabetes (Idd) loci influencing disease in NOD mice.  Idd 
loci have been incorporated into NOD congenic mice (containing the NOD background with 
protective Idd regions from B6 background). NOD.B10 Idd9.3 congenic mice (strain 1106) offers 
a model for studying the candidate genes in Idd9.3 loci, with CD137 being the strongest 
candidate gene in the region. In Chapters 2 and 3 we have shown several studies showing a 
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strong effect of CD137 on disease and on T-cell/Treg function. We showed that agonist anti-
CD137 antibody treatment prevents diabetes in NOD mice, and increases the frequency of 
CD4posCD25pos T cells in vivo (Figure 2.1 & 2.5). NOD.B10 Idd9.3 mice have more CD137pos 
Tregs with age compared to NOD mice, and that CD137pos Tregs expressing the B10 allele 
accumulate specifically in NOD: NOD.B10 Idd9.3 mixed bone marrow chimeras (Figure 3.2 & 
3.7). The significance of this is found in our data showing functionally superior suppressive 
capacity of CD137pos Tregs compared to CD137neg Tregs (Figure 2.9 & 2.10). In addition, we 
showed that CD137pos Tregs are the major cellular source of an alternately spliced CD137 
product, soluble CD137 (Figure 3.12). Finally, NOD.B10 Idd9.3 mice show increased serum 
soluble CD137 with age, correlated with increased accumulation of CD137pos Tregs and 
protection from diabetes (Figure 3.14). Here we integrate our prior studies by showing the 
mechanistic connection of anti-CD137 antibody therapy with soluble CD137 production.  
 
First, using a CD25 blocking antibody to deplete Treg cells in vivo, we show that CD4posCD25pos 
Tregs are essential for anti-CD137 mediated diabetes protection. The anti-CD137 antibody 
treatment initiated a signaling response in CD137pos Tregs, resulting in the redistribution of a 
downstream adaptor molecule, TRAF2 from the cytosol to the membrane, a response not seen 
in CD137neg Tregs. Mouse CD137 is known to be alternately spliced in T cells to produce two 
different isoforms; full length CD137 protein that is bound to cell surface and a soluble CD137 
isoform, in which the transmembrane-encoding exon 8 is spliced out [161]. Previously we have 
shown that CD137pos Tregs produce high levels of soluble CD137, as well as the full length, 
membrane-bound protein (Figure 3.12). Here we show that soluble CD137 produced by 
CD137pos Treg increases after anti-CD137 treatment and accumulates in the serum of the 
injected mice. Others have found that soluble CD137 is suppressive to T cells and that it can 
initiate activation induced cell death (AICD) [166]. We show here that blockade of CD137L 
abrogated CD137pos Treg mediated transwell suppression of T cells in the absence of APC, 
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indicating an active role for soluble CD137 in proliferative suppression. Soluble CD137-Fc 
chimeric protein also suppressed CD4 T cell proliferation in vitro. To confirm the suppressive 
role of soluble CD137, we used a lentiviral construct to produce recombinant soluble CD137 in 
vitro.  Virally-made soluble CD137 protein was purified from the culture supernatant using 
affinity chromotography and structurally characterized to exist predominantly as a dimer by 
western blot and analytical ultra-centrifugation (AUC). Purified soluble CD137 was found to be 
suppressive in vitro and greatly reduced the incidence of diabetes in female NOD mice. Taken 
together, these results show a strong association between anti-CD137 and soluble CD137 
production in vivo and confirm that soluble CD137 is a novel immunosuppressive molecule able 
to reduce the incidence of diabetes in NOD mice. 
 
 
4.2 METHODS 
 
4.2.1 Mice and reagents:  
 
NOD mice were maintained under specific pathogen-free conditions in our institution‘s animal 
facilities. Mice were handled in accordance with the animal care guidelines of University of 
Cincinnati School of Medicine. Urinary glucose analysis was performed once a week using Tes-
tape (Shionogi, Osaka Japan) to assess diabetes progression. Agonist anti-CD137 monoclonal 
antibodies (clone 3H3) were previously described [11]. CD4-APC-Cy7, CD25-FITC, and anti-
CD137-APC antibodies were purchased from BD pharmingen. Anti-mouse CD137L (clone TSK-
1) blocking antibodies and IgG2a isotype control (clone RTK2758) antibodies were purchased 
from BioLegend (California). CD3/CD28 coated beads and recombinant mouse IL-2 were 
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purchased from Invitrogen. CD137-Fc conjugated recombinant protein was purchased from 
R&D Systems (Minnesota).  Primers for GAPDH (4352339E-0801016), Beta-2 microglobulin 
(Mm00437762_m1), Foxp3 (Mm00475156_m1), IL-10 (Mm00439616_m1), TGF- 
(Mm01178819_m1) and Bcl-xl (Mm00437783_m1) were purchased from Applied Bioscience. 
We used custom designed primers for membrane bound and soluble CD137 (Applied 
Bioscience). Anti-TRAF2 (clone C-20) antibodies and anti-CD137 (clone 6D295) were 
purchased from Santa Cruz Biotechnology. Polyclonal secondary antibodies to mouse IgG - 
H&L (AP) (clone ab6729) and goat anti-rabbit IgG (AP) were purchased from Invitrogen and 
Southern Biotech, respectively. AP-stained proteins were visualized using the BCIP/NBT 
Substrate Solution purchased from PerkinElmer Life Sciences. 
4.2.2 Anti-CD137 Treatment:  
 
NOD mice were treated with 330μg of anti-CD25 antibody or PBS twice at a one week interval. 
Starting one day after the second injection, the mice were either untreated or treated three times 
with 200µg of anti-CD137 at 3-week spaced intervals as described in chapter 1 (Figure 2.1). 
The mice were tested for glucososuria each week. Diabetes was confirmed when blood glucose 
levels reached >300 mg/dl. In experiments where Treg cells were analyzed after anti-CD137 
treatment, the mice were treated with 100μg of anti-CD137 twice at a one week intervals and 
sacrificed for analysis one day after the last antibody treatment. 
4.2.3 RT-PCR:  
 
CD4 T cells were purified from splenocytes using CD4 magnetic beads (Miltenyl Biotech, 
California). The isolated CD4 T cells were blocked with 2.4G2 Ab and stained with CD4-APC-
Cy7, CD25-FITC, and anti-CD137-APC Abs as described above. The cells were then sorted 
using a BD FacsAria machine (BD Bioscience) into CD4posCD25negCD137neg and 
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CD4posCD25posCD137pos cell subsets. Whole cell mRNA was extracted from the purified cells 
using an RNeasy mini kit (Qiagen) and converted into cDNA (Promega Reverse Transcription 
System). Quantitative Real Time Polymerase Chain Reaction (RT-PCR) was performed on the 
amplified cDNAs using TaqMan primers for Gadph or B2m and Bcl-xl using a StepOnePlus 
Real-Time PCR system (Applied Biosystems). The experimental CT values for genes-of-interest 
were subtracted from the CT values for control housekeeping genes (either Gadph or B2m) and 
the data plotted using GraphPad Prism 5 (Version 5.02). 
4.2.4 Treg Transwell Suppression Assay:  
 
100,000 sorted CD4posCD25negCD137neg T cells were cultured with 50,000 CD3/CD28-coated 
beads (Invitrogen) in the bottom wells of a 96 well transwell plate (Corning). 25,000 
CD4posCD25posCD137pos Tregs were cultured in the top wells with 50,000 CD3/CD28-coated 
beads. In some wells, 20μg/ml of CD137L (TKS-1) blocking antibodies were added to the 
bottom wells. The transwell plates were incubated at 37°C in 5% CO2 and the cells pulsed with 
1 µCi [3H] thymidine on Day 3. Cells in the bottom wells were later harvested and counted using 
a beta scintillation counter as indicated. 
4.2.5 Proliferation Assay with thymidine:  
 
CD4posCD25negCD137neg cells were stained and sorted using BDAria flow sorter (BD Bioscience) 
to 90-95% purity. 50,000 of the sorted CD4posCD25negCD137neg T cells were cultured with 
20,000 CD3/28 beads in triplicate wells in the presence or absence of 1μg/ml of soluble CD137-
Fc. 20μg/ml of either CD137L blocking antibodies or IgG2a isotype control antibodies were 
added to select wells. All cells were subsequently pulsed-labelled with 1 µCi [3H] thymidine on 
Day 3, and 16 hours later, thymidine incorporation was assessed using a beta scintillation 
counter. 
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4.2.6 Proliferation Assay with CFSE:  
 
Magnetically-sorted NOD CD4 T cells were stained with 0.5μM of carboxyfluorescein 
succinimidyl ester (CFSE) before being added to a 96-well u-bottom plate.  100,000 CD4 T cells 
per well were cultured under one of the following three conditions: Unstimulated (control), 
stimulated (20,000 CD3/CD28 beads), or stimulated with 15μg of purified recombinant soluble 
CD137. The CFSE-labeled cells were grown for 3 days at 37°C in 5% CO2, and then on day 3, 
the labeled cells were harvested, blocked with 2.4G2 Ab and stained with a combination of 
CD4-PCP, propidium iodine, and Annexin V-APC.     
4.2.7 Cell death:   
 
NOD CD4 T cells were purified using magnetic column. 100,000 of CD4 T cells per well were 
left uncultured or stimulated with 20,000 CD3/CD28 beads. In some wells 15μg of purified 
recombinant soluble CD137 were added to the bead stimulated wells.  The cells were then 
stained with CD4-FITC and PI on day 3. Percentage of dead cells was determined by gating on 
PI positive cells.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
4.2.8 ELISA: 
 
Mouse 4-1BB DuoSet Elisa system (R&D Systems, California) was used to detect soluble 
CD137 from serum and culture supernatants. The kit uses rat anti-mouse 4-1BB capture 
antibody and biotinylated goat anti-mouse 4-1BB detection antibody to detect soluble CD137 
protein. Recombinant mouse 4-1BB, provided in the kit, was used as a standard.  
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4.2.9 Production of soluble CD137: 
A sequence-verified, bacterial cDNA clone for Mus musculus soluble CD137 (B10 ‗wild type‘ 
allele) was obtained from Open Biosystems (Clone ID 1497753). This cDNA was originally 
ligated into the pT7T3-Pac vector, flanked by unique EcoRI and NotI sites; Using agarose gel 
electrophoretic analysis and ethidium bromide staining, we confirmed that the soluble CD137 
clone releases the expected ~916 bp fragment after digestion with EcoR1 and Notl. We excised 
the soluble CD137 DNA band and inserted it into the multiple cloning site (MCS) of LeGO-iG2 
using standard subcloning procedures. The soluble CD137 minigene was inserted immediately 
downstream from the strong Spleen Focus-Forming Virus (SFFV) promoter in the LeGO-iG2 
lentiviral vector, (between the two unique restriction sites EcoRI and NotI) as previously 
described [245]. This location permits co-expression of sCD137 along with a downstream 
enhanced green fluorescent protein (EGFP) reporter gene, permitting green fluorescence to be 
used to monitor the efficiency of viral transduction and bicistronic protein expression. 
Immortalized mouse fibroblasts (NIH3T3) and human embryonic kidney (HEK293) cells were 
transduced with VSVg-enveloped lentiviral particles made with either the parent vector LeGO-
iG2 or LeGO-iG2-sCD137.   The resultant transduced cells were cultured in 10.0% CO2 at 37° C 
and split as needed in antibiotic (pen strep) and L-glutamine supplemented DMEM media 
containing 10% FBS (Fetal Bovine Serum). The supernatant from confluent cultures was 
collected over several weeks and tested for the production of soluble CD137 by ELISA (see 
ELISA in methods). NIH3T3 and HEK293 cell lines exhibiting stable EGFP expression were 
subsequently sorted for high (top 10%) and medium (middle 40-70%) EGFP expression using a 
Beckman Coulter MoFlo XDP flow cytometry. The sorted cells were subsequently re-plated and 
cultured for an additional five days in IMDM with 10% FBS before checking soluble CD137 and 
EGFP expression by ELISA and flow cytometry, respectively. High CD137 expressors were 
later used for large-scale protein purification and for archiving producer stocks.  
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4.2.10 Purification of Soluble CD137:  
 
To purify soluble CD137 protein from culture supernatants, we generated an anti-CD137 affinity 
chromatography column. For this, we first purified anti-CD137 antibodies using 3H3 
antibody/hybridoma generously given to us by R. Mittler [131]. The antibody-producing cells 
were cultured in IgG-depleted Fetal Bovine Serum (FBS) at a cell density of 1x106 cells per 
flasks or in roller bottles, and split as required for 4 weeks. After this time period, the cells were 
serum-starved for two weeks to obtain optimal antibody production.  The secreted antibody was 
subsequently coupled to GE Life Sciences CNBr-activated Sepharose™ 4B column, according 
to the manufacturer‘s instructions. This results in strong covalent bound between the antibody 
and CNBR-activated sepharose beads. Coupling efficiency was assessed by running the elution 
buffer, i.e., 3.5M MgCl2, over the column and checking for release of the anti-CD137 antibody 
(3H3) from the CNBR-activated beads. A NanoDrop ND-1000 spectrophotometer was used to 
confirm that no CD137 antibody was lost from the column. Supernatant from HEK293:LeGO-
iG2-sCD137 High cells was used for the purification due to their superior production of soluble 
CD137.  The supernatant was 0.22μ filtered before being run over the column.  The flowthrough 
supernatant was tested after each run by ELISA (see ELISA methods) to ensure the depletion 
of soluble CD137 due to binding to the column.  After elution from the antibody column, soluble 
CD137 protein was dialyzed three times in Tris-Buffered Saline (TBS) and two times into 
phosphate buffered saline (PBS).  The amount of purified soluble CD137 and degree of 
concentration was determined using a Ross Recorders spectrophotometer, ELISA, and 
NanoDrop ND-1000. 
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4.2.11 Western Blot: 
 
 For assaying the redistribution of TRAF2 in cells after anti-CD137 treatment, 
CD4posCD25negCD137neg, CD4posCD25posCD137neg and CD4posCD25posCD137pos T cell subsets 
were sorted and lysed for 30 min on ice in the presence of broad specificity protease inhibitors 
(Sigma, cat no. P8340). The lysed cells were then briefly centrifuged for 30 sec at 6000 rpm to 
separate cellular proteins into either soluble (cytoplasmic) or insoluble (membrane-associated) 
fractions (Arch RH et al., 2000).  After separation of recovered proteins on a 10% SDS-PAGE 
gel (Invitrogen) under +DTT reducing conditions, samples were transferred into a nitrocellulose 
membrane and immunostained. Low molecular weight, pre-stained protein markers (BioRad) 
were used as size controls.  Primary anti-TRAF2 antibodies were added to the blots initially, 
followed by goat anti-Rabbit IgG Alkaline Phosphatase (AP) conjugate secondary antibodies. 
The AP-antibody-bound proteins were then stained using NBT (nitro-blue tetrazolium chloride) 
and BCIP (5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt) as described above. The 
TRAF2 protein bands were imaged and analyzed using AlphaImager hardware and AlphaView 
software supplied by the manufacturer (AlphaInnotech). For the soluble CD137 western blot, 
15μl of soluble CD137 protein samples were mixed in either 15μL of reducing (10.0 ml 0.5 M 
Tris-HCl, 2.0 g SDS, 0.1 g Bromophenol Blue, 1.543 g of Dithiothreitol, 12.5 ml of 80% 
Glycerol, up to 50 ml with H20) or non-reducing (10.0 ml 0.5 M Tris-HCl, 2.0 g SDS, 0.1 g 
Bromophenol Blue, 12.5 ml 80% Glycerol, up to 50 ml with H20) sample buffer.  The samples 
were then boiled for 5 minutes and cooled to RT. 25ul of each sample was loaded onto 12% 
Tris-glycine gels (Novex) and run at 125V for 105 minutes in a XCell II apparatus (Invitrogen). 
Low molecular weight pre-stained SDS-PAGE protein markers (BioRad, cat. no. 161-0305) 
were used as size markers. Next the protein was transferred onto nitrocellulose paper. 
Afterwards, the blots were blocked using 10% BSA (Bovine Serum Albumin) in TBS-T (Tris-
Buffered Saline with 2.0% Tween 20) and.  The primary anti-CD137 antibody (Millipore, rat anti-
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mouse 4-1BB clone MAB3733) added to the blots. Afterwards, polyclonal secondary antibody to 
mouse IgG - H&L (AP) was added. The AP antibody-bound proteins were later stained using 
NBT and BCIP and their relative gel mobility and molecular size compared to the pre-stained 
protein markers, and recombinant CD137-Fc protein.  
4.2.12 Analytical ultra-centrifugation (AUC): 
 
Sedimentation velocity experiments were utilized to determine the size distribution of soluble 
CD137 at 20°C using a Beckman XL-I analytical ultracentrifuge.  Soluble CD137 in PBS was 
spun at 48,000 rpm and successive scans were obtained at 280 nm using the absorbance 
optical system.  Raw sedimentation data were deconvoluted to produce sedimentation 
coefficient distributions and molecular weight estimates using the c(s) analysis routine in the 
program SEDFIT [246]. 
4.2.13 Histology:  
 
NOD female mice 4-6 weeks old were treated once a week for four weeks with either PBS or 
200 μg of sCD137.  After 225 days or at the first onset of disease the mouse was sacrificed. The 
pancreas was removed and stained using hematoxylin and eosin by The Pathology Research 
Core at Cincinnati Children‘s Hospital Medical Center. Pancreatic tissues were fixed for 24 h in 
10% buffered formalin. Tissues were embedded in paraffin and stained with hematoxylin and 
eosin. To quantitatively assess pancreatic inflammation, the scoring system was adapted from 
previously described scoring systems validated in NOD mice [247, 248]. Based on that, the 
pancreatic inflammatory blinded scoring was performed where score ranged from 0 to 5  (score 
0: normal islet, score 1: peri insulitis, with a T cell depth of 5 or less and no penetration into the 
islet, score 2: full circumferential insulitis or peri insulitis with a T cell depth of 5 or greater, no 
penetration into the islet, score 3: full circumferential insulitis or peri insulitis with a T cell depth 
 116 
of 5 or greater, less than 50% coverage of the islet by T-cell infiltrate, score 4: full 
circumferential insulitis or peri insulitis with a T cell depth of 5 or greater, more than 50% 
coverage of the islet by T-cell infiltrates, score 5: scar or complete absence of β-cells.) An 
overall pancreatic insulitis score was obtained by adding the individual scores and dividing by 
the total number of islets counted per group (minimum of 36 islets were counted per group). 
4.2.14 NOD treatment with soluble CD137:  
 
Female NOD mice were treated with either PBS or 200ug of soluble CD137, once a week for 
four weeks. The blood glucose levels / diabetes progression was tested once a week using Tes-
Tape for the duration of the experiment. 
 
4.2.15 Data analysis:  
All statistical analysis was performed using the unpaired T test or the Mann-Whitney test in 
GraphPad Prism 5 (Version 5.02). Survival analysis was performed using the log-rank test in 
GraphPad. 
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4.3 RESULTS 
 
4.3.1 CD4posCD25pos T cells are essential for anti-CD137 mediated diabetes protection. 
 
Previously we demonstrated that agonistic anti-CD137 treatment prevents diabetes in NOD 
mice, and that anti-CD137 binds to CD4posCD25posCD137pos Tregs in vivo (Figure 2.1 & 2.5). To 
test whether CD4posCD25pos Tregs are essential for anti-CD137 mediated disease protection, we 
pretreated NOD mice with anti-CD25 antibody to deplete CD4posCD25pos T cells (as confirmed 
by FACS). We have previously published that ~95% of peripheral CD25pos cells are FoxP3pos at 
this age (Figure 3.5).  CD25 depletion was followed by three doses of anti-CD137 Ab injection at 
one-week intervals as described previously (Figure 2.1). Control mice were treated with anti-
CD25 alone or PBS.  
Figure 4.1 
 
Figure 4.1: CD4posCD25pos T cells are essential for anti-CD137 mediated diabetes 
prevention.  
0 50 100 150 200 250
0
10
20
30
40
50
60
70
80
90
100
110
C D 25
Anti-CD137
P BS
C D 25/Anti-CD137
Days after treatment
P
e
rc
e
n
t
s
u
rv
iv
a
l
* P= 0.0156
 118 
Seven week old NOD female mice were treated with 330μg of anti-CD25 antibody or PBS twice at a one 
week interval. One day after the second injection, the mice were either mock treated or treated three 
times with 200µg of anti-CD137 (clone 3H3, provided by Dr. R. Mittler, Emory University, Atlanta, GA) at 
3-week intervals. The groups consist of: CD25 alone (n=11), 3H3 alone (n=9), PBS alone (n=7), and both 
CD25 and 3H3 (n=11). The mice were tested for glucosuria weekly thereafter. The P value was 
calculated using the logrank statistic in GraphPad. 
 
Mice treated with anti-CD137 antibody were significantly protected from diabetes consistent with 
our result previously described in chapter 2 (Figure 4.1).  Mice that were pre-treated with anti-
CD25 antibody prior to anti-CD137 treatment, however, showed no protection from diabetes 
(Figure 4.1), demonstrating that the presence of CD25pos Tregs at the time of anti-CD137 
treatment was necessary for the observed protective effect. Anti-CD25/anti-CD137 combined 
treatment, anti-CD25 alone and PBS treated mice all succumbed to diabetes within 50-150 days 
with no statistically significant differences in outcome; notably treatment with anti-CD25 alone 
did not hasten the onset of diabetes (Figure 4.1). These results confirm that CD4posCD25pos T 
cells are indispensable for preventing diabetes with anti-CD137 therapy in NOD mice. The 
combined data suggest that CD137pos Tregs, targeted by anti-CD137 antibody treatment, are 
important for the preventing of diabetes progression.  
 
4.3.2 Anti-CD137 treatment induces TRAF2 signaling response in CD137pos Tregs in vivo  
 
CD137 belongs to TNFR superfamily of receptors that bind to TNFR-associated factors (TRAFs) 
intracellularly when stimulated [175]. Since TRAF1/2 has been shown to be upregulated by 
CD137 stimulation in T cells [10], we next tested whether anti-CD137 antibody treatment could 
cause downstream signaling of CD137 in Tregs. We treated NOD mice with anti-CD137 
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antibody in vivo and after 24 hours isolated CD4posCD25negCD137neg, CD4posCD25posCD137neg 
and CD4posCD25posCD137pos T cells by cell sorting.  
 
Figure 4.2 
 
Figure 4.2: CD137
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CD4posCD25posCD137pos T cells following binding to CD137 antibody in vivo (after treatment) but 
not in CD4posCD25negCD137neg or CD4posCD25posCD137neg T cells (Figure 4.2). These data 
indicate that anti-CD137 antibody treatment specifically targets CD137pos Tregs in vivo and 
initiates the CD137 mediated TRAF2 downstream signaling pathway in these in these cells.  
 
4.3.3 Anti-CD137 treatment enhances soluble CD137 production from CD137pos Treg in 
vitro and in vivo 
 
We have previously shown that NOD CD137pos Tregs produce high levels of soluble CD137 
when cultured in vitro with IL-2 alone (Figure 3.12). Here we tested if anti-CD137 treatment 
alters soluble CD137 production from CD137pos Tregs in vitro. We isolated CD137pos Tregs from 
anti-CD137 antibody treated (which binds to anti-CD137 in vivo) or untreated mice. Untreated 
CD4posCD25neg T cells were used as a control. We then assayed soluble CD137 production in 
CD137pos Tregs sorted from the respective mice. CD137pos Tregs from anti-CD137 treated mice 
produced significantly higher levels of soluble CD137 than untreated Tregs (Figure 4.3a). These 
data indicated that Tregs stimulated by anti-CD137 antibody in vivo produced high levels of 
soluble CD137. As seen before, CD4posCD25neg T cells from untreated NOD did not produce 
any soluble CD137 in our in vitro conditions (Figure 3.12). 
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Figure 4.3 
 
Figure 4.3: Anti-CD137 treatment increases soluble CD137 production and serum soluble 
CD137.  
(a) NOD mice (n=2) were treated with 100μg of anti-CD137 antibody or left untreated (n=2). Sorted 
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sacrificed after 24 hrs and their serum tested for soluble CD137 with ELISA as described in the methods 
section. Statistical analysis was performed using GraphPad Prism (unpaired t-test.) 
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These results show that the increased production of soluble CD137 by CD137pos Tregs could 
result in increased expression of serum soluble CD137 after anti-CD137 treatment. 
 
4.3.4 Soluble CD137 from CD137pos Tregs suppresses CD4pos T cells through CD137L 
 
The production of soluble CD137 in vivo has been associated with decreased T cell 
proliferation, and increased activated induce cell death and DNA fragmentation [165]. Our lab 
has previously shown that in untreated NOD mice, CD137pos Tregs are the primary cellular 
source of soluble CD137 (Figure 3.12). Hence we tested here whether soluble CD137 produced 
from CD137pos Tregs can suppress CD4pos effector cells in a contact independent manner in 
vitro. We have previously shown that NOD CD137pos Tregs can suppress effector T cells at 1:2 
Treg to T effectors ratio in a contact independent transwell system (Figure 2.11). Others have 
shown that soluble CD137 binds to CD137L in vitro [162]. Thus we used a CD137L blocking 
antibody (TKS1.1) to test if we could block soluble CD137 mediated suppression of CD4pos 
effector T cells in a transwell assay. To eliminate any confounding effects due to expression of 
CD137L on splenic macrophages or dendritic cells [249], we used anti-CD3/CD28 coated beads 
for stimulation instead of APC.  
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Figure4.4 
 
Figure 4.4: Blockade of CD137L decreases transwell, contact independent suppression 
mediated by CD137pos Tregs.  
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IgG2a isotype antibody (n=3 experiments) were added to the bottom wells.  The cells were pulsed with 
3H labeled thymidine on day 3 and harvested after 16 hours. Statistical analysis was performed using 
GraphPad (unpaired t-test.)   
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significantly decreased transwell suppression mediated by CD137pos Tregs (P=0.001), while 
isotype antibody had no effect on suppression (Figure 4.4). These observations suggested that 
soluble factors produced by CD137pos Tregs including soluble CD137 suppressed the 
proliferation of CD4pos effector T cells through CD137L. This conclusion is consistent with our 
previous observation that CD137pos Tregs produce high levels of soluble CD137 in a contact-
dependent APC-independent suppression assay (Figure 3.13).  
 
4.3.5 Soluble CD137-Fc suppresses CD4 T cells in vitro 
 
Our previous data suggested that soluble CD137 from CD137pos Tregs directly suppresses 
CD3/CD28 stimulated CD4pos T effector cells in vitro, and does not act simply by passively 
blocking CD137: CD137L interactions between T cells. To more directly explore the mechanism 
of soluble CD137-dependent suppression, we used a recombinant mouse CD137-Fc chimeric 
protein in a Treg-free assay. We cultured CD4posCD25negCD137neg T cells with CD3/28 beads in 
the presence of soluble CD137-Fc (Figure 4.5). The addition of soluble CD137-Fc significantly 
reduced the proliferation of CD3/CD28 stimulated CD4 T cells (P=0.0001), showing that soluble 
CD137-Fc protein can directly suppress CD4posCD25negCD137neg T cells in vitro, consistent with 
prior results [244]. 
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Figure4.5 
 
 
Figure 4.5: Soluble CD137-Fc directly suppresses T cells in an APC and Treg 
independent manner.  
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abrogated the suppression mediated by CD137-Fc, confirming that CD137L is essential for 
suppression of CD4pos effector T cells by soluble CD137. Our results demonstrate that the 
interaction of soluble CD137 directly with CD137L negatively regulates CD4pos effector T cells 
as hypothesized previously [162, 165]. 
 
4.3.6 Production of recombinant soluble CD137 in vitro 
 
It was possible that the Fc-portion of the soluble CD137-Fc molecule had an effect on its action 
or mechanism, so we sought to develop a pure form of soluble CD137 as it is expressed in vivo 
to test for suppression and effects on disease in vivo. To produce soluble CD137 we first 
subcloned a soluble CD137 minigene into the lentiviral expression vector, LeGO-iG2 (Figure 
4.6a). The LeGO-iG2 vector is bicistronic and has an EGFP reporter gene immediately 
downstream from the CD137 insert, which allows for co-expression of the two transgenes from 
the highly active, spleen focus forming viral (SFFV) promoter. The LeGO-iG2 construct is also 
self-inactivating [250, 251], which allows for the viral production of soluble CD137 protein 
without contamination from viral particles. VSVg-enveloped LeGO-iG2-sCD137 viral particles 
were made in separate producer cells and then used to transduce two different eukaryote cell 
lines, NIH3T3 and HEK293 cells (see methods). Stably transduced cell lines were sorted for 
medium and high EGFP expression (Figure 4.6b) and the sorted cells were subsequently 
checked for soluble CD137 production by ELISA.  
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Figure4.6 
 
 
Figure 4.6. Lentivirally-transduced HEK293 cells produce recombinant soluble CD137 
protein in vitro. 
(a) Schematic of the lentiviral vector, LeGO-iG2-sCD137, used to express soluble protein.  The wild type 
(B10) mouse sCD137 cDNA was inserted between the unique restriction sites EcoRI and NotI.  The 
soluble CD137 minigene is expressed from the strong SFFV promoter with a downstream EGFP reporter 
used to mark cells with integrated vector.  (b) Transduced 0.5x10
6
 NIH3T3 (left) or HEK293 (right) cells 
were sorted based on medium or high EGFP expression. The transduced cells were initially cultured in 
EGFP
5’ LTR EcoRI NotI 3’ LTR
LeGO-iG2-sCD137 (8.73 kb)
SIN-LTR Ψ RRE cPPT SFFV sCD137 IRES EGFP wPRE SIN-LTR
a.
b.
c.
0
1000
2000
3000
4000
5000
High EG FP Expression
M edium EG FP Expression
Unsorted
s
C
D
1
3
7
(p
g
/m
l)
100 10
1 102 10
3
104
20
40
60
80
100
NIH3T3
High Sorted
Medium Sorted
Unsorted
100 10
1 102 10
3
104
20
40
60
80
100
HEK293
EGFP
 128 
DMEM for three weeks and stable EGFP expression was later assessed by FACs using a FACSCalibur 
flow cytometer. (c) Mouse NIH3T3 fibroblasts and human embryonic kidney (HEK293) cells were 
transduced with LeGO-iG2-sCD137 lentiviral particles.   The sorted cell lines were checked for soluble 
CD137 expression by ELISA. One representative example of multiple transductions. 
 
HEK293-EGFP high expressers produced the greatest amount of soluble CD137 protein (Figure 
4.6c).  Hence we used this cell line for large scale purification and characterization of the 
soluble protein. Lentivirally-produced soluble CD137 protein, made in either mouse NIH3T3 or 
human HEK293 cell lines, exhibited similar gel mobility and other physical characteristics 
(multimeric size, number of glycoprotein isoforms), indicating that the proteins produced from 
the mouse and human cell lines are comparable to each other (data not shown). 
 
4.3.7 Recombinant Soluble CD137 exists predominantly as a dimer 
 
Next we characterized the structure of the soluble CD137 protein isolated from HEK293 high 
EGFP producer cells. Western blotting was performed comparing purified and unpurified 
HEK293-made proteins on an SDS-PAGE gel under both reducing (with DTT) and non-reducing 
(without DTT) conditions.  Soluble CD137 protein isolated without purification from the medium 
is mainly a ~55 kDa homodimer under non-reducing conditions and a ~35 kDa monomer under 
reducing conditions (Figure 4.7a, lane 3 & 8).  These observations are consistent with previous 
studies, which reported that soluble CD137 exists as both a 30kDa monomer and a 55kDa 
homodimer [162, 252].  Affinity chromatography was used to purify soluble CD137 from the 
supernatant of the HEK-293 high-EGFP producing cell line (see methods). Since ethylene glycol 
(EG) and magnesium chloride (MgCl2) help to avoid the degradation or alteration of proteins 
during disassociation from affinity columns [253], we used these solvents during elution. After 
elution (under non-reducing buffer conditions), we performed western blot analysis on purified 
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protein using two different amounts of protein (0.45μg and 0.75μg). The observed sizes of the 
purified protein were equivalent to our previous observations with unpurified protein and again 
yielded a homodimer migrating at ~55kDa and a monomer at ~35kDa (Figure 4.7a, lane 2 & 4), 
indicating that neither binding nor elution from the affinity column affected the apparent physical 
structure of the protein. 
Figure4.7 
 
Figure 4.7. Recombinant soluble CD137 protein exists primarily as dimers. 
(a) Western blot was performed on purified and unpurified soluble CD137 protein secreted into the media 
of transduced HEK293 high-EGFP sorted cells and separated on a 12% Tris-Glycine SDS-page gel under 
non-reducing (-DTT, lanes 1-6) or reducing (+DTT, lanes 7-10) conditions. Purified soluble CD137 of 
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different concentration (0.45μg, 0.75μg), or an unpurified aliquot of equal volume was loaded in each lane 
at 15μL per lane.  Low molecular weight protein standards served as size markers (lanes 1 and 6).  0.2μg 
of CD137-Fc fusion protein served as an antibody specificity control (lanes 5 and 10). (b) Analytical ultra-
centrifugation (AUC) was performed on purified soluble CD137 from HEK293 high-EGFP cells.  1 OD of 
protein in PBS was used as the starting concentration.  500μL of soluble CD137 was separated by AUC 
for 24 hours.  The sCD137 multimers were characterized by sedimentation velocity and their molecular 
sizes estimated by curve fitting data analysis.   
 
It is important to note that soluble CD137 exists predominantly as a dimer under non-reducing 
conditions, but as a monomer under reducing conditions, strongly suggesting that the dimer is 
linked by a disulfide bond (Figure 4.7a, lane 2 & 4 vs. lane 7 & 9).  This is in accordance with 
sequence homology data indicating the existence of homodimerization domains in the CD137 
structure (Pubmed – Protein search / NCBI Conserved Protein Domains). Other TNFR family 
members (e.g. CD27 and CD40) are also known to exist as dimers through intermolecular 
disulfide bonds [254]. Three distinct monomer bands were also seen on the reduced western 
blot, suggesting that the purified protein is differentially glycosylated (0, 1, or 2 modifications; 
Figure 4.7a, lane 7 & 9).  This is consistent with the predicted protein sequence that suggests 
soluble CD137 protein harbors two canonical N-linked glycosylation sites (Pubmed – Protein 
search / NCBI Conserved Protein Domains). To further confirm the structure of purified protein, 
we used sedimentation velocity analytical ultra-centrifugation (AUC), the gold standard for 
analyzing protein structure.  Consistent with the western blot results, AUC showed that the bulk 
of soluble CD137 is present as a 54.3kDa dimer, with a small amount of monomer appearing as 
a shoulder at 26.9kDa (Figure 4.7b). Interestingly 12% of the total soluble CD137 formed higher 
order oligomers and/or aggregates at elevated concentrations (Figure 4.7b). There are two 
possible explanations for this. First at non-physiologically high concentration of the protein we 
used for AUC, it may interact through non-specific interactions. The other possibility is that 
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soluble CD137 contains uncharacterized protein-protein association domains which allow for 
different multimeric forms.   
 
4.3.8 Purified Soluble CD137 suppresses proliferation of CD4 T cells in vitro  
 
Having produced a more physiologic soluble CD137 protein, we next tested the ability of our 
recombinant purified soluble CD137 to suppress T cell proliferation in vitro. We cultured CFSE-
labeled CD4 T cells with CD3/CD28 beads with or without purified soluble CD137. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 132 
Figure 4.8 
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Figure 4.8. Purified soluble CD137 suppresses CD4 T cell proliferation in vitro.  
(a, b) CD4 T cells were CD4 magnetic bead purified from 6-8 week old NOD mice and labeled with 
carboxyfluorescein succinimidyl ester (CFSE) in vitro.  1x10
5
 CD4 T cells, stimulated with 20,000 
CD3/CD28 beads, were cultured in a U-bottom 96-well plate for 3 days with or without 15μg of purified 
soluble CD137. After three days in culture, the cells were harvested and stained with CD4. The amount of 
proliferation was assessed by CFSE FACS. (a) One representative of four independent experiments for 
CFSE dilution without soluble CD137 (left) and with soluble CD137 (right) are shown. (b) The percent of 
cells within each cell subset was calculated and graphed as histograms (n=4). (c) The cells were cultured 
as mentioned before. After three days in culture, the cells were harvested and stained with CD4 (FITC) 
and amount of cells that were stained with propidium iodide (PI) staining (n=3). Statistical analysis was 
performed using the GraphPad Prism (unpaired t-test). 
 
Addition of soluble CD137 significantly reduced the CFSE dilution of CD4 T cells, with a 
reduction in the number of cells entering the later cell cycles and an increased number of cells 
that did not enter the cell cycle at all (Figure 4.8a, b).  The percent of cells dividing multiple 
times is significantly reduced in the presence of soluble CD137. This is especially evident in the 
percent of cells in the third, fourth and fifth cell divisions with the addition of soluble CD137 
(Figure 4.8b, c). These data show that our purified protein is biologically active and functionally 
suppressive. We also observed that the culture treated with soluble CD137 did not have 
increased cell death compared to untreated bead stimulated cells (Figure 4.8c). Hence purified 
soluble CD137 is functionally suppressive but not physiologically harmful to cells under the 
conditions examined. 
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4.3.9 Soluble CD137 reduces the incidence of diabetes in NOD mice 
 
Next we tested if purified recombinant soluble CD137 when injected in vivo can prevent 
diabetes in NOD mice. We treated seven week old female NOD mice with 200 μg of purified 
soluble CD137 or PBS control, once weekly for four weeks. Urinary glucose was monitored for 
diabetes. PBS treated NOD mice showed the typical incidence of diabetes by 178 days of age 
(Figure 4.9a).  In contrast, soluble CD137 treated NOD mice showed protection from diabetes 
(Figure 4.9a). These results convincingly demonstrate that our recombinant soluble CD137 is 
functional in vivo and can prevent the onset of T1D in NOD mice. These in vivo results confirm 
that soluble CD137 can have a positive biological effect in vivo to downregulate immunity.  
Pancreatic histology with Hematoxylin and Eosin staining (H&E) of the control versus soluble 
CD137 treated mice showed that soluble CD137 treatment did not completely eliminate 
recruitment of pathogenic cells to the islets but reduced the number of islet infiltrates, 
suggesting a regulatory effect of soluble CD137 (Figure 4.9b). Blinded scoring of the pancreatic 
sections for histological insulitis confirmed that soluble CD137 treatment reduced insulitis in 
pancreatic islets (Figure 9c).  
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Figure 4.9 
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Figure 4.9. Purified soluble CD137 prevents diabetes in vivo and reduces pancreatic islet 
infiltration.  
a) Seven week old female NOD mice were treated with either PBS or with 200 μg of soluble CD137, once 
a week for four weeks (n=8 per group).  The blood glucose level of the treated animals was tested for 
diabetes over time. H&E staining of the pancreas from treated vs. control mice.  b, c) NOD female mice 4-
6 weeks old  were treated once a week for four weeks with either PBS (n=9), 200ug of soluble CD137  
(n=7). Incidence of diabetes was measured once a week using urine glucose levels tested by tes-tape 
(Japan).  After 225 days or at the first onset of disease the mouse was sacrificed. The pancreas was 
removed and stained using hematoxylin and eosin (H&E). b) One representative pancreatic section for 
PBS treated NOD and soluble CD137 treated NOD under 40x magnification. c) The slides were blindly 
scored as mentioned in the methods section and graphed as histograms. The P value was calculated 
using the logrank statistic (a) or unpaired t-test (c) in GraphPad Prism. 
 
In summary, we have established that CD4posCD25pos T cells are essential for anti-CD137 
antibody mediated diabetes protection and that the Tregs treated with anti-CD137 produce high 
levels of soluble CD137 in vitro and in vivo. We have also shown that purified soluble CD137 is 
functionally suppressive to CD4 T cells in vitro. Recombinant purified soluble CD137 prevented 
the development of diabetes and significantly reduced the number of islet infiltrates in NOD 
mice. The data presented here strongly supports a role for soluble CD137 in both anti-CD137 
antibody mediated diabetes protection and antibody-independent diabetes protection in NOD 
mice. 
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4.4 DISCUSSION 
 
 
Our previous studies in chapter 2 showed that anti-CD137 antibody treatment increased the 
number of CD4posCD25pos T cells in NOD mice and that anti-CD137 antibodies bound 
specifically to a subset of CD4posCD25pos Tregs in vivo while preventing diabetes. The anti-
CD137 treated CD4posCD25pos T regulatory cells were also protective against diabetes in 
adoptive cell transfer experiments (Figure 2.6).  Here we have confirmed that CD4posCD25pos T 
cells are essential for anti-CD137 mediated diabetes prevention since elimination of 
CD4posCD25pos T cells by anti-CD25 antibody before anti-CD137 treatment abrogates disease 
protection (Figure 4.1). We conclude therefore that anti-CD137 antibody mediated diabetes 
protection via these CD4posCD25posCD137pos T cells (i.e., anti-CD137 antibody-bound 
CD4posCD25pos T cells).  
 
The pro-survival members of the TNFR family such as CD137 are known to signal through a set 
of signaling adapter proteins known as TRAFs [255]. Upon receptor ligation, the TRAF1 and 
TRAF2 molecules are recruited to the TRAF-binding motifs in the cytoplasmic tails of CD137 
[255]. The association of TRAF2, in particular, with the cell membrane (insoluble fraction) in 
anti-CD137 treated CD137pos Tregs confirmed that the antibody signals intracellularly through 
CD137 (Figure 4.2a).  Importantly, TRAF2 was not found to be redistributed in CD4 T cells, 
which did not contain CD137 on their cell surface (Figure 4.2a). These observations are 
consistent with the previous observation that CD137 co-stimulation promotes the survival of T 
cells by signaling through TRAF1 and TRAF2 with the eventual phosphorylation and activation 
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of NF-KB and AP-1 [10, 179, 256]. Previous studies have shown that CD137 costimulation led 
to upregulation of pro-survival molecule Bcl-xl, which promoted the expression of several 
survival and effector genes in T cells [10, 145].  Overall, our findings confirmed and supported 
the idea that anti-CD137 antibody treatment specially targeted CD137 expressing 
CD4posCD25pos Tregs and resulted in a downstream signaling cascade arising from CD137 
signaling.  
 
Cultured CD137pos Tregs produced significantly higher levels of soluble CD137 from anti-CD137 
treated mice compared to untreated mice (Figure 4.3a). It is possible that CD137pos Tregs from 
the treated mice proliferate to a greater extent than the untreated mice and hence produce 
higher levels of soluble CD137, although we have not tested that possibility here. Previously, we 
showed that CD137pos Tregs from untreated mice proliferated upon IL-2 culture in vitro (Figure 
3.12). Importantly, we also observed that soluble CD137 increased significantly in the serum of 
NOD mice after anti-CD137 treatment (Figure 4.3b). Previously, we showed that anti-CD137 
antibody treatment increased the frequency of CD4posCD25pos Tregs in vivo (Figure 2.3).  Hence 
the observed increased serum soluble CD137 after treatment could result from both the 
increase in Tregs and the increased production of soluble CD137 from these same CD137pos 
Tregs after treatment. The increased levels of detected soluble CD137 in vivo after antibody 
treatment could also result from accumulation of soluble CD137 and anti-CD137 antibody 
complexes, which would be expected to stabilize the soluble CD137 protein.  However, the 
increased soluble CD137 production by CD137pos Tregs after antibody treatment in vitro 
suggested that the increase in serum soluble CD137 is not due wholly to an increase in the half-
life of soluble CD137. It is also possible that other cell types express soluble CD137 following 
antibody treatment but we have not explored that possibility here. Elevated soluble CD137 
serum levels have also been seen in other autoimmune disease models [241, 257]. The 
increased production of soluble CD137 may be a common response following over-activation of 
 139 
the immune system in such cases and may be an essential mechanism for the protective effect 
seen anti-CD137 antibody treatment.  
 
To investigate a possible role for soluble CD137 in diabetes protection, we first tested its 
functions in vitro. Previously we have seen that NOD CD137pos Tregs suppressed T cell 
proliferation in vitro in a contact independent system (Figure 2.11). Transwell CD137L blockade 
experiments described here showed that CD137pos Tregs suppressed CD4 effector T cell 
proliferation in a contact independent manner, likely through secretion of soluble CD137 (Figure 
4.3). Notably, CD137L blockade alone had no effect on the proliferation of 
CD4posCD25negCD137neg T cells, suggesting that the suppressive signal does not arise from 
competition for CD137L binding (Figure 4.4) (i.e. that the effect is not simply a passive effect of 
soluble CD137 blocking the CD137L receptor). Indeed soluble CD137 has been shown 
previously to bind to CD137L in vitro [162]. The protein expression of CD137L in CD4 T cells by 
FACS was very low, (data not shown), similar to the results published by another group [168]. 
Despite these negative observations, it is clear that soluble CD137, in our in vitro culture 
conditions, actively suppressed the proliferation of CD4posCD25negCD137neg T cells and does not 
simply act by passively blocking interactions between membrane-bound CD137 and CD137L 
molecules expressed on separate, but otherwise similar, T cells. We also showed that soluble 
CD137-Fc fusion protein resulted in suppression through CD137L on CD4 effector T cells, 
further confirming the effect of soluble CD137 on suppression of CD4 T cells (Figure 4.5).  
 
To test directly the hypothesis that soluble CD137 can act in an endocrine-type manner, we set 
up an in vitro system for the production and purification of soluble CD137. Analysis of our 
recombinant protein showed that soluble CD137 is primarily a 54.3kDa dimer, with a smaller 
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fraction existing as 26.9kDa monomer. The dimeric form of soluble CD137 is likely linked by an 
intermolecular disulfide bond, which can be reduced to monomer protein in the presence of 
DTT.  Our results are consistent with previous findings indicating that soluble CD137 exists as 
both homodimers and monomers [162, 252]. They also agree with in silico sequence analysis of 
the soluble CD137 protein (Pubmed – Protein search / NCBI Conserved Protein Domains).  
Analytical ultra-centrifugation also showed that less than 12% of the purified soluble CD137 
protein forms higher-order multimeric forms, which is consistent with another report which has 
also shown multimeric forms of soluble CD137  [162]. Thus, we produced, purified and 
characterized for the first time, to our knowledge, a recombinant soluble CD137 protein, which 
can be used for functionally studies both in vitro and in vivo. 
 
More importantly, we found that the purified soluble CD137 protein is functionally suppressive in 
vitro during T cell proliferation experiments (Figure 4.8).  The purified soluble CD137 protein 
reduced the number of T cells entering cell division in purified CD4 T cells in vitro using a CFSE 
dilution assay (Figure 4.8a) but did not increase cell death (Figure 4.8b). It is possible that 
soluble CD137 induces cell cycle arrest or anergy in activated CD4 T cells, although we have 
not studied that here. Our new results supported our previous observations that blockade of 
CD137L abrogated the suppression of CD4 T cells (most likely) due to the secreted soluble 
CD137 produced by Tregs (Figure 4.3). We also tested and verified that our soluble CD137 is 
non-toxic to T cells and that it does not cause cell death (Figure 4.8b). It has been shown 
previously that expression of soluble CD137 correlates with T cell suppression and cell death 
and that soluble CD137 arises late in the immune response to prevent excessive immune 
activation [165]. Our present results confirmed CD4 T cell suppression but did not show 
increased cell death as observed before.  However our results are consistent with our previous 
observations that indicated that soluble CD137-Fc is suppressive to CD4 T cells in vitro (Figure 
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4.6) and also matches another observation from another group that showed suppression with 
soluble CD137-Fc [244].  
 As suggested previously, soluble CD137 suppression was found to be mediated through 
CD137L. Like other members of TNF ligand super family, CD137L also mediates ―reverse‖ 
signaling and causes activation of APCs (macrophages, B cells, monocytes) [249, 258, 259].  
However its role in T cells is not well established. The question as to how soluble CD137 
inhibited proliferation is interesting. Prior studies have shown that soluble CD137-Fc does not 
induce activation of monocytes, B cells and DC through CD137L [249, 260, 261]. In these 
studies, CD137L cross-linking with immobilized CD137-Fc was essential for activation of APC. 
Similarly, cross-linking at least two trimeric CD137L was required to elicit significant 
costimulatory activity [262]. The three dimensional molecular modeling of CD137L showed that 
a single extracellular cysteine residue in the tail (Cys-51) could form a disulfide bond under 
physiological condition and that cross-linking CD137L in vitro formed dimers of trimers [262, 
263]. By contrast, we hypothesized that soluble CD137 (predominantly dimers) binds to CD137L 
on T cells without cross-linking it, and thus initiates inhibitory signals, consistent with our results. 
Other well-known immune signaling molecules differ in their stimulatory effects according to 
whether they are plate bound or soluble—the most notable being anti-CD3 antibody, which can 
stimulate Treg-mediated suppression in soluble form but not when plate bound. Similarly, 
soluble CD137L cannot induce proliferation in CD3 stimulated T cells, while cross-linked 
CD137L can stimulate these cells [262].  These studies indicated that in the absence of cross-
linking, an inhibitory signal can be generated by soluble CD137, but further biochemical studies 
will be needed to verify this hypothesis.  
Most significantly of all, we found that soluble CD137 treatment significantly reduced the 
incidence of diabetes in NOD mice, indicating that our purified protein is functional and 
immunosuppressive in vivo (Figure 4.10a).  The histology from the soluble CD137 treated mice 
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suggested that the pathogenic NOD immune cells are not completely deleted, but their entry 
into the islet is regulated (Figure 4.1b, c). Since anti-CD137 treatment increased serum soluble 
CD137 Figure 4.4b), the antibody-mediated diabetes protection likely acts at least partly through 
the same pathway, that is, through the production and suppressive function of soluble CD137. 
Since anti-CD137 treatment increased the fraction of Tregs in NOD (Figure 2.3), it is possible 
that the diabetes protection is rendered by other mechanisms of Treg suppression, along with 
soluble CD137. Our results strongly suggested that after injection, anti-CD137 antibody targeted 
Tregs in vivo, which initiated an internal signaling event that caused an increase in TRAF2 in the 
Treg cells.  These cells could then produce higher levels of soluble CD137. The increase in 
secreted soluble CD137 after treatment caused an increase in total suppressive capacity 
against pathogenic effector cells. This downregulation of autoimmune activation is likely 
sufficient to prevent the further progression of diabetes. Treatment with anti-CD137 antibody 
also likely activated a positive feedback loop that increases the expression of soluble CD137. 
This, in-turn, may be important for suppressing pathogenic effector cells during diabetes 
progression. Since CD137L blocking antibody alone in vitro did not affect the proliferation of 
CD4 T cells (in an APC-free assay), indirect suppression through CD137-CD137L blockade 
between T cells does not appear to play as much of a role as direct suppressive effect of 
soluble CD137 via CD137L. However we do not know whether there would be an effect of 
CD137L blockade in an in vitro system containing APC. Furthermore, in an in vivo situation, 
soluble CD137 can bind to both CD137L expressing APC and activated T cells and further 
prevent CD137 costimulation of pathogenic cells. Thus soluble CD137 may suppress 
pathogenic T cells in vivo by directly initiating negative signaling through CD137L or by blocking 
T:APC CD137-CD137L interactions or both. The production and secretion of soluble CD137 by 
T regulatory cells appears to be a novel mechanism by which they can suppress, and more 
importantly, immunoregulate pathogenic effectors cells, to avert the incidence of diabetes.  
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Our experiments with soluble CD137 have opened new opportunities for the development of 
potent immunosuppressive therapies that make use of soluble immune molecules, which are 
implicated in the pathology of various autoimmune diseases. While we do not yet fully 
understand the mechanisms by which soluble CD137 exerts its immunosuppressive effects, and 
we have only begun to explore its possible uses in systemic and site specific immunotherapy, it 
serves as a compelling candidate and prototype for further investigation. The adaptation and 
use of naturally-occuring, soluble isoforms of immune signaling molecules for the purpose of 
immunosuppression, is a promising alternative to current immunosuppressive therapies, which 
utilize artificial or man-made molecules, which can have unintended and/or uncontrolled side 
effects.  
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5. SUMMARY & SIGNIFICANCE 
 
5.1 Proposed models 
 
5.1.1 Proposed model for soluble CD137 function and B10 Idd9.3 protection 
 
We have shown that while CD137pos and CD137neg Tregs expressed equal levels of Foxp3, 
CD137pos Tregs are functionally superior to CD137neg Tregs in vitro. The functional superiority of 
CD137pos Tregs is associated with diabetes protection in NOD.B10 Idd9.3 mice that accumulate 
significantly increased numbers of CD137pos Tregs with age compared to NOD mice.  The 
functional superiority of CD137pos Tregs is not explained by effects of IL-10 or TGF- 
expression. Rather, we showed that CD137pos Tregs are the primary cellular source of high 
levels of soluble CD137 ex vivo and in vitro. Further studies showed that CD137L blockade 
decreased the suppression mediated by CD137pos Tregs in a contact-independent APC-free 
assay, indicating that soluble CD137 produced by CD137pos Tregs could suppress through 
interaction with CD137L. Soluble CD137-Fc chimeric protein and recombinant soluble CD137 
suppressed CD4 T cells in vitro, via interaction with CD137L (in a Treg-free, APC-free assay), 
directly proving a role of soluble CD137 in T cell regulation. The potential importance of soluble 
CD137 in diabetes was indicated by increased levels of serum soluble CD137 in NOD.B10 
Idd9.3 congenic compared to NOD mice, likely explained by our finding of increased 
accumulation of CD137pos Tregs in NOD.B10 Idd9.3 compared to NOD mice. We directly 
showed a possible effect of soluble CD137 on diabetes by treating NOD mice with recombinant 
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soluble CD137, which prevented disease. Thus the long-term accumulation of peripheral B10 
Idd9.3 expressing CD137pos Tregs and increased production of soluble CD137 may both play a 
critical role in disease protection in NOD.B10 Idd9.3 congenic mice.  In addition, the disease 
protection afforded by anti-CD137 antibody treatment is also associated with increased soluble 
CD137. All of these lines of evidence point to a key role for the subset of CD137pos Tregs in 
immune regulation, as well as for a critical role for soluble CD137 in regulating the effector T cell 
response. Both factors may play a role in diabetes pathogenesis and explain the protective 
effect of the B10 Idd9.3 allele against Type one diabetes. 
 
The mechanism for soluble CD137 mediated suppression is not yet known in detail. We showed 
that recombinant soluble CD137 directly suppressed proliferation of CD4pos effector T cells. It 
has been shown that soluble CD137 binds to CD137L in vitro [162]. It is conceivable that 
soluble CD137 simply blocked the interaction between membrane bound CD137 and CD137L, 
thus preventing T cell costimulation. However, we showed that soluble CD137 downregulates T 
cell proliferation directly in an APC-free setting. Moreover, this soluble CD137-mediated 
downregulation is unlikely to be due to interrupting T:T CD137:CD137L interaction, because in 
our APC-free system, adding CD137L blocking antibody did not affect anti-CD3/CD28 mediated 
proliferation of CD4 T cells. However in the presence of APC in vivo, soluble CD137 may block 
CD137-CD137L costimulation and thereby also indirectly downregulate pathogenic T cell 
activation although we have not tested that here.   
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Figure5.1 
 
Figure 5.1: Model for differences in CD137-CD137L bi-directional signaling.  
a) CD137L signaling in B cells has produced activation and enhanced antibody production, but CD137L 
knockout mice can develop B cell lymphoma (i.e. unregulated proliferation) . b) CD137L signaling in 
APCs (monocytes, dendritic cells & macrophages) has produced maturation, activation and differentiation 
with IL-12 and TNF- production. c) CD137L signaling is required for maintenance and proliferation of 
CD8 T cells after secondary response but has no known effect on CD4 T cell primary and secondary 
response d) Soluble CD137 produced by CD137
pos
 Tregs binds to CD137L on APC without trimerization 
and does not induce activation or proliferation. Soluble CD137 interaction with CD137L on T cells 
suppressed proliferation and prevented diabetes in NOD mice.  
 
Understanding the effects of soluble CD137 requires an appreciation that the CD137:CD137L 
system shows bi-directional signaling, as seen in other members of the TNF and TNFR family. 
Hence while we showed that direct stimulation of CD137 via an agonist antibody prevents 
diabetes by mediating signaling in the TRAF2 pathway in CD137pos Tregs (Chapters 2 and 4), 
the effect of soluble CD137 (produced after CD137 stimulation on Tregs) is mediated via 
CD137L. Moreover, while we investigated the effect of soluble CD137 on T cell activation, the 
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effect could be different on other cell types, and in fact the literature is contradictory in this 
regard. Previous studies showed various effects of CD137L signaling on various cell types. 
CD137L stimulation on B cells showed contradictory results as indicated in Figure 5.1a. 
Crosslinking of CD137L in activated B cells by plate bound rCD137 protein produced enhanced 
proliferation and Ig secretion [261]. However overexpression of CD137L caused B cell 
deficiency in mice after 3 weeks of age and could be due to prolonged suppression of growth 
signals [47]. Similarly, CD137 ligand signaling is essential to suppress B cell lymphoma 
development indicating negative regulation via CD137L on B cells [264].  Supporting this, 
microarray analysis showed that lack of CD137L in B cells causes overexpression of molecules 
associated with cell growth (Stat-1, Elf-1, CIITA, AID, Bcl-10 and Rad21) and plasma cell 
differentiation (Bach-2, Spi-B and Bcl-6) [264].  
 
In dendritic cells, CD137L signaling induced IL-12 production, maturation, activation and 
differentiation [176, 258]. The expression of CD137L on a macrophage cell line produced 
increased expression of ICAM-1, TNF, MCP-1, IL-6, IL-1b, IL-1R antagonist and M-CSF 
resulting in increased survival [260]. Another study showed that CD137L signaling induced the 
expression of IL-6, IL-8, and TNF- and resulted in monocyte activation [249]. These studies 
showed that CD137L signaling in dendritic cells, macrophages and monocytes is stimulatory 
resulting in activation and effector function (Figure 5.1b). However, most of these studies used 
plate bound CD137, which could have very different effects than soluble CD137. In particular, 
plate bound CD137 might be better able to cross link CD137L, and cannot result in receptor 
internalization (compared to soluble CD137). 
 
The effect of CD137L reverse signaling in T cells has mostly been studied in viral infection. 
Absence of CD137L had no obvious effect on the primary CD8 T cell response but reduced 
secondary CD8 T response during viral infection, with no effect on CD4 T cells [172, 173]. 
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CD137L signaling is important in the maintenance of CD8 T cell after viral clearance but not for 
initial priming or programming of memory [169, 171]. CD137L knockout on transgenic OTII CD4  
T cells has a minor effect on primary response and no effect in secondary response [174]. 
These studies showed that CD137L signaling in CD4 and CD8 T cells has different effects 
during viral infection and that CD137L reverse signaling is important for secondary memory CD8 
T cell response (Figure 5.1c).  
 
The proliferative effect of membrane bound or plate bound CD137 signaling on different cell 
types differed from our observation that showed a suppressive effect of soluble CD137 on CD4 
T cells. This disparity of CD137L signaling could be due to the differences in membrane bound 
versus soluble form of CD137 receptor. The question as to how a soluble form of a molecule 
can be biologically different from a fixed (membrane or plate bound CD137) form is interesting. 
It is not known if soluble CD137 versus membrane-bound CD137 bind to CD137L with variable 
affinity and subsequently elicit differential signaling. Membrane bound and soluble form of 
CD30, another member of TNF receptor superfamily, bind to its ligand, CD153 with different 
affinity [265]. Hence it is possible that membrane and soluble CD137 binds to the ligand with 
different affinity which could affect ligand signaling as also seen in the Epidermal Growth Factor 
Receptor (EGFR) [266]. Site-directed mutagenesis of human CD137L to map the receptor 
binding sites of the CD137-CD137L trimer showed that mutation of residues Lys127 and Gln227 
to alanine caused 170 and 80 fold decrease in binding affinity, respectively [267]. The authors 
predicted that since these mutations are on exposed sites of CD137L, they can have a direct 
effect on receptor binding. Similarly the absence of exon 8 in soluble CD137 could alter the 
binding affinity with CD137L compared to full-length CD137 or even destabilize the trimer 
structure. Upon receptor binding, the cytoplasmic domains of the CD137 ligand become fixed in 
a specific conformation, resulting in recruitment of adaptor proteins and molecules for 
downstream signaling. The affinity of the binding will thus affect the structure of the ligand and 
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affect downstream signaling. Similar observations have been made in a study where different 
IFN variants signal through the same cell surface receptors, IFNAR1 and IFNAR2 but cause 
different physiological effects based on their binding affinities and receptor recognition 
chemistries [268].  Although the binding affinity of soluble versus full-length CD137 has not been 
studied yet, it is essential to recognize that exon deletion could impact the signaling response. 
 
This disparity of CD137L signaling in APC versus T cells could result from the effect of CD137L 
cross-linking on signaling. Prior studies have shown that cross-linking of CD137L with 
immobilized CD137 (membrane or plate bound CD137) is essential for monocyte, B cell and DC 
survival/activation [249, 260, 261] and that soluble CD137 is not sufficient to induce activation of 
APC (Figure 5.1d). Cross-linking CD137L with immobilized CD137 is essential for activation 
signaling in APC [263]. As with other members of TNF superfamily, surface CD137L likely 
aggregates to form trimers [269, 270]. It has been shown that human CD137L exists as 
homotrimers [262, 267]. In other TNF-TNFR complexes, a trimeric form of the ligand binds to a 
trimeric form of the receptor [270-272]. Similarly, CD137-CD137L may also bind with this 
stoichiometry although it has not been confirmed by a crystal structure of the CD137-CD137L 
complex. A study has shown that the trimeric form of CD137L only costimulates via CD137 
when cross-linked [262].  Since we show in Chapter four that soluble CD137 is predominantly 
dimeric, it might not be able to cross-link CD137L as do trimers of two membrane-bound CD137 
molecules, and therefore could signal differently. Treating macrophages with soluble CD137-Fc 
does not induce TNF production, suggesting that soluble CD137 cannot cross-link CD137L, and 
furthermore soluble CD137-Fc could only mediate TNF production when anti-Fc was added 
(thus allowing crosslinking) [259]. Since soluble CD137 exists predominantly as dimers, it could 
bind differently to CD137L on T cells, and thus could send inhibitory signals, consistent with our 
T cell proliferation results (Figure 4.1d). Other well-known immune signaling molecules differ in 
their effect according to whether they are plate bound or soluble—the most notable anti-CD3 
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antibody, which can stimulate Treg mediated suppression in soluble form but not when plate 
bound. Similarly, soluble CD137L cannot induce proliferation in CD3 stimulated T cells, while 
cross-linked CD137L can stimulate these cells [262]. Cross-linking is essential to its T cell co-
stimulation activity. The absence of cross-linking may explain the inhibitory signaling observed 
with soluble CD137, compared to membrane bound CD137. These studies indicate the variation 
and complexity of CD137L signaling in various cell types and different state of the receptor and 
further biochemical studies of soluble CD137 will be needed to verify this hypothesis. 
5.1.2 Proposed model for anti-CD137 mediated NOD diabetes protection  
 
Immune modulation by agonist CD137 antibody previously showed diverse effect on various 
diseases; on viral clearance [273], tumor regression [274, 275] and prevention of asthma [276] 
and autoimmunity [137, 180, 277, 278]. Based on the disease model, the immune response to 
anti-CD137 antibody has also shown contradictory results. For example, anti-CD137 treatment 
increased IFN- production by CD8 T cells in autoimmune uveoretinitis [277], allergic asthma 
[276], experimental autoimmune encephalomyelitis (EAE) mouse models [278] but reduced IFN-
 production in autoimmune diabetes in NOD mice [137]. It is unclear how stimulation through 
CD137 can trigger enhanced immune responses to viruses and tumors but at the same time 
suppress autoimmune responses. It is possible that the immune microenvironment and the 
proportion of activated T cells, APCs, or T regulatory cells play a crucial role in such differences. 
Since the effect of anti-CD137 antibody is broad depending on the disease model, we have 
focused on the effect of anti-CD137 antibody on autoimmunity.  
 
Studies have shown that anti-CD137 treatment inhibits autoimmunity by various mechanisms. 
Initial studies with anti-CD137 treatment in the EAE model showed that it increased IFN-
production, promoted initial proliferation of antigen specific CD4 T cell and ultimately caused 
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activation induced cell death, nine days after immunization [148]. In collagen type II–induced 
arthritis (CIA) anti-CD137 treatment suppressed CD4 T cell recall response to antigen and 
caused expansion of CD11c+CD8+ cells which produced IFN- and subsequently induced 
production of indoleamine 2,3-dioxygenase (IDO) in macrophages and DCs [180]. IDO is known 
to suppress adaptive T-cell immunity by catabolizing the essential amino acid tryptophan from 
the cellular microenvironment and by inhibiting IL-2 expression [279, 280] . Another study of 
anti-CD137 treatment on experimental autoimmune uveoretinitis (EAU) model, consistent with 
the CIA model, also showed that antibody treatment expanded CD11c+CD8+ T cells that 
produced IFN-, which increased the levels of IDO in CD11c+ dendritic cells and decreased the 
proliferation and absolute number of CD4 T cells by inducing CD4 T cell death. [277]. These 
studies have associated anti-CD137 mediated inhibition of autoimmunity to CD8 T cell mediated 
IFN- production which leads to production of IDO by DC and macrophages that suppresses 
CD4 T cells proliferation (Figure 5.2a). As shown in Figure 5.2b CD137-primed CD8 T cells 
suppressed CD4 T cells in a TGF- dependent manner [281, 282] 
 
Figure5.2 
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Figure 5.2: Model for mechanism of autoimmunity prevention by anti-CD137 antibodies.  
The mechanism applicable to anti-CD137 mediated diabetes prevention is shown within the boxed area. 
a) In NOD mice, the anti-CD137 antibodies bind to CD4
pos
CD25
pos
CD137
pos 
Tregs and increase their 
number. These CD4
pos
CD25
pos
 Tregs from anti-CD137 treated mice can act directly on effector cells to 
prevent diabetes in NOD (and Graft Versus Host Disease (GVHD)). The expanded Treg population 
produces high levels of soluble CD137 that downregulates CD4 T cell proliferation in vitro and contributes 
to decreased diabetes in NOD mice. b) In other autoimmune models, anti-CD137 treatment has been 
shown to expand CD8 T cells that produce IFN- which induces the production of indoleamine 2,3-
dioxygenase (IDO) from DC and macrophages. The production of IDO suppresses pathogenic CD4 T cell 
function and prevents autoimmunity. c) Alternatively, the expanded CD8 T cells also produce TGF- and 
suppress pathogenic T cells to prevent autoimmunity. d) In the absence of IFN- anti-CD137 treatment 
can induce IL-6 production that inhibits Th-17 differentiation and favors Treg differentiation. The 
expansion of the Treg compartment again prevents autoimmunity in various immune models. 
 
Subsequent studies on the effect of anti-CD137 treatment on EAE showed that the disease 
could also be suppressed independent of CD8 T cells (after CD8 depletion) and IFN- 
production (using IFN- knockout mice) [278]. In IFN-knockout mice, CD137 treatment reduced 
IL-6 expression from CD4 T cells, which inhibits Th-17 and favors Treg differentiation [278] 
(Figure 5.2c). Furthermore, the anti-CD137 treated IFN- knockout mice increased expression of 
Foxp3 in CD4 T cells and increased the total number of Foxp3posCD4pos Tregs [278]. This 
increase in Treg was independent of IL-2 levels. Thus in several models, anti-CD137 mediated 
prevention of autoimmunity is thus associated with increase in T regulatory cells that are potent 
suppressors of pathogenic effector cells. 
 
We have demonstrated that anti-CD137 antibody prevented the onset of diabetes in NOD mice 
(Figure 2.1). The antibody preferentially bound to CD4posCD25posCD137pos Tregs and increased 
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their fraction in vivo (Figure 2.3).  As shown in Figure 5.2d, our result is consistent with the study 
in EAE which also showed that anti-CD137 treatment increased the percentage of Foxp3 
expressing CD4 T cells [278]. Other groups have also shown the in vitro and in vivo expansion 
of CD4posCD25pos T cells by CD137L-Fc and CD137L-strepavidin [138, 160]. CD137-induced 
Treg expansion in vivo is dependent on IL-2 levels [283]. Adoptive transfer models into NOD-
scid mice showed that the antibody treated CD4posCD25pos T cells were suppressive and 
protective against diabetes (Figure 2.6). Our results are consistent with another study that has 
also shown adoptive transfer of anti-CD137-primed Tregs prevented Graft versus host disease 
(GVHD) [283]. These CD137L-Fc or CD137L-strep stimulated Tregs remained functionally 
suppressive in vitro and in vivo [138, 160]. Apart from the quantitative increase in Treg numbers 
that aid in suppression, we have also identified a new mechanism for Treg suppression. We 
showed that soluble CD137 is functionally suppressive in vitro and reduces the incidence of 
diabetes in vivo (Figure 4.9a). Anti-CD137 treatment increases soluble CD137 production by 
CD137pos Tregs in vitro, in addition to the increase in the level of serum soluble CD137 (Figure 
4.4). The recombinant soluble CD137 does not cause cell death in CD4 T cells in vitro (Figure 
4.8b). CD137L blockade abrogated Treg mediated suppression that probably acts through 
soluble CD137 but we have not clearly identified the mechanism for suppression. The 
suppression of CD4 T cells after anti-CD137 treatment in various disease models [140, 277] is 
consistent with our result of increased soluble CD137 mediated suppression. Although the 
mechanism of suppression is not clear, our results suggests that anti-CD137 mediated diabetes 
prevention in NOD mice is through expansion of T regulatory cells that are functionally superior 
in contact dependent suppression and also produce the immunosuppressive soluble CD137 
molecule.  
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5.2 Future directions and therapeutic implications 
 
Diabetes in NOD mice is a complex, multigenic, and immunologically ―delicate‖ disease. The 
whole immune system acts in an orchestrated manner to mediate disease; DCs present auto-
antigens for initiating an immune response, CD4 and CD8 T cells are necessary for disease 
progression, and B cells play an important role in autoantibody production and as APCs. The 
many interventions that prevent diabetes in NOD may therefore act at various time points and 
on different cell subsets to disrupt the development of disease. We have seen that anti-CD137 
treatment prevents diabetes in NOD mice [137]. Anti-CD137 treatment has been shown to 
reverse a number of autoimmune diseases [149, 181, 277] but antibody treatment after the 
diabetogenic T cells transfer into a NOD-scid mice worsened diabetes in the recipient mice 
[137]. It is important to understand these discrepancies and what they imply for productive 
research using the NOD model. While systemic administration of soluble CD137 is effective in 
preventing diabetes in NOD mice, we do not know at this point if soluble CD137 will be effective 
in reversing T1D. To understand the role of soluble CD137 during various stage of the disease, 
it is important to understand the effect of soluble CD137 on various immune cells types (CD8 T 
cells, DCs, B cells etc) during culture in vitro and after treatment in vivo.  
 
To further understand the mechanism of soluble CD137 suppression, it is necessary to test the 
direct role of soluble CD137 in suppression. For this we plan to use soluble CD137 for 
suppression of CD137 deficient CD4 T cells (hence lacking CD137-CD137L costimulation). CD4 
T cells from CD137 deficient mice have shown enhanced proliferation [284, 285] and soluble 
CD137 mediated suppression of CD137 deficient CD4 T cells would indicate the direct role of 
CD137 in suppression. We can also use T cells from CD137L knockout mice to test the 
importance of CD137L in soluble CD137 mediated suppression. The absence of CD4 T cell 
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suppression in CD137L knockout mice in the presence of soluble CD137 would further indicate 
that soluble CD137 mediates its suppression through CD137L. 
 
We can also test the variation between soluble versus membrane-bound CD137 in CD137L 
signaling in T cells. As with other members of TNF superfamily, membrane bound CD137 binds 
to CD137L as a trimer and cross-links it. On the other hand, soluble CD137 dimer could cross-
link CD137L differently than membrane bound CD137 and initiate signaling that causes 
suppression of CD4 T cell proliferation. It is important to test if cross-linking CD137L by surface 
CD137 (or by surface bound CD137-Fc or anti-Fc bound CD137-Fc) on T cells would signal 
differently compared to cross-linking CD137L by soluble CD137 or soluble CD137-Fc.  
Suppression with soluble CD137 but not with plate bound CD137-Fc or anti-Fc bound CD137-
Fc on CD4 T cells would indicate that different degrees of cross-linking CD137L on CD4 T cells 
are important for suppression. Similar studies on different cell types will help us understand the 
proliferative versus suppressive effect in CD137L signaling in various immune cells.  Our current 
understanding of the CD137 ligand signaling pathway on T cells is limited and a systematic and 
comprehensive analysis of the signaling pathway is required to further understand the 
mechanism of suppression. 
 
Ideally we would like to use tissue-specific cellular therapy to deliver soluble CD137 to the 
pancreatic islets, where it could bind to and downregulate CD137L in ligand-expressing islet 
cells. Given the recent demonstration that T cell accumulation in the islets is largely driven by 
antigen specificity [32], we plan to use a lentiviral approach with transduced BDC2.5 T cells 
(specific for an islet autoantigen) to deliver the therapeutic agent. An alternate approach is to 
use retrogenically modified Tregs to deliver soluble CD137 locally. As others have shown we 
plan to use the retrogenic approach to over-express the soluble B10 CD137 minigene, [286]. 
Retrogenic mice (potentially useful as sources of soluble CD137 expressing cell subsets for use 
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in cellular therapy) will be made by reconstitution of LeGOiG2-solubleCD137-tranduced bone 
marrow cells or empty vector into a lethally irradiated NOD recipient. Preliminary studies with 
CD137-modified lentivirus, LeGOiG2-solubleCD137, effectively transduced both T cells for 
BDC2.5 site-specific delivery and bone marrow cells for making retrogenic mice. The lentiviral 
system described above is also highly modular, and will allow us to rapidly splice in and out 
different candidate genes, as well as test different cell types for gene delivery and therapeutic 
effectiveness. Hence these dual approaches will be very useful when used in conjunction with 
genetic studies oriented towards identifying potential candidate genes and their function. CD137 
is the major candidate gene in the NOD Idd9.3 genetic interval. Our studies showed that 
NOD.B10 Idd9.3 congenic mice have increased accumulation of CD137pos Tregs compared to 
NOD mice supporting the hypothesis that CD137 is the Idd9.3 candidate gene. This hypothesis 
is further strengthened by the mixed bone marrow chimera results which also showed increased 
fraction of Idd9.3 CD137pos Tregs compared to NOD CD137pos Tregs. These studies would 
further support detailed genetic studies to demonstrate whether CD137 is the Idd9.3 gene. A 
knockout of CD37 in NOD.B10 Idd9.3 Tregs could worsen diabetes in NOD.B10 Idd9.3 mice 
which would probably represent the strongest evidence, in addition to the many findings we 
have produced, supporting Cd137 as the Idd9.3 candidate gene. The NOD model has been 
very successful in identifying common immunogenetic pathways shared between mouse and 
human T1D [287, 288] and further understanding of mouse genetic control of diabetes has great 
potential for insights in human T1D. By focusing on genes implicated in immunopathogenesis of 
T1D, and by delivering variants of these genes to the islets in T1D, we hope to study the effect 
of immune molecules that are genetically associated with the disease.  
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 APPENDIX A 
 
Supplemental Figure1 
 
Supplemental Figure 1. The CD62Lhi or CD69hi expression on CD137pos Tregs are not 
entirely CD69low or CD62Llow respectively.  
NOD female splenocytes, 4-8 weeks old were stained with CD4APC, CD25PercpCy5.5, CD137PE, 
CD69FITC and CD62LAPCCy7 and processed through FACS Cantos.  The CD69 and CD62L staining 
was analysed on CD137
pos
 Tregs using FlowJo. 
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Supplemental Figure2 
 
Supplemental Figure 2. NOD and NOD.B10 Idd9.3 CD137neg Tregs both equally upregulate 
CD137 in vitro.  
Splenocytes from 4-7 week old NOD and NOD.B10 Idd9.3 females were sorted for 
CD4
pos
CD25
neg
CD137
neg
 T cells and CD137
neg
 and CD137
pos
 Tregs as described above. 25,000 sorted 
cells were cultured with 25U/ml IL-2 and 1.25ug/ml anti-CD3 for three days. The cultured cells were 
stained for CD4, CD25 and CD137 and analyzed by flow cytometry; CD137 MFI for each subset is shown 
beneath each FACS plot. One representative of three experiments. 
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